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Summary 
Chemerin is a newly identified adipokine and exerts its functional effects by 
binding to its natural GPCR, known as CMKLR1. Chemerin is highly expressed in 
the adipose tissue and in lower levels in other body tissues; and is known to play an 
important role in adipocyte differentiation and metabolism. Chemerin circulates at 
the normal physiological concentrations of approximately 3-4nM in humans, and 
circulating chemerin levels positively correlate with various facets of metabolic 
abnormalities; such as insulin resistance, type 2 diabetes, high triglycerides, 
hypertension, and associated risks of development of diseases of cardiovascular 
system. Endothelial Cells (ECs) line the vasculature of the entire circulatory system 
and form a direct contact with the bloodstream. In this project, the role of chemerin 
in EC biology was proposed, and was studied in terms of activation of important 
signalling Mitogen-activated Protein Kinases (MAPKs) including Extracellular 
signal-regulated Kinase (ERK) 1/2, ERK5, p38, Stress-activated Protein Kinase/c-
Jun NH2-terminal Kinase (SAPK/JNK); and Akt/Protein Kinase B (PKB) and 
Adenosine Monophosphate Protein Kinase (AMPK)-α in a time- and concentration-
dependent manners. These signalling kinases regulate the activity of different 
transcription factors which then regulate the expression of different genes. Chemerin 
increased the expression of Hypoxia-inducible Factor (HIF)-1α, a hypoxia-inducible 
transcription factor which is known to regulate the Vascular Endothelial Growth 
Factor (VEGF) gene expression. Interestingly, VEGF165, the most potent 
angiogenic isoform of VEGF protein expression was down-regulated by chemerin in 
a concentration-dependent manner; whereas, chemerin upregulated the protein 
expression of VEGF165b, an opposite anti-angiogenic counterpart of VEGF165. 
Chemerin mediated EC proliferation, migration and capillary tube formation; which 
are the key processes implicated in the process of normal and pathological 
angiogenesis. Chemerin altered the protein expression levels of Cell Adhesion 
Molecules (CAMs) including E-selectin, ICAM-1 and VCAM-1 – increased the 
activity of Nuclear Factor (NF)–kappa (κ) B pathway – and encouraged Endothelial-
Monocyte cell adhesion in a concentration-dependent manner. Nitric Oxide (NO), 
not only keeps the vascular health in check by downregulating the expression levels 
of adhesion molecules, but also acts as a potent vasodilator. Endothelial Nitric Oxide 
Synthase (eNOS), an enzyme constitutively expressed in the endothelial cells 
regulates the production of NO in the endothelium. Chemerin increased eNOS 
activity by causing eNOS phosphorylation at Ser1177, and dephosphorylating at 
Thr495 phosphorylation sites. Chemerin increased the protein expression of non-
constitutively expressed enzyme, inducible Nitric Oxide Synthase (iNOS), which is 
mainly induced during injury or inflammation and is known to produce 100- to 
1000-times more NO compared to that of eNOS. However, interestingly, chemerin 
failed to show any significant changes in the amounts of combined nitrite and nitrate 
(NOx) levels in HMEC-1 cells; whereas, nitrite (NO2
–
) levels were decreased in a 
concentration-dependent manner. 
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1.1 Vascular Endothelium 
1.1.1 Normal Vascular Endothelium 
1.1.1a Origin, structure and functions of endothelial cells 
 
In 1973, Endothelial Cells (ECs) were cultured for the very first time by Jaffe 
and colleagues which lead to the revolution in the field of EC biology (Jaffe et al., 
1973a). ECs are a single epithelial-like cells that line the innermost layer of all blood 
vessels in the circulatory system, forming a direct contact with flowing bloodstream, 
and modulating various biological systems in the blood (Baldi et al., 2000). Adult 
vascular endothelium weighs approximately 1000g and comprises of 1.6x10
13 
cells 
with a surface area between 1-7m
2
. ECs participate in five primary physiological 
functions in the body; (1) the most basic and important feature of ECs is the capacity 
to maintain blood in its fluid state by preventing blood clot formation (Arnout et al., 
2006) (2) ECs control the exchange of fluids and other macromolecules between the 
blood and the tissues mainly at the capillary level (Minshall and Malik, 2006), (3) 
ECs control blood flow at the arterial and arteriolar level of circulation (Busse and 
Fleming, 2006), (4) a fourth important physiological function of the ECs is stopping 
the inflammatory responses (Ley and Reutershan, 2006) and, finally (5) ECs 
participate in maintaining control of body’s immune system (Choi et al., 2004). In 
normo-physiological states, ECs remain in a dormant state,  retain an anti-thrombotic 
surface, and maintain the normal vascular homeostasis.  
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1.1.2 Diseased Vascular Endothelium 
 
Abnormal EC functioning is coined as ‘Endothelial Dysfunction (ED)’ and is 
defined as the failure of ECs to perform normal functions which may be due EC 
injury or death. In clinical scenario, ED is defined as the failure of ECs to respond to 
increased blood flow by releasing excessive amounts of endothelium Nitric Oxide 
(NO) and causing local vasodilation (Giannotti and Landmesser 2007). 
1.1.2a Endothelial cell activation, injury and inflammation 
 
EC activation is characterised as a new EC function that benefits the host; e.g., 
role of ECs in controlling the inflammatory responses at different levels which are 
important in innate and adaptive immunity of the body.  
1.1.2b Vascular disease - EC angiogenesis  
 
The mesodermal precursor cells, which are formed by the differentiation of 
angioblast from the early vascular plexus, subsequently form primitive blood vessels, 
and the process is characterised as vasculogenesis (Folkman and Shing, 1992b). The 
cardiovascular (CV) system is the very first functional organ system that develops in 
the vertebrate embryo, and acts as a nutrient supply as well as a waste removal 
system, promoting embryonic growth and differentiation. Later in adult life, it serves 
as a nutrient and waste pipeline and also as a primary communicatory system 
between all distant organs and body tissues. ECs then arrange in a single layer and 
line the innermost layer of all blood vessels. More ECs are generated after the 
primary vascular plexus, which then form new capillaries from the pre-existing 
vessels by sprouting or splitting from their original vessel, and the process is termed 
as angiogenesis. Angiogenesis is an essential process in the normal growth; and 
under normo-physiological conditions, angiogenesis mainly occurs in wound healing 
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and tissue repair processes. Angiogenesis is also implicated in disease states such as 
cancers, diabetic retinopathy, as well as in inflammatory diseases such as rheumatoid 
arthritis. Process of angiogenesis involves the degradation of Extracellular Matrix 
(ECM) by matrix degrading enzymes such as Matrix Metalloproteinases (MMPs), 
followed by EC migration, proliferation and formation of tube-like structures. 
Vascular Endothelial Growth Factor (VEGF) is the most common endothelial-
specific growth and chemotactic factor and is widely studied as an angiogenesis-
activating factor (Keswani et al., 2011).  
Vascular Endothelial Growth Factor and Angiogenesis 
Vascular Endothelial Growth Factor (VEGF) was initially identified as a 
Vascular Permeability Factor (VPF) (Senger et al., 1983), and was isolated as a 
soluble heparin-binding heterodimeric glycoprotein (Ferrara and Henzel, 1989, 
Zhang et al., 2011). A number of other proteins that share structural similarities with 
VEGF are grouped together in a VEGF family, including VEGF-A (commonly 
known as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E isoforms and Placental 
Growth Factor (PIGF) (Nittoh et al., 1997b). Alternative splicing of human VEGF 
gene results in the formation of pro-angiogenic, and opposite anti-angiogenic 
counterparts, latter been grouped together in VEGFxxxb family (xxx representing 
the number of amino acids) (Appendix 5, Fig. 5.1a, page number 248) (Craine et al., 
1995). The pro-angiogenic VEGF isoforms include VEGF121, VEGF165, VEGF189 
and VEGF206, each having 121, 165, 189 and 206 amino acids (Ohuchi et al., 1997c) 
- VEGF145 and VEGF183 are other two less frequently produced isoforms of VEGF 
(Neufeld et al., 1999). VEGF165 (commonly represented as VEGF) is a secreted 
protein and is the most predominant and biologically active isoform of VEGF, and is 
known to share properties with that of native VEGF protein (Hirasawa et al., 1997b). 
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VEGF165 is the principal isoform that is known to play important role in normal and 
pathological angiogenesis (Ferrara and Davis-Smyth, 1997), as well as in 
vasculogenesis (Folkman and D'Amore, 1996). New vessel formation and growth are 
highly complex and co-ordinated processes involving the activation of a number of 
different receptors by external stimuli (Ferrara, 2000, Carmeliet, 2000). In addition 
to its mitogenic actions, VEGF165 also stimulates fluid and protein extravasation 
from blood vessels (Dvorak et al., 1995a), mediates calcium influx (Brock et al., 
1991, Seymour et al., 1996), and is known to release NO in primary HUVECs cells 
(van der Zee et al., 1997, Ahmed et al., 1997).  
Vascular Endothelial Growth Factor Receptors and Angiogenesis 
VEGFR1 (fms-like tyrosine kinase, Flt-1), VEGFR2 [Kinase insert-domain 
containing receptor, KDR (in humans) and fetal liver kinase (flk)-1 (in mouse)] and 
VEGFR3 (Flt-4) are three different tyrosine kinase receptors that are stimulated upon 
VEGF binding. Both VEGFR1 and VEGFR2 are co-expressed on EC surfaces 
(Ferrara and Davis-Smyth, 1997), whereas, VEGFR3 is mainly expressed on the 
lymphatic endothelium and in tumour blood vessels during neovascularisation 
(Nakamura et al., 1997). VEGF binds both VEGFR1 and VEGFR2 receptors, 
however, VEGFR2 is the main signalling receptor implicated in VEGF-dependent 
angiogenesis (Waltenberger et al., 1994). Upon stimulation, VEGFR2 becomes 
activated (Nittoh et al., 1997b) and autophosphorylates at multiple phosphorylation 
sites (Dougher-Vermazen et al., 1994). Carboxy terminal of VEGFR2 receptor 
contains different Serine (Ser) and Tyrosine (Tyr) phosphorylation sites which are 
crucial for VEGFR2 phosphorylation and functions (Nguyen et al., 1993a, Nguyen et 
al., 1992, Folkman and Shing, 1992a). Different tyrosine phosphorylation sites 
include Tyr1175, 1214, and 1223, and are essential for VEGFR2 activity and 
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functions. VEGFR2 phosphorylation at Tyr1214 is essential for complete 
autophosphorylation of VEGFR2 receptor (Koch et al., 1995); and receptor 
phosphorylation at Tyr1175 is crucial, as mice carrying Tyr-to-Phe substitution at 
position 1173 (corresponds to Tyr1175 in human VEGR2) are reported to die at the 
embryonic stage due to lack of vasculogenesis or angiogenesis (Palframan et al., 
2001). VEGFR2 phosphorylation at Tyr1175 results in the recruitment of p85 and 
Phosphoinositide-3-Kinase (PI3K) (Weidner et al., 1992), and activates downstream 
signalling pathways such as Protein Kinase C pathway (PKC) (Takahashi et al., 
2001). Signalling via VEGFR2 receptor is essential for the VEGF-stimulated 
proliferation, chemotaxis, sprouting and survival of cultured ECs in vitro, as well as 
angiogenesis in vivo (Okamoto et al., 1997). Other VEGF isoforms, such as VEGF-B 
binds to VEGFR1 and is known to play a role in extracellular matrix degradation, 
cell adhesion, and migration; both VEGF-C and VEGF-D bind VEGFR2 and 
VEGFR3 receptors, and primarily affect the development of the lymphatic 
vasculature via VEGFR3 activation (Sakata et al., 1997). VEGF-E is implicated in 
mediating angiogenesis via VEGFR2 signalling, however, not through VEGFR1 
(Nittoh et al., 1997b).  
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Hypoxia Inducible Factor -1 and Angiogenesis 
Hypoxia Inducible Factor (HIF)-1 is a heterodimeric transcription factor, 
composed of an alpha (α), and a beta (β) subunit. HIF-1α is induced by altered 
oxygen levels, whereas, HIF-1β is expressed in an oxygen-independent manner. 
Under normoxic conditions, HIF-1α is rapidly degraded by ubiquitin-proteasome 
system and is rarely detectable; however, in hypoxic conditions, HIF-1α expression 
increases due to decreased ubiquitination and degradation, which then regulates the 
expression of different genes including VEGF (Shimaoka et al., 2001). HIF-1α 
activates and regulates the VEGF gene transcription by binding to the Hypoxia 
Response Element (HRE) in the gene promoter region (Laughner et al., 2001). A 
number of other factors such as cytokines, growth factors, and oxidative stresses are 
also known to modulate HIF-1α transcriptional activity.  
Matrix Metalloproteinases and Angiogenesis 
Matrix Metalloproteinases (MMPs), also known as matrixins are the enzymes 
that are involved in the degradation of extracellular matrix, a process vital for normal 
growth, development and morphogenesis. So far, twenty three different types of 
MMP have been characterised, which are further divided into secreted MMPs and 
Membrane-Type MMPs (MT-MMPs). Both secreted MMPs, MMP-2 and -9, have 
been intensively implicated in the process of angiogenesis (van Hinsbergh et al., 
2006). Upon stimulation, these MMPs become activated and are regulated at 
transcriptional, translational and zymogen stages (Ohuchi et al., 1997a); and their 
activities are inhibited by Tissue Inhibitors of Metalloproteinases (TIMPs). 
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1.1.2c Vascular disease – vascular inflammation  
 
Cell Adhesion Molecules and Vascular Inflammation  
The endothelial Cell Adhesion Molecules (CAMs) are the molecules expressed 
on the surface of EC and maintain vessel homeostasis, wound healing, coagulation, 
inflammation, immune responses and related diseases such as atherosclerosis and 
angiogenesis. CAMs are grouped together into four main families; the integrins, the 
immunoglobulins, the selectins and the cadherins. E-selectin is one of the selectin 
molecules and is absent in normal tissues, however, is expressed in the endothelium 
of post-capillary venues in inflammatory states, such as rheumatoid arthritis. E-
selectins are involved in leukocyte adhesion to the vessel wall, as well as known to 
play a role in angiogenesis (Koch et al., 1995). The specific antibodies directed 
against E-selectin protein inhibit the tube formation in vitro (Nguyen et al., 1993b). 
The Intracellular Cell Adhesion Molecule (ICAM)-1 and Vascular Cell Adhesion 
Molecule (VCAM)-1 are the adhesion molecules of immunoglobulin superfamily, 
and are involved in cell-cell adhesion and leukocyte transmigration. ICAM-1 is 
constitutively expressed on the EC surfaces and immune cells. There are five 
different isoforms of ICAM (ICAM-1, 2, 3, 4 and 5) which all bind leukocyte 
integrins. Resting endothelium does not bind leukocytes, however, when activated 
by inflammatory cytokines or external stimuli, protein expression levels of adhesion 
molecules is increased. CAMs facilitate the entry of leukocytes into inflamed tissues, 
promoting angiogenesis and neovascularisation, which constitute as the key 
processes implicated in the initiation and progression of inflammatory diseases such 
as rheumatoid arthritis, tumour growth, and wound repair (Folkman and Shing, 
1992a). These molecules are shed from the EC surfaces and circulate freely in the 
bloodstream, for example soluble forms of E-selectin (sE-selectin) and VCAM- 
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(sVCAM-1) are known to induce HUVEC and microvascular ECs chemotaxis in 
vitro and in vivo (Koch et al., 1995).  
Monocyte Chemoattractant Protein-1 and Vascular Inflammation 
Monocyte Chemoattractant Protein (MCP)-1 is a chemoattractant protein that 
acts as a major recruitment protein across ECs, resulting in chemo attraction and 
infiltration of circulating monocytes across the endothelial- and epithelial-cell barrier 
(Randolph and Furie, 1995). In in vivo models, MCP-1 is also reported to mediate 
monocyte infiltration to High Endothelial Venules (HEV)-draining lymph nodes of 
inflamed skin (Palframan et al., 2001).  
Nuclear Factor-kappa B Signalling Pathway and Vascular Inflammation  
Nuclear Factor (NF)-κB signalling pathway is widely implicated in the 
pathogenesis of inflammatory diseases such as atherosclerosis (de Winther et al., 
2005). There are five different transcription factors which are grouped together in 
NF-κB group of transcription factors and include c-Rel, relB, p65 (relA), p105/p50, 
and p100/p52. The protein inhibitors of NF-κB, denoted as IκBs, keep the NF-κB 
dimers in an inactive state. Upon stimulation by pro-inflammatory stimuli, the IκB 
Kinase (IKK) phosphorylates IκB proteins on specific Serine residues, which cause 
ubiquitination and consecutive proteasomal degradation of the dimer complex. The 
NF-κB dimers get released and accumulate in the nucleus, which upon stimulation 
get activated and are implicated in regulating the expression of different pro-
inflammatory cytokines, adhesion molecules including VCAM-1, ICAM-1 and E-
selectin and other chemokines such as MCP-1 (de Winther et al., 2005). Activated 
NF-κB in ECs is also known to encourage endothelial-monocyte cell adhesion (Hajra 
et al., 2000).  
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1.1.2d Vascular Disease – endothelium nitric oxide  
 
Endothelial Nitric Oxide Synthase and NO Production 
Endothelial Nitric Oxide Synthase (eNOS) is one of the three Nitric Oxide 
Synthases (NOSs) enzymes which were initially characterised in 1989 (Palmer and 
Moncada, 1989). The three different isoforms of NOSs are; neuronal Nitric Oxide 
Synthase (nNOS), inducible Nitric Oxide Synthase (iNOS) and endothelial Nitric 
Oxide Synthase (eNOS) and were all cloned and purified between 1991 and 1994. 
These NOSs were named after the type of tissue they were first identified in, and are 
also denoted as type I or NOS-I or NOS-1 (nNOS), type II or NOS-II or NOS-2 
(iNOS) and type III or NOS-III or NOS-3 (eNOS). These NOSs have also been 
differentiated on the basis of their constitutive – nNOS and eNOS, and inducible – 
iNOS expression; as well as on their calcium-dependence – eNOS and nNOS, and -
independence – iNOS.  
Initially identified in 1989, eNOS was cloned in 1992 (Janssens et al., 1992, 
Marsden et al., 1992). eNOS is phosphorylated and dephosphorylated on a number 
of different sites, however, eNOS phosphorylation at Ser1177, and 
dephosphorylation at Thr495 are the two significant sites that primarily regulate the 
activity of eNOS (Dimmeler et al., 1999, Fleming et al., 2001). Additionally, eNOS 
phosphorylation at Ser116 and Ser617 is also reported to regulate the enzyme 
activity and functions (Bauer et al., 2003, Boo et al., 2003). Over-expression of 
eNOS reduces blood pressure and plays an important role in blood pressure 
regulation (Ohashi et al., 1998). Calmodulin (CaM) is another protein that interacts 
with eNOS (Bredt and Snyder, 1990), and is required for the activity of all three 
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different NOSs by increasing the rate of electron transfer from Nicotinamide 
Adenine Dinucleotide Phosphate-hydroxylase (NADPH) to the reductase domain.  
In 1987, Palmer and colleagues demonstrated the release of NO from the 
vascular endothelium for the very first time (Palmer et al., 1987) and characterised 
L-arginine as a substrate molecule for NO synthesis (Palmer et al., 1988). Initially, 
NO was characterised as a Endothelium-Derived Relaxing Factor (EDRF) by 
Furchgott and Zawadzki (Furchgott and Zawadzki, 1980). NO generated by the 
vascular endothelium is a major regulator of vascular homeostasis, and altered NO 
levels are implicated in the development of a number of diseases of the vascular 
system. NO also acts as an inhibitor of platelet aggregation and retains the anti-
thrombotic properties of endothelium (Radomski et al., 1987). NO modulates 
leukocyte adhesion to the vascular wall and is also implicated in the down-regulation 
of expression of CAMs such as P-selectin (Davenpeck et al., 1994), E-selectin (De 
Caterina et al., 1995), VCAM-1 (Khan et al., 1996) and ICAM-1 (Biffl et al., 1996). 
NO is also suggested to play an important role in maintaining vascular integrity, as 
the absence of eNOS enzyme, which is implicated in NO production, results in 
increased fluid and protein flux (Kubes, 1995). NO increases vascular permeability 
by increasing VEGF protein expression, which then activates eNOS in a NO-
dependent manner (Feng et al., 1999). eNOS-derived NO is reported to be involved 
in EC angiogenesis (Jenkins et al., 1995, Kroll and Waltenberger, 1998, Ziche and 
Morbidelli, 2000), as well as in capillary tube organisation (Papapetropoulos et al., 
1997). VEGF, the most potent angiogenic factor increases the NO production via up-
regulating eNOS activity (van der Zee et al., 1997, Hood et al., 1998), which then 
mediates the migratory and proliferatory actions of VEGF (Papapetropoulos et al., 
1997, Pribylova et al., 1995). Shear stress of blood flow on the EC surface is the 
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most important activator of eNOS that results in the activation of a number of 
pathways; especially PI3K pathway which activates Akt1 at Ser473 phosphorylation 
site, which then phosphorylates eNOS at Ser1177 (Ayajiki et al., 1996, Go et al., 
1998, Dimmeler et al., 1999, Fulton et al., 1999), finally leading to NO production 
which is also known to promote angiogenesis (Liu et al., 2002). Angiogenesis 
induced via pathways independent of VEGF are also known to be modulated by 
angiogenic properties of NO (Ziche et al., 1994, Leibovich et al., 1994, Vodovotz et 
al., 1999).  
Caveolae and NO Production 
Caveolae are small cell-surface invagination of approximately 50 to 100nm 
(Yamada, 1955, Rothberg et al., 1992), and are characterised as ‘Ω-shaped’ 
structures in the cell membrane. Caveolin-1 is highly expressed in ECs and 
constitutes the largest amount in the caveolae (Lisanti et al., 1994). eNOS enzyme is 
reported to be localised in a caveolae, and interacts with caveolin-1 and caveolin-3 – 
the coat proteins of a caveolae – via a caveolin-binding motif in the eNOS (Garcia-
Cardena et al., 1996). In resting ECs, both caveolin-1 and caveolin-3 are reported to 
bind to eNOS, and this interaction inhibits the activity of eNOS enzyme, hence, 
interfering with NO production (Bucci et al., 2000). Caveolae are also known to 
increase vascular permeability, as VEGF treatments are reported to induce caveolae 
clustering, and results in the formation of vesiculovacuolar organelles (VVOc) 
(Vasile et al., 1999); whereas, prolonged VEGF treatments resulted in the formation 
of fenestrae (Chen et al., 2002). Caveolin-1 is also reported to inhibit the activity of 
eNOS which may further contribute to the regulation of vascular permeability. These 
findings suggest an important role for caveolin-1 in cell-to-cell interactions, and also 
with extracellular matrix and many other different proteins (Wary et al., 1998). 
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Calcium/Calmodulin binding to eNOS competitively disrupts the eNOS-caveolin-1 
binding, and dissociates eNOS from caveolin-1 protein, hence, increasing the 
activity of eNOS enzyme. Caveolin-1 also plays an important role in the process of 
angiogenesis; as caveolin-1 protein expression is reported to be down-regulated 
during EC proliferation, however, is markedly increased during EC differentiation 
and vessel formation (Liu et al., 2002).  
Heat Shock Protein 90 and NO Production 
Heat Shock Proteins (HSPs) are ubiquitously expressed proteins and are 
essential for maintaining cellular homeostasis, and are known to trigger various 
cellular responses after exposure to external stress stimuli. There are different classes 
of HSPs, however, HSP90 is the most important signalling HSP and is a key 
organiser of several cytoplasmic complexes. Five different isoforms of HSP90 have 
been identified, however, HSP90α and HSP90β are the major cytosolic isoforms. 
Both HSP90 isoforms share approximately 85% sequence homology, contain an 
ATP-binding domain in NH2-terminal region, a dimerised COOH-terminal, and a 
highly charged mid-domain which encourages substrate-protein interactions (Hainzl 
et al., 2009, Csermely et al., 1998). Both these isoforms are known to regulate eNOS 
enzyme activity, NO and superoxide production (Cortes-Gonzalez et al.).  
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1.2 Chemerin, a Novel Adipochemokine 
1.2.1 Discovery of Chemerin 
Chemerin was initially identified as a product encoded by Tazarotene-induced 
Gene (TIG)-2 in psoriatic skin lesions. TIG-2, also known as Retinoic Acid Receptor 
Responder 2 (RARRES2), is a cDNA product of 830 base pairs and encodes 164 
amino acids long protein (Nagpal et al., 1997). Later in 2003, Meder and colleagues 
defined TIG-2 as a natural ligand to a previously known orphan G Protein-Coupled 
Receptor (GPCR), known as Chemokine-like Receptor 1 (CMKLR1) (previously 
denoted as ChemerinR and ChemR23) (Samson et al., 1998, Meder et al., 2003). In 
the same year, Wittamer and colleagues characterised chemerin as a natural ligand to 
CMKLR1 receptor (Wittamer et al., 2003). Throughout this thesis text, human 
chemerin receptor is represented as CMKLR1. 
1.2.2 Chemerin Synthesis and Structure 
1.2.2a Chemerin synthesis 
 
Chemerin is translated as a 163 amino acid long pre-proprotein, called pre-
prochemerin. Following the removal of 20 amino acid long NH2-terminal signal 
sequence, pre-prochemerin gets secreted as a 143 amino acid long peptide, and is 
named as prochemerin (Wittamer et al., 2003, Meder et al., 2003). Prochemerin is of 
low biological activity and undergoes extracellular COOH-terminal processing by a 
number of serine and cysteine proteases of the inflammatory, coagulation and 
fibrinolytic cascades - plasmin and carboxypeptidases are also reported to convert 
inactive chemerin peptides into active chemerin fragments (Wittamer et al., 2003, 
Zabel et al., 2005a, Meder et al., 2003, Zabel et al., 2008, Zabel et al., 2006a, Zabel 
et al., 2005b). Chemerin circulates at the normal physiological concentration of 3nM 
in humans and 4nM in mice.  
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1.2.2b Chemerin structure 
Unlike other chemokines, chemerin has a disordered NH2-terminus, three β-
pleated sheets, and a COOH-terminal α-helix (Zabel et al., 2006b). However, both 
NH2-terminal domain and COOH-terminal peptide possess chemotactic properties 
involving GPCR binding and activation (Das et al., 2000). Prochemerin shares 
structural similarities with cathelicidins, cystatins and other related proteins such as 
kininogen (a bradykinin precursor). Similar to chemerin, these proteins are also 
synthesised as pro-proteins, and undergo COOH-terminal cleavage to generate 
bioactive peptides (Kolligs et al., 2000). Secreted prochemerin protein is of low 
biological activity and shows poor CMKLR1 receptor binding and activation. 
Prochemerin is further cleaved at the COOH-terminal end which results in the 
formation of a number of active and inactive chemerin fragments with different 
affinities for CMKLR1 receptor. 
1.2.3 Proteolytic Processing of Chemerin and Chemerin-derived Peptides 
1.2.3a Proteolytic processing of chemerin 
A number of different serine proteases and enzymes of inflammatory and 
coagulation cascades are reported to be involved in the proteolytic processing of 
prochemerin at the COOH-terminal end. Serine protease, cathepsin G converts 
prochemerin (21-163)  into chemerin (21-156) after the removal of seven amino acid 
residues from the COOH-terminal end. Elastases remove six, eight or eleven amino 
acids from the precursor molecule, prochemerin, resulting in the formation of 
chemerin (21-157), (21-155) and (21-152) respectively. Plasmin-mediated cleavage 
forms chemerin (21-158), and  tryptase cleaves native prochemerin into two different 
chemerin fragments; chemerin (21-158) and chemerin (21-155). These chemerin 
fragments further act as substrates to a number of different enzymes; for example, 
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inactive chemerin (21-158)  further undergoes second cleavage by carboxypeptidases 
N and B (CPN and CPB) resulting in the formation of chemerin (21-157), the most 
active chemerin fragment (Du et al., 2009). In addition, neutrophil-derived enzymes, 
proteinase 3 and mast cell chymases (Guillabert et al., 2008), – and Angiotensin-
Converting Enzyme (ACE) (John et al., 2007) also convert various different active or 
inactive chemerin fragments into shorter, less active or inactive chemerin fragments 
such as (21-155), chemerin (21-154) and chemerin (21-155) respectively (Fig. 
1.2.3a.1, page number 16). Urokinase Plasminogen Activator (uPA) and tissue 
Plasminogen Activator (tPA), which are known to convert inactive plasminogen into 
plasmin, are also reported to convert inactive prochemerin into active chemerin 
fragments (Du et al., 2009). These different chemerin fragments circulate in the 
blood, and chemerin fragments isolated from a number of different body fluids and 
tissues are of different lengths compared to its precursor prochemerin; for example, 
chemerin purified from hemofiltrate lacks nine amino acids in the COOH-terminal 
region, and serum-derived chemerin lacks only eight amino acid residues (Zabel et 
al., 2005a, Guillabert et al., 2008). Chemerin isolated from ovarian cancer ascitic 
fluid lacks only six amino acids from COOH-terminal end (Wittamer et al., 2003). 
Chemerin lacking six COOH-terminal amino acids, chemerin (21-157), is the most 
abundant and active chemerin fragment present in the bloodstream. 
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Figure 1.2.3a.1a Proteolytic processing of prochemerin into different chemerin  
fragments 
This figure shows the proteolytic processing of pre-prochemerin (1-163) into mature 
prochemerin (21-163) after the removal of N-terminal signal peptide. Cathepsin G 
removes seven amino acids from C-terminal end, resulting in the formation of 
chemerin (21-156); elastase forming chemerin (21-157) after the removal of six 
amino acids, chemerin (21-155) after removing eight amino acids, and chemerin (21-
152) after the removal of eleven amino acids. Plasmin removes five amino acids and 
forms chemerin (21-158), and tryptase cleaves five and eight amino acids resulting 
in the formation of chemerin (21-158) and chemerin (21-155) respectively. 
Prochemerin undergoes multiple cleavages, such as trypsate cleavage forming less 
active chemerin (21-158) which then undergoes further cleavage by CPN or CPB 
resulting in chemerin (21-157) formation. Active chemerin (21-156) and chemerin 
(21-157) peptides are prone to undergo further cleavages resulting in the formation 
of inactive chemerin fragments. Solid arrows represent activation pathways; broken 
arrows represent inactivation pathways. Adapted from (Kukkonen et al., 1996a). 
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1.2.3b Chemerin-derived peptides and their functions 
Chemerin (21-157) and chemerin (21-156) are potent chemoattractants in 
comparison to their precursor protein, prochemerin (Zabel et al., 2005a, Wittamer et 
al., 2005), however, chemerin (21-157) is the most active and abundant form of 
biologically active chemerin. Chemerin (21-158), which is formed by plasmin and 
trypsate-mediated cleavage, is of low biological activity and undergoes further 
cleavage by CPN and CPB resulting in the formation of most active chemerin (21-
157) peptide (Du et al., 2009). Active chemerin fragments are further cleaved into 
less active or inactive chemerin fragments; Chemerin (21-155) is a less active 
peptide, whereas, chemerin (21-154) is an inactive fragment (Guillabert et al., 2008), 
and biological activity of chemerin (21-152) remains unknown. Wittamer and 
colleagues (2004) found that the chemerin peptides obtained after the removal of 
amino acids from the NH2-terminus region show very poor CMKLR1 binding 
affinity, in comparison to other shorter chemerin fragments derived from COOH-
terminal end. Chemerin (149-157) [Y
149
FPGQFAFS
157
] is the shortest COOH-
terminal-derived nine amino acid long fragment, termed as a Nona-peptide or a 
nonamer, and is reported to retain most of the activity of full length active chemerin 
(21-157) fragment (Wittamer et al., 2004). In addition, mouse nonamer or a Nona-
peptide [L
148
FPGQFAFS
156
] is also reported to show similar properties (Luangsay et 
al., 2009). Cash and colleagues (2008) described that mouse chemerin-derived 
chemerin-15 peptide [A
140
GEDPHGYFLPGQFA
154
] possess anti-inflammatory 
properties in vitro as well as in mouse models of peritonitis (Cash et al., 2008). 
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1.2.4 Chemerin Expression  
Chemerin is primarily expressed in a number of tissues including liver, white 
adipose tissue, lungs, pituitary gland; and in lower levels in skin, adrenal glands, 
pancreas and kidneys (Wittamer et al., 2003). Prochemerin mRNA transcripts are 
also present in various epithelial cells (Luangsay et al., 2009), ECs (Du et al., 2009, 
Kaur et al., 2010), fibroblasts (Vermi et al., 2005), chondrocytes and platelets 
(Aksela et al., 1996a). Under normal physiological conditions, inactive prochemerin 
circulates at a relatively higher concentrations in plasma compared to serum 
concentrations. Adipose tissue (Kukkonen et al., 1996a) and liver (Eriksson et al., 
1996) are reported to be the major sources of prochemerin secretion in the body. Du 
et al. (2009) reported that chemerin is also stored in platelet granules and is released 
upon platelet activation by different platelet activating factors (Du et al., 2009). 
1.2.5 Functions of Chemerin 
 
Chemerin is reported to play a number of different functions in the body and is 
mainly implicated in adipogenesis and adipocyte metabolism (Roh et al., 2007, 
Goralski et al., 2007), known to exhibit pro- and anti-inflammatory properties, and in 
angiogenesis (Bozaoglu et al., 2010). 
1.2.5a Chemerin in adipogenesis and adipocyte metabolism  
Both chemerin and its natural receptor, CMKLR1 are expressed in adipocytes, 
however, CMKLR1 is also highly expressed in stromal vascular cells. Adipose tissue 
acts as a major source of chemerin secretion (Goralski et al., 2007, Bozaoglu et al., 
2007, Roh et al., 2007). In 2007, Bozaoglu and colleagues reported for the first time 
that chemerin expression was higher in Psammomys obesus, which is an animal 
model of obesity and type 2 diabetes (T2D), compared with normoglycemic lean 
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model. In 3T3L1 adipocytes, chemerin expression is reported to increase during 
differentiation into mature adipocytes; whereas, in comparison, CMKLR1 expression 
down-regulates. Both chemerin and CMKLR1 receptor knockdown is reported to 
rresult in malfunctioning of normal mature adipocytes due to alteration in the 
expression levels of specific genes that help in maintaining glucose and lipid 
homeostasis. Muruganandan and colleagues (2011) showed that during Bone 
marrow Mesenchymal Stem Cell (BMSC) differentiation into adipocytes, chemerin 
expression levels increase and positively correlate with Peroxisome Proliferator-
Activated Receptor (PPAR)–γ, which is the most important regulator of adipogenesis 
(Eriksson et al., 1996). Inflammatory cytokines such as TNF-α and IL-1β are 
reported to increase chemerin synthesis and secretion in 3T3-L1 adipocytes, human 
primary adipocytes, and in mouse adipocytes in vivo (Uibo et al., 1996) via acting 
through pathways involving the activation of NF-κB pathway, and by 
phosphorylating Extracellular signal-regulated Kinase (ERK) 1/2 (Kukkonen et al., 
1996d). Chemerin expression in adipocytes was also reported to be induced by Free 
Fatty Acids (FFAs), through the activation of transcription factor Sterol Regulatory 
Element-Binding Proteins 2 (SREBP2) (Joukov et al., 1996). In obese states, 
circulating chemerin levels positively correlate with Body-Mass-Index (BMI), 
Waste-to-Hip (WHR) ratio, glucose levels, hypertension and circulating triglycerides 
(Bozaoglu et al., 2007), which all are well-documented risk factors associated with 
development of insulin resistance as a result of abnormal glucose uptake in muscles, 
and storage in adipose tissue; ultimately resulting in the pathogenesis of 
Cardiovascular Diseases (CVDs) such as, Atherosclerosis Cardiovascular Diseases 
(ASCVD) (Fig. 1.2.5a, page number  21). 
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1.2.5b Pro- and/or anti-inflammatory chemerin behaviour 
As CMKLR1 is selectively present on the cells of the immune system, 
chemerin binding to CMKLR1 stimulates the receptor and promotes chemotaxis of 
all leukocyte cell populations expressing CMKLR1 receptor (Wittamer et al., 2004, 
Luangsay et al., 2009, Vermi et al., 2005, Aksela et al., 1996a). Recently, Hart and 
Greaves (2010) reported that chemerin promotes macrophage adhesion to the 
extracellular matrix protein fibronectin, and VCAM-1 as well as encourages the 
clustering of Very Late Antigen (VLA)-4 and -5 integrins (Hart and Greaves, 2010).  
1.2.5c Chemerin in EC angiogenesis  
Chemerin promotes EC angiogenesis by mediating EC migration, proliferation 
and capillary tube formation in Human Microvascular Endothelial Cell (HMEC)-1 
line. Chemerin increased the activity of matrix degrading enzymes, such as Matrix 
Metalloproteinases (MMP)-2 and -9, thereby, promoting angiogenesis (Kaur et al., 
2010, Bozaoglu et al., 2010).  
 
 
 
 
 
 
 
 
  21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
.2
.5
a
  
R
el
a
ti
o
n
sh
ip
 o
f 
ch
em
er
in
 w
it
h
 v
a
ri
o
u
s 
m
et
a
b
o
li
c 
ri
sk
 f
a
c
to
rs
 a
n
d
 i
m
p
li
ca
ti
o
n
s 
fo
r 
th
e 
ca
rd
io
m
et
a
b
o
li
c 
 s
y
n
d
ro
m
e 
T
h
is
 f
ig
u
re
 s
h
o
w
s 
th
at
 w
it
h
 i
n
cr
ea
se
d
 a
d
ip
o
si
ty
, 
ch
em
er
in
 s
ec
re
ti
o
n
 i
s 
in
cr
ea
se
d
 a
n
d
 p
o
si
ti
v
el
y
 c
o
rr
el
at
es
 w
it
h
 b
o
d
y
-m
as
s-
in
d
ex
, 
W
as
te
-t
o
-h
ip
 
ra
ti
o
, 
lo
w
 H
D
L
-C
, 
h
ig
h
 L
D
L
-C
 a
n
d
 i
n
cr
ea
se
d
 b
lo
o
d
 p
re
ss
u
re
. 
C
h
em
er
in
 s
ec
re
ti
o
n
 p
o
si
ti
v
el
y
 a
ff
ec
ts
 t
h
e 
in
fl
am
m
at
o
ry
 p
ro
te
in
, 
C
R
P
 i
n
 t
h
e 
b
lo
o
d
st
re
am
 w
h
ic
h
 i
s 
an
 a
cu
te
 i
n
fl
am
m
at
o
ry
 p
ro
te
in
 a
n
d
 i
s 
u
se
d
 a
s 
a 
h
al
lm
ar
k
 o
f 
in
fl
am
m
at
o
ry
 d
is
ea
se
. 
C
h
em
er
in
 r
es
u
lt
s 
in
 i
n
su
li
n
 r
es
is
ta
n
ce
 
w
h
ic
h
 t
h
en
 i
n
h
ib
it
s 
g
lu
co
se
 u
p
ta
k
e 
in
 m
u
sc
le
 t
is
su
es
 r
es
u
lt
in
g
 i
n
 i
n
cr
ea
se
d
 c
ir
cu
la
ti
n
g
 g
lu
co
se
 l
ev
el
s 
an
d
 t
h
e 
d
ev
el
o
p
m
en
t 
o
f 
A
S
C
V
D
s.
 
  22 
1.3 Chemerin Receptors 
1.3.1 Chemokine-like Receptor 1, a Natural GPCR Chemerin Receptor 
Chemerin binds to its natural GTP Protein-Coupled Receptor (GPCR) known 
as Chemokine-like Receptor 1 (CMKLR1) (previously denoted as chemerinR and 
ChemR23 in humans) (Samson et al., 1998, Wittamer et al., 2003). Chemerin 
receptor is presented as CMKLR1 throughout the text of this thesis. 
1.3.1a Cloning of CMKLR1 gene and structure 
 
In 1996, the human CMKLR1 gene was first cloned using Polymerase Chain 
Reaction (PCR) with degenerate oligonucleotides based on conserved region in the 
third and sixth transmembrane domain of the 7-transmembrane (7-TM) G protein 
linked somatostatin receptor subtypes 1-4 (Gantz et al., 1996). This gene encoded a 
putative 371 amino acid 7-TM receptor, and was found to share 40% nucleotide 
sequence similarity to somatostatin receptors 1-4. Later in 1998, Samson and 
colleagues cloned an identical gene known as ChemR23 (Samson et al., 1998), that 
is now denoted as CMKLR1, and is located on human chromosome 12q.24.1 
(Murphy et al., 2000). Structurally, CMKLR1 is more closely related to 
chemoattractant receptors such as anaphylatoxin C3a and C5a receptors rather than 
to the members of other chemokine receptors such as CC- or CXC- (Samson et al., 
1998). The murine orthologue of the human CMKLR1 (mCMKLR1) gene, known as 
DEZ, and is reported to share 80.3% sequence homology with CMKLR1 (Methner et 
al., 1997). 
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1.3.1b CMKLR1 receptor expression and functions 
CMKLR1 is expressed in haemopoitic tissues such as thymus, bone marrow, 
spleen, fetal liver and lymphoid organs, and in lower levels in a number of other 
body tissues (Wittamer et al., 2003). Wittamer and colleagues reported that 
CMKLR1 is also present in blood monocytes, monocyte-derived human 
macrophages and immature Dendritic Cells (iDCs), and in low levels in un-
stimulated CD4
+
 T lymphocytes and Polymorphonuclear (PMN) cells (Wittamer et 
al., 2003, Arita et al., 2007), and in ECs (Kaur et al., 2010). As CMKLR1 is 
primarily expressed on the cells of the immune system, upon chemerin binding, 
CMKLR1 directs the migration of dendritic cells to the lymphoid organs and 
inflamed tissues (Vermi et al., 2005). Additionally, Resolvin E1 (RvE1), an 
eicosapentaenoic acid-derived lipid is also known to bind CMKLR1 and exerts anti-
inflammatory effects (Arita et al., 2007). CMKLR1 also acts as a co-receptor for 
immunodeficiency viruses including Simian Immunodeficiency Virus (SIV) 
(Samson et al., 1998) and Human Immunodeficiency Virus (HIV)-1 (Martensson et 
al., 2006). 
1.3.2 G-Protein Receptor 1  
G-Protein Receptor 1 (GPR1) is another GPCR receptor to which chemerin 
binds with an affinity similar to that of CMKLR1, however, showing relatively poor 
intracellular cell signalling in G protein-mediated pathways (Fig. 1.3.1a, page 
number 26). Barnea and colleagues (2008) identified chemerin as a ligand to GPR1 
while developing an assay to identify ligands for orphan receptor GPR1. Upon 
chemerin binding, GPR1 internalises weakly compared to CMKLR1, and shows 
weak calcium mobilisation and ERK1/2 MAPK activity in cell lines expressing 
GPR1. GPR1 is characterised as a decoy receptor for chemerin, and chemerin-
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induced functional responses are still unknown. GPR1 is expressed in the central 
nervous system, adipose tissue and in the skeletal muscles (Barnea et al., 2008). 
1.3.3 Chemokine (C-C motif) Receptor-like 2 
In 2008, Zabel and colleagues identified Chemokine (C-C motif) Receptor-like 
2 (CCRL2) as another orphan GPCR to which chemerin binds (Zabel et al., 2008). 
Human CCRL2 was first cloned and identified in Polymorphonuclear (PMN) cDNA 
library in 1998 (Qunibi et al., 2004), and is located on 3p21 chromosome alongwith 
other chemokine receptors (Meyer, 2004b). Human CCRL2 is also denoted as 
CKRX, HCR or CRAM and is represented as L-CCR in mice. CCRL2 is a functional 
chemokine receptor and shares 40% sequence homology with other chemokine 
receptors; CCR1, CCR2, CCR3 and CCR5. Human CCRL2 is expressed in majority 
of human hematopoietic cells including monocytes, macrophages, DCs, neutrophils, 
T cells, natural killer cells, mast cells and CD34
+
 bone marrow precursors 
(Kukkonen et al., 1996b, Herlidou et al., 2004, Meyer, 2004b, Meyer et al., 2004). 
Well-known inflammation mediating agents including Lipopolysaccaride (LPS) and 
TNF-α are reported to increase CCRL2 receptor expression (Meyer, 2004b, Meyer, 
2004a). CCRL2 binds to a number of chemokines including CCL2, CCL5, CCL7 
and CCL8 (Enkvist et al., 1996) and CCL19 (Kukkonen et al., 1996c). CCRL2 is 
also activated by agonists such as MCP-1, -2 and -3, RANTES, and by ‘joint fluid’ 
taken from rheumatoid arthritis patients (Meyer et al., 2004, Meyer, 2004c, Sakurai 
et al., 2005). Comparatively, chemerin NH2-terminal binds CCRL2 receptor instead 
of COOH-terminal, and is reported not to mediate any intracellular signalling 
pathways. The CCRL2 receptor only acts as a sponge or decoy receptor (Cash et al., 
2008), facilitating the presentation and also increasing the COOH-terminal chemerin 
availability to the other neighbouring cells expressing CMKLR1 (Zabel et al., 2008) 
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(Fig. 1.3.1a, page number 26). CCRL2 receptor lacks –DRY– motif, a motif 
involved in GPCR coupling, at the cytosolic end of transmembrane segment 3. In 
2010, Otero and colleagues showed that CCRL2 knockout mice were protected 
against ovalbumin-induced airway inflammation, and showed normal recruitment of 
circulating DCs to the lungs, however, defective trafficking of antigen-loaded lung 
DCs to mediastinal lymph nodes (Kukk et al., 1996a). It is still unclear whether this 
defective DC function is due to CCRL2 acting as a silent receptor; or more 
interestingly, due to NH2-terminal chemerin binding to CCRL2, and presenting 
COOH-terminal to nearby cells (Fig. 1.3.1a, page number 26), thereby, increasing 
the local availability of bioactive chemerin to functional chemerin receptor, 
CMKLR1. 
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Figure 1.3.1a Chemerin binding to its receptor; CMKLR1, GPR1 and CCRL2 
This figure shows chemerin binding to its natural receptor, CMKLR1, as well as to 
other two orphan GPCR receptors, GPR1 and CCRL2; and the events triggered upon 
ligand binding. Chemerin binding to CMKLR1 results in strong signalling and 
internalisation, resulting in final functional outcome; whereas, chemerin binding to 
GPR1 causes receptor internalisation, however, functions are poorly understood. N-
terminal chemerin binds CCRL2 receptor, which acts as decoy receptor and presents 
C-terminal chemerin to neighbouring functional receptors. Adapted from (Wong et 
al., 2011). 
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1.4 G Protein-Coupled Receptors  
1.4.1 G Protein Coupled Receptors and G Proteins 
1.4.1a G protein-coupled receptors and families 
 
The G Protein-coupled Receptors (GPCRs) family is the largest family of 
proteins in the human genome (Ponticos et al., 1998). There are 720-800 human 
GPCRs accounting for 2% of human genome (Fredriksson et al., 2003). These 
receptor genes are further classified into three main families on the basis of sequence 
similarities – as A, B and C or 1, 2 and 3 respectively (Garthwaite et al., 1989). 
GPCR family A is the largest group, and consists of rhodopsin-like receptors and 
contains the opsins, olfactory GPCRs, small molecule/peptide hormone, and 
glycoprotein hormone GPCRs. The ligand binding site for class A GPCRs is located 
within the 7-TM bundle. Family B is a relatively small GPCRs containing family 
and comprises of ~25 GPCRs for gastrointestinal peptide hormones (e.g., secretin), 
corticotrophin-releasing hormone, calcitonin and parathyroid hormone. Family C has 
17 GPCRs for mGluR, the γ-aminobutyric acid type B (GABAB), calcium-sensing 
receptors (CaR) as well as some taste receptors (Pierce et al., 2002). An additional 
Frizzled-Smoothened (F/S) receptor-like class contains 11 GPCRs. The GPCRs with 
specific ligands are classified as natural GPCRs, and receptors with no ligands are 
known as orphan  receptors. GPCRs are complex receptors and are 
compartmentalised into three different components; (1)  a 7-TM receptor loop with 
an extracellular ligand-binding NH2-terminal and an intracellular functional COOH-
terminal, (2) a heterotrimeric G proteins including alpha (α), beta (β) and gamma (γ)-
subunits, and (3) an effector. Upon ligand binding, activated receptor interacts with  
heterotrimeric G proteins, and activates a number of different downstream signalling 
cascades (Fig. 1.4.1a, page number 29).  
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1.4.1b G Proteins, receptor activation and effectors 
 
The heterotrimeric G proteins consist of an α-subunit and a βγ-complex. The α-
subunit is divided into four major different classes that include Gαs (stimulatory), 
Gαi/o (inhibitory),  Gαq/11 and Gα12/13, which are further sub-divided into three, eight, 
four and two subtypes respectively. The β-subunit has five different subtypes, and γ-
subunit has twelve different subtypes (Rees et al., 1989). In the absence of an 
external stimuli, GDP-bound α-subunit and the βγ-complex are associated together. 
Upon receptor activation, the heterotrimeric G protein complex undergoes an 
activation-inactivation cycle and involves: (1) exchange of GDP for GTP on the G 
protein α-subunit, (2) dissociation of GTP-bound α-subunit from the receptor as well 
as from the βγ-complex which both separately modulate the activity of a number of 
different enzymes and effectors within the cell and finally, (3) the hydrolysis of GTP 
by the GTPase enzyme which results in the formation of GDP-bound α-subunit that 
re-associates with the βγ-complex making receptor inactive (Palmer and Moncada, 
1989). In general, G proteins are referred by their α-subunits; Gs heterotrimeric 
complex contains Gαs, Gq for Gαq, and Gi contains Gαi. Gαs is stimulatory α-
subunit that stimulates effector adenylase cyclase (AC), Gαi inhibits the stimulation 
of AC, and Gαq complex results in the activation of phospholipase C (Pierce et al., 
2002). Prolonged GPCR stimulation results in receptor de-sensitisation or down-
regulation leading to decreased G protein activity and intracellular signalling 
(Houvenaeghel et al., 2006) (Fig. 1.4.1a, page number 29). 
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1.5 Mitogen-Activated Protein Kinases  
Mammalian Mitogen-Activated Protein Kinases (MAPKs) are activated by a 
number of stimuli including hormones (insulin), growth factors [Platelet Derived 
Growth Factor (PDGF) and Epidermal Growth Factors (EGF)], and inflammatory 
cytokines (TNF)-α, and various other environmental stresses such as osmotic shock, 
radiations and ischaemic injury. These stimuli bind to a number of different 
receptors expressed on the cell membranes and activate different MAPKs which 
further co-ordinate diverse cellular activities like mRNA expression, cell cycle 
machinery, cell metabolism, motility, survival, apoptosis and differentiation. There 
are six different distinct groups of mammalian MAPKs: Extracellular Regulated 
Kinases (ERK1/2), Jun NH2-terminal Kinases (JNK1/2/3), p38 (α/β/γ/δ), ERK7/8, 
ERK3/4 and ERK5. Each MAPK is a member of separate module and is regulated 
by a wide variety of external stimuli. In general, the ‘core signalling module’ 
consists of three sequentially acting kinases that include (1) MAPK, (2) MAPK 
kinase (MAPKK), and (3) MAPK Kinase Kinase (MAPKKK) (Fig. 1.5.1a, page 
number 35). The MAPKKKs, also known as MAP3Ks or MEKKs, are Serine 
(Ser)/Threonine (Thr) kinases that are activated via phosphorylation, and/or their 
interaction with G proteins of Ras/Rho family in response to external stimuli. 
Activation of MAP3Ks further results in the activation of MAPKK by 
phosphorylating Serine (Ser)/ threonine (Thr) residues, causing Thr/Tyrosine (Tyr) 
phosphorylation of MAPKs which further have transcription factors as their primary 
substrates and regulate the activity of a number of different genes and proteins, 
ultimately determining the biological response. 7-TM or GPCR are known to 
activate each of the different families of MAPKs via both Gα- and βγ-dependent 
mechanisms resulting in the phosphorylation of different MAPK via activation of a 
particular receptor (Fig. 1.5.1a, page number 35). 
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1.5.1 Extracellular Regulated Kinases 1/2 MAPKs 
 
Extracellular Regulated Kinases 1/2 (ERK1/2) MAPKs are the most widely 
studied mammalian MAPKs and are activated by a number of extracellular and 
intracellular stimuli including GPCR ligands, cytokines, osmotic stress, and various 
different growth factors (Fig. 1.5.1a, page number 35) (Lewis et al., 1998). Both 
these ERK1 and ERK2 MAPKs isoforms share 83% sequence homology and are 
expressed in varying levels in different tissues. ERK1/2 MAPKs activation or 
signalling is initiated by cell membrane Receptor Tyrosine Kinases (RTKs) or 
GPCRs (Goldsmith and Dhanasekaran, 2007). ERK1/2 MAPKs play crucial role in 
cell proliferation by controlling both cell growth, and cell cycle progression and 
require persistent ERK1/2 activation (Aksela et al., 1996b). In addition to cell 
proliferation, ERK1/2 MAPKs are also known to play an important role in 
angiogenesis, cell migration, invasion and metastasis (Vapalahti et al., 1996), as well 
as in mesoderm formation (Yao et al., 2003). Interestingly, Bhat and colleagues 
reported that although ERK1/2 MAPKs play important role in cell survival, however, 
they are also known to induce cell death (Bhat and Zhang, 1999). A number of 
studies showed that ERK2 and MEK1 isoforms are essential for embryonic 
development compared to that of ERK1 and MEK2; as mice lacking ERK2 or 
MEK1 isoforms showed defective placenta development, whereas, ERK1- or 
MEK2-deficient mice showed normal growth (Giroux et al., 1999, Belanger et al., 
2003). 
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1.5.2 Extracellular Regulated Kinase 5 MAPK 
 
Extracellular Regulated Kinase 5 (ERK5), also known as Big MAP Kinase-1 
(BMK1) is a stress-activated MAPK, and was identified as a 90kDa MAPK. ERK5 
MAPK is activated by a number of external stimuli such as oxidants, osmotic stress, 
and inflammatory cytokines (Abe et al., 1996) (Fig. 1.5.1a, page number 35). Similar 
to that of ERK1/2 MAPK, ERK5 MAPK is implicated in the regulation of cell 
proliferation (Kato et al., 1998). A decade ago, ERK5 MAPK has was reported to 
play an important role in cardiovascular development, and mice lacking ERK5 
MAPK died due to lack of angiogenesis in the embryonic and extra-embryonic 
tissues (Sohn et al., 2002). Endothelial-specific ERK5 knockout  mice are reported to 
show cardiovascular defects (Hayashi et al., 2004), however, no defects were seen in 
cardiomyocyte-specific ERK5 knockout model; suggesting that ERK5 is one of the 
important MAPK in ECs (Hayashi and Lee, 2004). 
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1.5.3 p38 MAPKs 
 
p38 MAPKs constitute a second stress-activated MAPK group and were first 
isolated as a 38kDa protein. There are four different splice variants of the p38 family 
including p38α, p38β (Jiang et al., 1996), p38γ (Li et al., 1996) and p38δ (Jiang et al., 
1997); and among these p38α is the most extensively studied MAPK. p38 MAPKs 
are activated by different external stress stimuli, inflammatory cytokines and various 
different growth factors such as interleukins, insulin-like analogues, and fibroblast 
growth factors (Freshney et al., 1994)  (Fig. 1.5.1, page number 35). A number of 
GPCR agonists such as TGF-β are also documented to activate p38 MAPKs and are 
known to mediate cellular functions such as chemotaxis, adherence, immune 
responses, and especially the role of p38 MAPKs in apoptosis is widely studied 
(Dong et al., 2002, Merritt et al., 2000). Upon activation, p38 MAPKs phosphorylate 
several different cellular targets, for example transcription factors and other proteins 
such as phospholipase A2 and microtubule-associated protein Tau. The p38 MAPKs 
are implicated in various different biological responses such as cell cycle arrest 
(Takenaka et al., 1998), apoptosis and cancers (Olson and Hallahan, 2004, Bradham 
and McClay, 2006), abnormal embryo development and differentiation (Allen et al., 
2000) and angiogenesis (Mudgett et al., 2000). The p38 MAPKs are known to play 
critical role in immune functions including production of inflammatory cytokines 
such as IL-1β, TNF-α and IL-6, induction of iNOS, and other adhesion molecules 
including VCAM-1(Pietersma et al., 1997). 
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1.5.4  Stress-Activated Protein Kinase/Jun-amino-terminal Kinase  
 
The Stress-Activated Protein Kinase/Jun-amino-terminal Kinases 
(SAPK/JNKs) are a group of MAPKs that are activated by exposure of cells to 
environmental stresses such as radiations, growth factors, and inflammatory 
cytokines (Semenzato et al., 2012, Hattori et al., 2011) (Fig. 1.5.1, page number 35). 
JNKs consist of 10 isoforms coded by three SAPK genes, SAPKα, - β and - γ (JNK-
2, -3 and -1, respectively): JNK1 (4 isoforms), JNK2 (4 isoforms), and JNK3 (2 
isoforms). SAPK/JNKs are implicated in a number of cellular functions such as cell 
proliferation and differentiation, cell apoptosis, and interestingly, also in cell 
protection (Zhang et al., 2012). JNKs are known to activate different substrates 
depending upon the type of stimuli involved and the ‘type’ of cells, hence showing 
different and opposite functional effects (Fogar et al., 2011, Rechel et al., 2011). 
SAPK/JNK/c-Jun interactions are also reported to play a central role in obesity 
related insulin resistance (Nittoh et al., 1997a) by interfering with insulin signalling 
which may serve as a possible link between Non-alcoholic Fatty Liver Disease 
(NAFLD) and Coronary Artery Disease (CAD) (Semenza, 2011).  
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Figure 1.5.1a The MAPK module signalling cascade 
A MAPKK Kinase Kinase (MAPKKK) is phosphorylated and, in turn 
phosphorylates a MAPK Kinase (MAPKK), which leads to the phosphorylation of a 
MAPK. The MAPKKKs, also known as MAP3Ks or MEKKs, are Serine 
(Ser)/Threonine (Thr) kinases that are activated via phosphorylation, and/or their 
interaction with G proteins of Ras/Rho family in response to external stimuli. 
Activation of MAP3Ks further results in the activation of MAPKK by 
phosphorylating Serine (Ser)/ threonine (Thr) residues, causing Thr/Tyrosine (Tyr) 
phosphorylation of MAPKs. An activated MAPK is then shuttled into the nucleus 
where it targets its specific substrates, such as transcription factors which ultimately 
lead to gene transcription and cell proliferation. Activation of ERK1/2 MAPK is 
important in cell proliferation, differentiation and development. p38 and JNK1/2/3 
MAPK are important in the processes of inflammation, apoptosis and development. 
ERK5 MAPK plays an important role in inflammation and angiogenesis. Adapted 
from (Krishna and Narang, 2008). 
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1.6 Akt/PKB Kinases 
 
Akt kinases are implicated in mediating a variety of essential cell functions 
such as cell proliferation, metabolism, transcription and the process of angiogenesis. 
Akt/PKB kinases are activated immediately upon ligand stimulation by various 
different growth factors and phosphorylate multiple substrates controlling various 
different short- and long-term cellular processes both at transcriptional and 
translational level (Baekkevold et al., 2001). There are three different Akt isoforms; 
Akt1 (de Winther et al., 2005), Akt2 (Ranu et al., 2000) and Akt3 (Hajra et al., 2000); 
Akt1 being the most predominant isoform of Akt in the ECs (Majumder et al., 2000). 
Akt is activated by phosphatidylinositol-3-phosphates (PIP3), the products of PI3K 
activity. Akt1 plays a prominent role in VEGF-induced responses, whereas the 
expression of Akt2 and Akt3 remains unchanged in Akt
-/- mice. Recently, activation 
of PI3K pathway has been widely established as the main signal transduction 
pathway employed by VEGFR2 to stimulate EC survival and proliferation. Various 
in vivo and ex vivo experiments have showed that activation of PI3K by VEGFR2 
receptor activation promotes EC survival, proliferation and angiogenesis, and 
manipulations of this pathway results in the inhibition of cell proliferation and  
angiogenesis (Semenza et al., 2001, Folkman, 1992, Ryan et al., 1992). It is also 
known that PI3K regulates angiogenesis by regulating expression of Tie-2 receptors 
(Folkman and Ingber, 1992).  
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1.7 5` Adenosine Monophosphate-activated Protein Kinase  
 
5` Adenosine Monophosphate-activated Protein Kinase (AMPK) is a 
heterotrimeric enzyme which is made up of an alpha (α), a catalytic unit; beta and 
gamma (β and γ) the two regulatory units. AMPK is known to play an important role 
as a metabolic sensor or ‘fuel gauge’ and is activated by change in the AMP/ATP 
ratio (Luo and Semenza, 2011). In ATP-deprived hypoxic conditions, AMPK 
regulates HIF-1α mRNA expression at transcription level which then induces VEGF 
mRNA expression under hypoxic condition, a key pro-angiogenic molecule 
(Hirasawa et al., 1997a). During AMPK phosphorylation, the AMPK γ-subunit 
undergoes conformational change, and exposes the Thr172 active site on the 
AMPKα subunit. AMPK activation in vivo improves blood glucose uptake, fatty acid 
and protein metabolism. In contrast, a very recent study published by Becker and 
colleagues (2010) reported that chemerin induced insulin resistance in mice skeletal 
muscles by reducing insulin-stimulated increase in Akt/PKB and AMPKα 
phosphorylation (Becker et al., 2010). Ernst et al (2010) found that acute 
recombinant chemerin administration in ob/ob and db/db mice resulted in glucose 
intolerance by lowering serum insulin levels, and showed no effect on glucose 
tolerance in wild-type mice fed on chow diet (Ernst and Sinal, 2010). Interestingly, 
chemerin significantly decreased liver glucose uptake in db/db mice in comparison 
to that of skeletal muscles (Kukkonen et al., 1996a). Also, Sell and colleagues 
demonstrated similar findings that chemerin impaired insulin signalling and glucose 
uptake in skeletal muscle cells in vitro (Sell et al., 2009). 
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1.8  Hypothesis  
Globally, obesity and associated abnormalities such as insulin resistance, type 
2 diabetes and related cardiovascular complications are increasingly becoming a 
major concern. Adipose tissue, in addition to storing fat, also acts as a major 
endocrine organ and secretes a number of hormones or molecules into the 
bloodstream which are collectively termed as ‘adipokines’ or ‘adipocytokines’. 
Altered secretion levels of these adipokines in obese states are implicated in a 
number of abnormalities such as inflammation, insulin resistance, type 2 diabetes 
and related cardiovascular complications. Chemerin is a newly identified 
adipocytokine, and adipose tissue acts as a major source of chemerin expression and 
secretion in the body. In obese states, circulating chemerin levels positively correlate 
with various facets of metabolic syndrome including insulin resistance, type 2 
diabetes, hypertension and circulating triglycerides – these states are associated with 
EC injury, which is an initial hallmark of EC inflammation, disease initiation and 
progression such as atherosclerosis. In obesity related diseased states, endothelial 
cell injury and endothelial dysfunction is the initial trigger for the development of 
diseases of the cardiovascular system – and  as previously mentioned – ED is defined 
as the failure of ECs to respond to increased blood flow by releasing excessive 
amounts of endothelium Nitric Oxide (NO) and causing local vasodilation. Chemerin 
circulating levels positively correlate with hypertension and NO plays an important 
role as a vasodilator, hence we hypothesised that chemerin interferes with the 
activity of eNOS enzyme – the endothelial specific enzyme which regulates the 
production of NO in the vascular endothelium, finally resulting in disturbed NO 
production, hence, leading to abnormal vessel wall functions such as increased cell 
adhesion molecules, dysregulated angiogenesis and promoting inflammation. 
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Chemerin, most commonly known for its cytokine like functions and is heavily 
implicated in the process of inflammation. Altered adhesion molecules expression 
and impaired NO production in the endothelium are well documented promoters of 
angiogenesis; hence, we also sought to elucidate the role of chemerin (21-157) in 
endothelial cell migration, proliferation and capillary tube formation. 
Therefore, in nutshell, we tested the hypothesis that whether chemerin (21-157): 
o down-regulates the activity of eNOS enzyme, resulting in  
o decreased NO production, causing 
o increased endothelial cell adhesion molecule expression, and finally 
promoting 
o endothelial cell angiogenesis, based on the initial presumption that CMKLR1 
receptor is expressed in the endothelial cells. 
Hereby, the specific aims of this project were to study the role of human 
recombinant chemerin (21-157) in EC functioning with specific aims to explore the 
role (s) of chemerin (21-157) in; (1) EC angiogenesis in terms of EC proliferation, 
migration and capillary tube formation, (2) mediating inflammation in the 
vasculature by altering the levels of endothelium specific Cell Adhesion Molecules, 
Nuclear Factor – kappa (κ) B pathway and endothelial-monocyte cell adhesion, and 
finally (3) the endothelial-specific eNOS enzyme activity and the specific protein 
kinase signalling pathways involved in regulating the activity of this enzyme. 
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2.1 Materials  
o List of buffer solutions and cell media – appendix number 1.1, page number 233. 
o DNA and protein markers – appendix number 1.2, page number 234. 
o List of chemicals and reagents – appendix number 1.3, page numbers 235-6. 
o Inhibitors – appendix  number 1.4, page number 237. 
o Lab apparatus and glass- and plastic-ware – appendix  number 1.5, page number 
238. 
o Lab equipment – appendix number 1.6, page number 239. 
o Specialised Assay Kits – appendix number 1.7, page number 240. 
o Antibodies – appendix  number 1.8, page numbers 241-2. 
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2.2 Research Methods 
2.2.1 Tissue Culture Methods 
2.2.1a  Cell culture materials and growth conditions 
Tissue culture flasks (T25, T75 and 175cm
2
), multi-well plates (6, 12, 24 and 
96 wells) and petri dishes were purchased from BD Falcon™ glassware. High purity 
polystyrene coated tissue culture flasks with canted-neck were used, which provide a 
state suitable for the cell attachment to flask surface (Aubier et al., 2006). Cells were 
incubated in Sanyo CO2 incubator with optimal conditions comprising of 37
o
C 
temperature, 5% carbon dioxide (CO2) environment at 95% relative humidity. 
Humidity in the incubators prevents evaporation and condensation from the tissue 
culture flasks and plates. CO2  maintains the cultures at optimal pH (6.9-7.4) by 
favouring bicarbonate-CO2 buffering system. CO2 levels must be maintained as 
excessive CO2 proves to be toxic and may alter cell metabolism (Min et al., 1996). 
Temperature is another variable which must be kept constant at 37
o
C as minor 
fluctuations of one or two degrees on either side may cause slower cell growth when 
temperature falls, and cell death at high temperatures.  
2.2.1b   Primary Human Umbilical Vein endothelial Cells (HUVECs) 
Primary Human Umbilical Vein Endothelial Cells (HUVECs) were isolated 
from umbilical veins as described originally (Jaffe et al., 1973b). Dr Raghu Adya (a 
post-doc in Dr Randeva’s lab) performed HUVEC cell isolation from umbilical 
cords.  
The entire procedures were carried out in a dedicated sterilised environment 
and all the cell media and solutions were pre-warmed at 37
o
C. The umbilical cords 
were obtained from mothers giving birth at maternity unit at University Hospital 
Coventry and Warwickshire (UHCW) (Coventry, UK). Ethical committee’s approval 
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and patients’ informed consent was obtained. Cords with blood clots, signs of 
damage, needle pricks and also those from infected parturient women (positive for 
HBV or HIV) were not considered suitable for experimental purposes and were 
discarded.  Umbilical cord was severed from the placenta soon after the baby was 
delivered, clamped at both ends, stored in a sealed polythene bag and transported to 
the laboratory. Cord was processed immediately after the arrival. The clamp was 
removed from one end of the cord and PBS was used to wash away any blood. A 
sterile glass cannula was inserted into the umbilical vein and secured in place using a 
plastic tie. Clamp was removed from the other end, and another PBS wash was 
performed to get rid of any remaining traces of blood. In order to remove any air 
bubbles trapped inside the vein, Phosphate Buffer Solution (PBS) was flushed 
through the cord a couple of times. Once cleaned, cord was clamped at one end and 
was filled with 1mg/ml collagenase solution in PBS, and second clamp was replaced 
at the other end. Cord was then wrapped in an aluminium foil and placed in a 
humidified incubator at 37
o
C for 15 minutes. Prolonged exposure to collagenase 
enzyme causes digestion of basement membrane and also disrupts underlying 
structures (Jaffe et al., 1973b). The cord was gently massaged to release the cells, 
and the collagenase solution containing detached cells was emptied out into a sterile 
falcon tube. Pre-warmed Medium 199 (M199; Invitrogen, Paisley, UK) was run 
through the cord, and the run-through was collected in the same tube. Cells collected 
were centrifuged at 1,500rpm for 15 minutes, supernatant was carefully discarded, 
and replaced with fresh 5ml cell medium. The contents were transferred to T25cm
2
 
tissue culture flask, and incubated in a humidified incubator at 37
o
C for a maximum 
of 5 minutes to encourage cell attachment to flask surface. Cell medium was then 
replaced with fresh new cell medium to remove any unattached or dead cells from 
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the flask. The cells were trypsinised with 0.5ml of trypsin/EDTA solution (Media 
Preparation Laboratory, Department of Life Sciences, The University of Warwick, 
UK) and incubated at 37
o
C for 3 minutes to release cells from the flask surface. 10ml 
of cell medium was added to the flask to inhibit further actions of trypsin solution, 
and the contents were decanted into a new falcon tube and centrifuged at 1,000rpm 
for 5 minutes. Cell supernatants were aspirated out, and remaining cell residue was 
re-suspended in a fresh cell medium containing 10% Fetal Calf Serum (FCS; Sigma 
Aldrich, Dorset, UK),  and transferred to a T75cm
2
 flask and replaced back in a 
humidified incubator at 37
o
C at 5% CO2 environment. 
Growth, maintenance and subculturing of HUVECs  
HUVECs were cultured in M199 medium supplemented with 10% FCS 
100IU/ml penicillin (Sigma Aldrich, Dorset, UK), 100μg/ml streptomycin (Sigma 
Aldrich, Dorset, UK), 30μg/ml Endothelial Cell Growth Supplement (ECGS; BD 
Biosciences, Bedford, MA, UK) and 10μg/ml heparin (Aventis Pharma, Milan, Italy) 
in a humidified incubator at 37
o
C at 5% CO2 environment.  
Cells were monitored on a regular basis for confluence and morphology using 
inverted phase microscope. When 80-90% confluence was reached, cells were either 
sub-cultured into culture plates for stimulation or split into new multiple culture 
flasks to allow further cell growth. Cells between passage numbers three and five 
were used for experiments. HUVEC cells were only used for the preliminary 
identification of chemerin receptors, and were not used for any other experiments 
included in this thesis. 
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2.2.1c   Human Macrovascular Endothelial Cells - EA.hy926 Cell Line 
Human macrovascular endothelial cell line, EA.hy926, was established in 1983 
by fusing human umbilical vein endothelial cells with permanent human alveolar 
adenocarcinoma cell line A549 (Edgell et al., 1983). EA.hy926 cell line was kindly 
provided by Dr C. J. Edgell (Universities of North Carolina School of Medicine, 
USA).  
Growth, maintenance and subculturing of EA.hy926 cell line 
EA.hy926 cell line was cultured in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen, Paisley, UK) supplemented with 10% FCS, 100IU/ml 
penicillin, and 100μg/ml streptomycin.  
Cells were monitored and examined on a regular basis for confluence and 
morphology using inverted phase microscope. Once cells reached 80-90% 
confluence, cells were either sub-cultured into plates for stimulation or split into new 
multiple culture flasks to encourage more cell growth. Cells between passage 
numbers three and fifteen were used for stimulating with chemicals of interest. 
EA.hy926 cells were cultured to identify the presence of chemerin and its receptors, 
and like HUVECs, were not used for any other experiments included in this thesis. 
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2.2.1d   Human Microvascular Endothelial Cell-1 (HMEC)-1 Cell Line 
Human Microvascular Endothelial Cell (HMEC)-1 line is the first 
immortalised human microvascular EC line that is known to retain most of the 
characteristics of normal human microvascular ECs. HMEC-1 cell line is the most 
widely used microvascular endothelial cell line, as it is easy to grow, and is three to 
seven times more denser in growth compared to regular microvascular endothelial 
cells and remains viable up to passage number 95 (Ades et al., 1992). HMEC-1 cell 
line was obtained from the Centre for Disease Control (CDC; Atlanta, Georgia, 
USA).   
Growth, maintenance and subculturing of HMEC-1 cell line 
HMEC-1 were cultured in MCDB medium (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% FCS, 100IU/ml penicillin, 100μg/ml streptomycin, 5ml of 
200mM L-glutamine (Media Preparation Laboratory, Department of Life Sciences, 
The University of Warwick, UK), 2μM hydrocortisone (Sigma-Aldrich, Dorset, UK) 
and 10ng/ml Epidermal Growth Factor (EGF; Invitrogen, Paisley, UK) (Carter et al., 
2003) for every 500ml of medium at 37
o
C at 5% CO2 environment. 
Medium was stored at 4
o
C, and was incubated at 37
o
C for 30 minutes prior to 
use. ECs were grown to approximately 80-90% confluence before sub-culturing, and 
split twice weekly. The medium was removed and the cells were washed with PBS 
twice to remove any traces of serum as it contains excess of proteins that deactivate 
the actions of trypsin and glycoproteins such as fibronectin. To release cells from the 
flask surface, approximately 3ml of 1x trypsin/EDTA solution was added to the flask 
and incubated for 3 minutes. Trypsin which is a proteolytic enzyme, aids the release 
of cells from the flask surface by breaking down the extracellular matrix, and EDTA 
chelates any remaining divalent cations. After 3 minutes, 5ml of fresh incubation 
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medium was added to the flask to inactivate the actions of trypsin. The cell 
suspension was then transferred to a tube and centrifuged for 3 minutes at 1,000rpm. 
The cell supernatants were discarded under sterile conditions in the tissue culture 
hood, and cell pellets were re-suspended in 10ml fresh  incubation medium.  
Cells were monitored on a regular basis for confluence and morphology using 
inverted phase microscope. Cells at 80-90% confluence were either sub-cultured into 
culture plates for stimulation or split into new multiple culture flasks to allow further 
growth. Cells between passages number ten and twenty five were used for 
stimulating with chemicals of interest for all experiments included in this thesis. 
Throughout this thesis, all the work was carried out in HMEC-1 cells, unless 
otherwise stated. 
2.2.1e Culturing HEK293T cell line   
The HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen, Paisley, UK) containing 10% FCS, 1% penicillin, and 
100μg/ml streptomycin in a humidified incubator at 37oC at 5% CO2 environment. 
HEK293T cells were sub-cultured regularly to avoid over-confluence. After 
aspirating out the cell medium, cells were washed using pre-warmed PBS, and 
incubated in 3 ml of trypsin/EDTA for  3 minutes. 5ml of fresh medium was added 
to the cells and the contents were transferred into a universal container. Cells were 
centrifuged at 1,000 rpm for 5 minutes and supernatant were discarded. Remaining 
cell residues were re-suspended into 5ml of fresh medium and added to flask 
containing 10ml of cell growth medium. 
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2.2.1f Cell count using haemocytometer  
Haemocytometer, also known as Neubauer Chamber, was used to calculate the 
number of cells in different cell suspensions. A haemocytometer is made up of a 
thick glass slide with four different counting chambers that  allow the determination 
of  number of cells per unit volume of a suspension.  
Preparing haemocytometer and cell count 
Prior to use, the haemocytometer glass slide and coverslip were thoroughly 
cleaned using 70% ethanol and counting chamber was set up under the microscope. 
The haemocytometer glass slide is typically engraved with a nine square counting 
grid, each square having dimensions of 1mm
2
 and is further divided into 16 or 25 
smaller squares. After trypsinising the cells, fresh cell medium was added to the cells 
to make a cell suspension. 50µl of resulting volume was mixed with equal volumes 
of Trypan Blue solution (Invitrogen, Paisley, UK). Trypan Blue is a dye which 
penetrates the cell membrane of dead cells, staining the dead cells blue, hence  
providing an estimation of  number of dead cells in a cell suspension. 20µl of the 
resultant cell suspension was added to the haemocytometer and cells were counted in 
four 1 mm
2  
areas and average cell number was counted. Cells in the left-hand side 
and top of the grid markings were included whilst those in the right-hand and bottom 
markings were excluded from the total count.  
The total number of viable cells in a suspension were calculated as below: 
Viable cells = Total cell volume x 2 x average number of counted cells x 10
4 
 
Total cell volume = in ml 
2 = Trypan Blue dilution factor 
Average cell number = total number of cells counted/4 
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2.2.1g Cell storage and revival 
Cells can be stored for longer periods in a freezing medium containing a 
cryoprotectant such as Dimethylsulphoxide (DMSO; Sigma Aldrich, Dorset, UK) 
which protects cells from disruption by preventing build-up of electrolytes during the 
freezing process (Lovelock and Bishop, 1959).  Both EA.hy926 and HMEC-1 cell 
lines were grown up to 80-90% confluence in 175cm
2
 tissue culture flasks in 25ml of 
growth medium. Cells were removed from the sides of the flask as described 
previously for each cell line using trypsin/EDTA solution. The density of viable cells 
was determined using a haemocytometer as described previously (Refer to section 
2.2.1f). Cell suspension containing 5x10
6
 cells was transferred into a sterile 15ml 
centrifuge tube and was centrifuged at 1,000rpm at RT for 2 minutes. The cell 
supernatants were discarded under sterile conditions and remaining cell residues 
were re-suspended in 5ml of freezing medium containing 50%  v/v FCS, 40% v/v 
growth media and 10% v/v DMSO and mixed thoroughly. 1ml of resultant cell 
mixture was transferred into previously labelled 1.5ml cryotubes, placed in a 
Freezing container (Nalgene
®
 Mr Frosty, Sigma-Aldrich, UK), and allowed to freeze 
in a -70
o
C freezer overnight for 2 days. The cryotubes were then transferred to a 
liquid nitrogen container for storage. To revive the cells from frozen stock, a 
cryotube vial of cells from liquid nitrogen was removed and placed immediately on 
dry ice for transport. The cells were thawed quickly by placing the cryotube in a 
water bath at 37
o
C, and the contents were transferred to a 25cm
2
 culture flask 
containing 5ml of respective growth medium. After overnight incubation, the cell 
medium was replaced with fresh cell medium, and the cells were cultured for another 
24 hours prior to transferring the contents  into T75cm
2 
flask for routine cell cultures. 
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2.3 Molecular Biology Techniques 
2.3.1 Total Ribonucleic Acid Extraction and Complementary 
Deoxyribonucleic Acid (cDNA) Synthesis  
 
Total Ribonucleic Acid (RNA) was extracted from endothelial cells using 
Qiagen RNeasy Lipid Tissue Mini Kit according to manufacturers’ guidelines 
(Qiagen, Crawley, UK). Extracted RNA was quantified, and checked for purity using 
NanoDrop spectrophotometer (Labtech International, Ringmer, UK). RNA 
concentrations were normalised and was reverse transcribed into cDNA using 
Moloney Murine Leukaemia Virus (M-MuLV) reverse transcriptase (Fermentas, 
York, UK) and random hexamers (Promega, Southampton, UK) as primers. 
2.3.2 Real Time Quantitative Polymerase Chain Reaction (RT-PCR) 
Quantitative PCR was performed on a Roche Light Cycler
TM
 system (Roche 
Molecular Biochemicals, Mannheim, Germany). PCR reactions were carried out in a 
reaction mixture containing 5µl reaction buffer (Fermentas, York, UK), 2.0mM 
MgCl2 (Biogene, Kimbolton, UK), 1µl of each forward and reverse primer (10 
µg/µl), 2.5µl of cDNA and 0.5µl of Light Cycler Master SYBR Green 1 (Roche, 
Manheim, Germany). PCR reactions were carried out as follows; denaturation at 
94
o
C for 1 min, then 40 cycles at 94
o
C for 30 seconds (sec), 60
o
C for 45 sec, and 
72
o
C for 30 sec, followed by a 7 minutes extension step at 72
o
C. As a negative 
control for all reactions, preparations lacking RNA or reverse transcriptase were used.  
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2.3.3 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is the most commonly known method for  
separating DNA products. 1 or 2% agarose gel in 1x Tris-Borate-EDTA (TBE; 
Media Preparation Laboratory, Department of Life Sciences, The University of 
Warwick, UK) was used to separate and visualise DNA bands. 1-2g agarose gel was 
weighed and dissolved in 1x TBE, heated in a microwave for 1 minute, and cooled at 
RT by gentle mixing on a magnetic stirrer. 1µl of 10mg/ml Ethidium Bromide (EB; 
Sigma Aldrich, Dorset, UK) was added to the gel. The gel was poured into the tank 
gently to avoid any air bubble formation, and well combs were carefully placed in 
the gel to make wells for sample loading. Gel was allowed to set for 30 minutes 
(preferably 1 hour) at RT. 15µl of sample volume was mixed with 2µl of agarose gel 
loading buffer (Fermentas, UK) and allowed to run at 70V for 45 minutes. 
2.3.4 DNA Sequence Analysis 
The PCR products from all samples were visualised using UV illuminator. 
PCR product bands were excised and isolated to purify DNA using QIAquick Gel 
Extraction Kit (QIAGEN, Crawley, UK). PCR products were sequenced in an 
automated DNA sequencer (Molecular Biology Lab, Department of Life Sciences, 
University of Warwick, UK), and the sequence data was analysed using Basic Local 
Alignment Search Tool (BLAST) from the National Centre for Biotechnology 
Information, in order to confirm the authenticity of the products.  
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2.3.5 Clone and Sequence Analysis 
2.3.5a Making competent Escherichia coli cells for transformation 
I observed and assisted Dr Jing Chen (Senior Research Fellow in Dr Randeva’s 
lab) in making competent Escherichia coli cells for transformation. 
1. A sterile wire was dipped with DH5α Escherichia coli cells from a glycerol 
stock, and streaked on a Liquid Broth (LB) plate containing no antibiotics and 
incubated overnight at 37
o
C. 
2. After overnight incubation, an isolated single colony was picked and suspended 
in a sterile flask containing liquid LB and incubated overnight in a shaking 
incubator at 250-300 rpm at 37
o
C. 
3. Using sterilised conditions, the neck of universal tube was sterilised by slightly 
exposing to flame. 125µl of overnight culture of Escherichia coli was added to 
the 20ml LB in the tube. The universal container was incubated in a shaking 
incubator at 250-300 rpm at 37
o
C for 2-3 hours. 
4. The optical density was measured using a Spectrophotometer at 600nm 
wavelength. The cells were then centrifuged at 300rpm for 10 minutes at 4
o
C 
and cell supernatants were discarded carefully. 
5. 10ml of 100mM ice cold calcium chloride was added to cell residues obtained 
from above step. The pellets were re-suspended by shaking and kept on ice for 
40 minutes, centrifuged at 3,000rpm for 10 minutes at 4
o
C, and kept in  a 
refrigerator prior to performing transformations.  
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2.3.5b Transformation into bacterial cells 
The reactions from 2.3.5a were added to 200µl of competent cells and kept on 
ice for 30 minutes, temperature shocked at 42
o
C for 40 seconds, and placed back on 
ice for further 30 minutes. 800µl of LB was added to cells and incubated at 250rpm 
at 37
o
C for 1 hour in a shaking incubator. The cells were then spread onto a plate 
with LB-medium and ampicillin and incubated overnight at 37
o
C. 
2.3.5c Purification and sequence analysis of recombinant DNA 
After overnight incubation of agar plates of transformed bacteria, single colony 
was picked using a sterile toothpick and added into a tube with 100ml of selective 
medium. Tube was incubated in a shaking incubator at 250rpm for 16 hours at 37
o
C. 
The recombinant pcDNA3.1 was extracted using QIAprep maxiprep kit (QIAGEN, 
Crawley, UK).  
1. After incubation, the broth culture were transferred to 50ml falcon tubes and 
centrifuged at 3,300 g for 25 minutes and supernatants were discarded carefully. 
2. Remaining residues were homogeneously re-suspended in 10ml of buffer P2. 
The mixture was mixed vigorously by inverting 4-6 times and incubated at RT 
for 5 minutes. 
3. 10ml of buffer P3 was added and mixed vigorously inverting 4-6 times, and 
incubated at RT for 20 minutes and contents were centrifuged at 13,000rpm for 
10 minutes. 
4. To allow DNA binding, a QIAGEN-tip was equilibrated by adding 10ml buffer 
QBT and column was allowed to empty by gravity flow. 
  53 
5. Cell supernatants from step 3 were applied to the QIAGEN-tip and allowed to 
enter the resin by gravity flow. 
6. Once the QIAGEN-tip column emptied out, 30ml of QC solution was allowed to 
move through the QIAGEN-tip by gravity flow. The column was wasted out 
twice. 
7. DNA bound to QIAGEN-tip column was eluted using 15ml of buffer QF and 
flow-through was collected in a conical glass container. 
8. Eluted DNA was precipitated out by adding 10ml of isopropanol at RT and 
centrifuged at 15,000g for 30 minutes at 4
o
C. 
9. Supernatants were carefully removed and residual DNA pellets were washed 
using 10ml of 70% ethanol. The mixture was centrifuged at 15,000g for 10 
minutes and supernatants were discarded. 
10. The remaining DNA pallets were air-dried for 5 minutes, re-suspended in 400µl 
distilled water, and DNA concentration was determined using Nanodrop at 
A260/280 nm. 
The DNA was submitted to Molecular Biology Services for DNA sequencing. 
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2.3.6 Transfections  
A number of transfection methods are used for transferring nucleic acids into 
mammalian cells yielding a large quantity of a single protein for studying the 
regulation and function of a specific genes of interest. Lipofectamine reagent was 
used to carry out transfections both in HMEC-1 and HEK293T.CMKLR1 cell lines. 
Transient transfection of clones using Lipofectamine reagent  
Lipid-mediated transfections involved the incorporation of DNA into 
mammalian cells, by way of liposome vesicles, positively charged lipid and 
negatively charged DNA bind to the cell and are internalised by endocytosis (Gross 
et al., 2005). 
2.3.6a Transient transfections in HMEC-1 cell line 
HMEC-1 cells were transiently transfected with dominant-negative G-proteins. 
Transient transfections of dominant-negative G proteins in HMEC-1 cell line 
HMEC-1 cells were plated in 6-well culture plates and were transfected with 
dominant-negative G proteins. Cells were transfected with empty pcDNA3.1, 
pcDNA3.1 (+)-Gα1, pcDNA3.1 (+)-Gα2, pcDNA3.1 (+)-Gαs, pcDNA3.1 (+)-Gq11 
using Lipofectamine (Invitrogen, Paisley, UK) and Opti-MEM
® 
medium (Invitrogen, 
Paisley, UK). 4µg of each plasmid DNA was added to 250µl of Opti-MEM
® 
medium 
(Solution 1). 10µl of Lipofectamine reagent per reaction was mixed with 250µl of 
Opti-MEM
® 
medium (Solution 2). Both solution 1 and 2 were mixed together and 
allowed to stand at RT for 30 minutes before adding the transfecting mix into the 
HMEC-1 cells. After 24 hours of incubation, cell medium containing transfection 
reagent mix was replaced with fresh pre-warmed MCDB medium containing 10% 
FCS and cells were further incubated for another 48 hours. Different chemerin (21-
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157) treatments were performed in G protein-transfected HMEC-1 cells (data not 
included). 
Transient transfection of NF-κB-Luc plasmid in HMEC-1 cell line 
Dr Raghu Adya carried out transient transfections of NF-κB-Luc plasmid in 
HMEC-1 cell line.  
The pcDNA3.1-NF-κB-Luc was transfected into HMEC-1 using 
Lipofectamine reagent. HMEC-1 cells were trypsinised and plated in 12-well culture 
plates at a final cell density of 3x10
5
 cells/well. Cells were transfected using a cis-
reporter plasmid containing luciferase reporter gene linked to five repeats of NF-κB 
binding sites (pcDNA3.1-NF-κB-Luc; Stratagene, La Jolla, CA). For each sample 
transfection, 5µl of pcDNA3.1-NF-κB-Luc [0.35µg/µl] was added to 125µl of Opti-
MEM
®
 medium in an eppendorf tube (Solution 1). Solution 2 was prepared in a 
separate eppendorf tube by adding 5µl of Lipofectamine and 125µl of Opti-MEM
®
 
medium. Both solution 1 and solution 2 were mixed and allowed to stand at RT for 
15 minutes. 250µl of the resultant solution was added to each well and incubated for 
12 hours in a humidified incubator at 37
o
C at 5% CO2 environment. Opti-MEM
®
 
medium was added to some wells which served as transfected control wells. A 
control plasmid with a luciferase gene insert was also transfected and used as a 
control in measuring luciferase activity. Following 12 hours incubation, the cell 
medium was replaced with MCDB medium containing 10% FCS and further 
incubated for 12 hours. Cells were treated with different chemerin (21-157) 
concentrations [0-10nM] and TNF-α [10ng/ml] for a maximum of 24 hours. 
Following cell treatments, cell lysates were collected and luminescence was 
measured using a dual luciferase reporter assay system (Luminometer, Promega, 
UK). For achieving HMEC-1 cell line stably expressing NF-κB-Luc, HMEC-1 cells 
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were transfected with pcDNA3.1-NF-κB-Luc in MCDB cell medium containing 
Geneticin (G)-418 sulphate (G418) [0.5mg/ml] (Invitrogen, Paisley, UK). The non-
transfected cells were killed within 5 days. A number of selected colonies were 
cultured for a total of 8 weeks in cell medium containing G-418. A number of clones 
were selected to measure NF-κB activation and luciferase activity as described above 
and cells were stored in liquid nitrogen as described previously (Section 2.2.1g, page 
number 48). 
2.3.6b Stable and transient transfections in HEK293T cells 
Both stable and transient transfections were performed  in  HEK293T cells. 
Stable CMKLR1 transfections in HEK293T Cell Line 
Dr Jing Chen carried out stable transfections of pcDNA3.1-CMKLR1 in 
HEK293T cell line.  
In order to generate HEK293T cells stably expressing CMKLR1 receptor 
(HEK293T.CMKLR1), pcDNA3.1-CMKLR1 was transfected into HEK293T cells 
in DMEM cell medium containing G418 [0.5mg/ml] (Invitrogen, Paisley, UK) and 
was replaced every three days. The non-transfected cells were killed within 5 days. 
After 2 weeks, the colonies were selected and isolated by using cloning rings, and 
then each colony was grown DMEM cell medium containing G418. Finally, a single 
cell from a resistant colony was transferred into a 96-well plate and cultured in G418 
containing DMEM medium for further 8 weeks.  
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Transient transfections of dominant-negative G proteins in stably transfected 
HEK293T cells  
HEK293T cells were plated in 6-well plates and were transfected with 
dominant-negative G proteins. Cells were transfected with empty pcDNA3.1, 
pcDNA3.1 (+)-Gα1, pcDNA3.1 (+)-Gα2, pcDNA3.1 (+)-Gαs, pcDNA3.1 (+)-Gq11 
using Lipofectamine reagent and Opti-MEM
® 
medium. Different chemerin (21-157) 
treatments were performed in G protein-transfected HEK293T.CMKLR1 cells (data 
not included). 
2.3.7 Sodium Do-decyl Sulphate Polyacrylamide Gel Electrophoresis  
Sodium Do-decyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
is the most commonly used technique for separating proteins.  
Sample preparation 
Samples for SDS-PAGE analysis were prepared from all different cell types. 
After treating the cells with different chemicals of interest, cells were washed with 
ice-cold PBS twice and were lysed in 1x Radioimmunoprecipitation Assay (RIPA) 
buffer (100mM Tris pH 7.4, 300mM NaCl, 20mM sodium pyrophosphate, 2mM 
EDTA, 200µM β-glycophosphate, 2% sodium vanadate, 1% Nonidet P40, 0.2% 
sodium deoxycholate, 0.2% sodium dodecyl sulphate) containing 2µl of protease 
inhibitor cocktail, 1µl of Phenylmethylsulfonyl Fluoride (PMSF) and 1µl of sodium 
orthovanadate solution. 120µl of 1x RIPA was added to each well of a 6-well plate, 
incubated on ice for 2-3 minutes, and cell lysates were collected in eppendorf  tubes 
and replaced back on ice. Samples were centrifuged at 8,000rpm for 5 minutes and 
protein concentrations were determined using BCA protein quantification method 
(Refer to section 2.4.1).  Cell lysates were mixed with 1x Laemmli buffer [(120 mM 
Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, β-mercaptoethanol and 0.01% 
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bromophenol blue (1:1 w/v)] and boiled in the water bath at 95
o
C for 5-6 minutes to 
denature the proteins. Samples were centrifuged at 4,000 rpm for 5 minutes at 4
o
C 
and  stored at -80
o
C until analyses. 
Preparing SDS-PAGE gels 
The polyacrylamide gels of different percentages were prepared. Resolving gel 
was prepared by adding protogel [30% Acrylamide: Bisacrylamide (37.5:1) 
(GENEFLOW Limited, UK)], resolving gel (GENEFLOW Limited, UK), deionised 
water, 10% Ammonium Persulphate (APS) (Sigma Aldrich, Dorset, UK) and N, N, 
N’, N’- tetramethyl-ethylenediamine (TEMED) (Sigma Aldrich, Dorset, UK) in a 
universal container and mixed gently. The mixture was poured between the gel casts 
leaving sufficient space for the stacking gel and allowed to polymerise at RT for 15-
20 minutes. The stacking gel was prepared by adding protogel, stacking gel, 
deionised water, APS and TEMED in a universal container, mixed gently, and the 
mixture was subsequently applied on top of the pre-set resolving gel. The comb was 
placed in the stacking gel to allow well formation and was allowed to stand at RT for 
20 minutes. The gels were placed in the gel holder tank and sufficient 1x protein gel 
running buffer (10g SDS, 30g Tris and 144g Glycine per litre solution) was added. 
Protein electrophoresis and detection  
Ten to thirty micrograms of protein sample was loaded in the gel wells, and 
was electrophoresed at a constant current of 40mA for approximately 60-120 
minutes. Following electrophoresis, the proteins were transferred onto activated 
Polyvinylidene Fluoride (PVDF) membranes (Millipore, UK) at 100V for 60 
minutes. The PVDF membranes were activated by placing the membranes in 
methanol for 20 sec, washed in water for 3 minutes and placed in transfer buffer for 
5 minutes. After the transfer (transfer buffer - 100ml of 10x Tris/Glycine (30g Tris 
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and 144g Glycine per litre solution), 200ml of methanol, and 700 ml dH2O to make a 
total volume of 1L), the membranes were blocked using 5% Bovine Serum Albumin 
(BSA) prepared in 1% TBS (24.2g Tris and 80g NaCl per litre solution) /0.1% (v/v) 
Tween-20 (TBS-T)  (represented as ‘5% BSA solution’ in this thesis text throughout) 
for 1 hour at RT. Membranes were incubated with specific primary antibodies 
constituted in 5% BSA solution at 4
o
C with gentle shaking overnight. Following 
overnight incubation, the primary antibodies were removed by washing with TBS-T 
solution every 15 minutes for four times. Membranes were incubated with 
corresponding secondary Horseradish-Peroxide (HRP)-labelled detection antibodies 
diluted in 5% BSA solution for 1 hour at RT. Membranes were washed for another 1 
hour using TBS-T solution every 15 minutes. A final 15 minutes membrane wash 
was performed in TBS only solution to remove any traces of Tween, which may 
interfere with chemiluminescence. The labelled antibody complexes were detected 
using Enhanced Chemiluminescence Plus detection reagent [ECL; GE Healthcare, 
Little Chalfont, UK] according to manufacturer’s instructions. Membranes were 
stored at 4
o
C in TBS solution for further stripping and re-probing. 
Stripping and Re-probing Membranes  
Membranes were stripped and  re-probed  with loading controls. The 
membranes were placed in 30ml stripping buffer (120ml of 10% SDS, 37.5ml of 1M 
Tris-HCl pH 6.8, 4.7ml β-mercaptoethanol and dH2O for a total volume of 600ml 
solution) in clear plastic containers and incubated in a shaking water bath at 50
o
C for 
30 minutes. After incubation, membranes were washed with TBS-T solution twice, 
each 15 minutes at RT. The membranes were blocked with 5% BSA solution for 1 
hour at RT and were incubated with specific antibodies overnight at 4
o
C  with gentle 
shaking. Following overnight incubation, the primary antibodies were removed and 
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the membranes were washed four times with TBS-T solution for 15 minutes each. 
Membranes were incubated with corresponding HRP-labelled secondary detection 
antibodies prepared in 5% BSA solution for 1 hour at RT and washed with TBS-T 
solution for 1 hour every 15 minutes. A 15 minutes TBS only membrane wash was 
performed in to remove any traces of Tween. Antibody complexes were detected 
using ECL Plus detection reagent according to manufacturer’s instructions. The band 
densities were measured using a scanning densitometer coupled to scanning software 
Scion Image™ (Scion Corporation, Maryland, USA).  
2.3.8 Immunostaining  
Immunostaining method was employed for studying specific cellular or tissue 
constituents. Sterilised coverslips were placed inside the wells of a 6-well plate and 
covered in poly-L-lysine [10µg/ml] solution (Sigma Aldrich, Dorset, UK) for 1 hour. 
Following incubation, poly-L-lysine solution was aspirated out and HMEC-1 cells 
were trypsinised and cultured on coverslips for 24 hours. After 24 hours the cell 
medium was removed and wells were gently washed with PBS twice. 2% 
formaldehyde was added to the wells and incubated for 30 minutes at RT and 
washed with PBS immediately after the incubation for 5 minutes. 3% BSA solution 
prepared in PBS containing 0.01% Triton X-100 was added to the wells for blocking 
for 1 hour at RT. Cells were incubated with mouse anti-CMKLR1 antibody [(1:400); 
Santa Cruz, MA, USA] constituted in PBS containing 0.01% Triton X-100 overnight 
at 4
o
C.  After overnight incubation, cells were washed with PBS containing 0.01% 
Triton X-100 for three times every 10 minutes. A detection antibody Alexa 680 
conjugated anti-mouse IgG in PBS containing 0.01% Triton X-100 [(1:400); Cell 
Signalling, Beverly, MA, USA] added to the wells and  incubated in the dark for 2 
hours.  The cells were washed three times for every 10 minutes with PBS containing 
  61 
0.01% Triton X-100. A glycerol drop containing 4´, 6-Diamidino-2-phenylindole 
hydrochloride (Sigma-Aldrich, Dorset, UK) was placed on a slide, and cells covered 
coverslip was attached to the slide with a drop of DAPI and mounted with nail 
varnish. Cells were mounted in VECTASHIELD mounting medium with DAPI 
(Vector Laboratories, Inc. Orton Southgate, Peterborough, UK) on microscope slides.  
Cells were observed under an oil immersion objective lens using a Leica model 
DMRE laser-scanning confocal microscope (Milton Keynes, UK).  
 2.3.9 Gelatin Zymography 
I only observed Dr Raghu Adya carrying out Gelatin zymography procedure.  
Gelatin zymography was used to measure the gelatinolytic activities of 
secreted  MMP-2 and MMP-9 in endothelial cell supernatants. Under non-reducing 
conditions, 10μl of culture supernatants were mixed with 10μl zymography sample 
buffer and were resolved using 10% SDS-PAGE containing 1mg/ml of gelatin 
(Sigma, St. Louis, USA). The gels were electrophoresed at 4
o
C and gels were 
washed twice for 30 minutes with denaturation buffer (2.5% Triton X-100) at RT, 
and incubated overnight in the incubation buffer (50mM Tris-HCl pH 7.5, 200mM 
NaCl, 10mM CaCl2, 1μM ZnCl2) at 37oC. Characterization of MMP activity was 
determined by inhibition with EDTA (10mM). Following day, gels were stained for 
1 hour (0.25% Coomassie brilliant blue R-250 in 45% methanol, 10% acetic acid), 
and de-stained in the same buffer without Coomassie (Media Preparation Laboratory, 
Department of Life Sciences, The University of Warwick, UK). White bands against 
a blue background were observed following de-staining which indicated gelatinolytic 
activities of the expressed MMPs. Gel Pro image analysis (Gel Pro 4.5, Media 
Cybernetics, USA)] was used to measure the intensities and fold increase was 
calculated. 
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2.4 Specialised Assays 
2.4.1 Bis-Chorionic Acid Protein Quantification Assay 
Bis-chorionic Acid (BCA) protein quantification assay was used to determine 
protein concentrations in cell lysates from different cell lines (Rampazzo et al., 2012) 
(Sigma Aldrich, Dorset, UK). Following cell treatments with different chemicals, 
cells were lysed in 1x RIPA and centrifuged at 8,000 rpm for 5 minutes. 5µl of each 
cell supernatant or standard was added to 96 well plate and a 195µl of a mixture of 
BCA solution, CuSO4 and PBS was added to each well (4µl CuSO4, 5µl PBS and 
200µl of BCA solution per sample). The plate was incubated for 20 minutes at 37
o
C 
and the absorbance was measured using a plate reader (Multiskan Ascent 96/384 
Plate Reader) at 570nm. 
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2.4.2 CellTiter 96® AQueous One Solution Cell Proliferation Assay  
HMEC-1 cell proliferation was determined using CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (MTS) kit (Promega, UK). This assay is a based on 
the colorimetric method for determining the number of viable cells in cell 
proliferation or cytotoxicity assays. HMEC-1 cells were trypsinised and cultured in 
96-well plate (provided in the kit) at the cell density of 2.5x10
5 
cells/well for 24 
hours in a humidified incubator at 37
o
C at 5% CO2 environment. Cells were serum-
starved in MCDB medium containing 1% FCS overnight and treated with different 
chemerin (21-157) concentrations [0-30nM] for  a maximum of 24 hours. After 24 
hours, the cell medium was replaced with 100μl of fresh MCDB medium containing 
1% FCS,  and 20μl MTS reagent was added to each well and incubated for 1 hour in 
a humidified incubator at 37
o
C at 5% CO2 environment. The absorbance was 
recorded at 490 nm using an ELISA plate reader (EL800, Bio-Tek Instruments, Inc., 
Winooski, VT, USA). The percentage increase in absorbance was calculated against 
untreated cells. 
 2.4.3 Wound-healing Cell Motility Assay 
Dr Raghu Adya carried out wound-healing cell motility assay.  
HMEC-1 cells were trypsinised and were plated in 6-well plates at the final 
cell density of 1x10
5 
cells/ml in MCDB cell medium containing 10% FCS and 
incubated overnight. In 75-80% confluent cells, a single scratch wound was created 
using a sterile p10 micropipette tip, and markings were created to serve as reference 
points in order to eliminate any possible variation caused by the difference in the 
width of the scratches. Cell medium was replaced with MCDB medium containing 1% 
FCS and incubated overnight. Cells were treated with different human recombinant 
chemerin (21-157) concentrations [0-30nM] (R and D systems, Abingdon, UK)  and 
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incubated for a maximum of 24 hours. VEGF [0.5µM] (Sigma Aldrich, Dorset, UK) 
was used as a positive control. Images were captured using phase contrast 
microscopy. The distance between the two sides of the scratch was analysed 
quantitatively by using Image Pro-plus software (Media Cybernetics, Bethesda, MD).  
2.4.4 In vitro Cell Invasion Assay 
Dr Raghu Adya carried out in vitro cell invasion assay.  
HMEC-1 cell invasion was studied using BD BioCoat™ Matrigel™ Invasion 
Chamber assay (BD Biosciences, San Jose, CA, USA). This assay is useful in 
studying the cell invasion of malignant and normal cells. BD BioCoat Matrigel 
Invasion Chambers consist of a BD Falcon™ TC Companion Plate with Falcon Cell 
Culture Inserts with an 8 micron pore size PET membrane with a thin layer of 
MATRIGEL Basement Membrane Matrix, latter acting as a reconstituted basement 
membrane in vitro. Before performing the experiments, equal number of Matrigel 
Culture Inserts and Control Culture Inserts were rehydrated using pre-warmed 
MCDB medium for 2 hours in a humidified tissue culture incubator at 37
o
C at 5% 
CO2 environment. After incubation, the cell medium was carefully removed without 
disturbing the layer of Matrigel™ Matrix on the surface. HMEC-1 cells were 
trypsinised and the cell suspension containing approximately 3x10
4
 cells/ml was 
prepared. 750μl of 1%FCS containing  MCDB medium treated with different 
chemerin (21-157) concentrations [0-30nM] was added to the BD Falcon™ TC 
Companion Plate. The rehydrated Culture Inserts were transferred to the wells 
containing the chemoattractant, and 250µl of  HMEC-1 cell suspension was added. 
The  BD BioCoat Matrigel Invasion Chambers were incubated for 24 hours in a 
humidified incubator at 37
o
C at 5% CO2 environment. After incubations, the non-
invading cells were scrubbed off using a cotton-tipped swab into the Culture Inserts 
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by applying firm pressure and swirling gently over the membrane surface. The cells 
invaded through the Matrigel™ Matrix were labelled with 4µg/ml Calcein-AM (BD 
Biosciences) for 90 minutes. Fluorescence of migrated cells was read at 494/517nm 
(excitation/emission) using a fluorescence plate reader. 
2.4.5 Endothelial Cell Capillary Tube Formation Assay 
I observed and assisted Dr Raghu Adya in carrying out endothelial cell 
capillary tube formation assay for generating data presented on page number 136 
(Fig. 4.3.11a), and carried out this assay myself for capillary tube formation 
experiment using chemerin (149-157) (Fig. 8.6a, page number 232).  
Capillary tube formation in HMEC-1 cells was determined using Growth 
Factor Reduced MatrigelTM Matrix (BD Biosciences, San Jose, CA, USA). Matrix 
Matrigel is obtained from soluble basement membrane extract of the Engelbreth-
Holm-Swarm (EHS) tumour which polymerises at the RT and forms a reconstituted 
basement membrane (Kleinman et al., 1986). Under sterilised conditions, Matrix 
Matrigel was thawed overnight at 4
o
C, and was diluted in MCDB medium 
containing 1% FCS. 200µl of Matrix Matrigel was added to pre-cooled 24-well 
culture plates and allowed to polymerise for 30 minutes in a humidified incubator at 
37
o
C at 5% CO2 environment. HMEC-1 cells were trypsinised and a final cell 
suspension containing 2x10
4
 cells/well was prepared in MCDB medium containing 
10% FCS. 300µl of the resultant cell suspension was added to Matrigel-coated plates 
and incubated for 2 hours in a humidified incubator at 37
o
C at 5% CO2 environment. 
Post-incubation, cell medium was carefully removed from the wells avoiding any 
damage to the coated gel, and was replaced with cell medium containing 1% FCS 
and incubated for 4 hours. Endothelial cells were treated with or without chemerin 
(21-157) [0-30 nM] or VEGF [0.5µM] for a maximum of 24 hours. Capillary-like 
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cell structures were captured with a digital microscope camera system (Olympus, 
Tokyo, Japan) Image-Pro Plus software was used to quantify tube formation; the 
tube lengths in 3-4 randomly selected fields in each of the wells were measured both 
for treated and untreated groups. 
2.4.6 Endothelial Cell Apoptosis Assay 
Endothelial cell apoptosis assay was studied using Cellular DNA 
Fragmentation ELISA kit (Roche diagnostics, UK). HMEC-1 cells were trypsinised 
and plated in 96-well plate at the cell density of 1x10
3 
cells/ml and incubated 
overnight. Cells were labelled with anti-BrdU solution (solution 7) at the final 
concentration of  10µM and incubated overnight. Cells were treated with different 
chemerin (21-157) concentrations [0-30nM] for 24 hours. After incubation, cell 
supernatants were carefully removed and 200µl of 1x incubation solution (solution 5) 
was added to each well and incubated for 30 minutes at RT. Cells were centrifuged 
at 250g for 10 minutes and 100µl of lysed cell supernatants were transferred to 
previously anti-DNA antibody coated microplates. To coat the microplates, 100µl of 
anti-DNA antibody 1x coating solution was added to each well and incubated 
overnight at 4
o
C. On the following day, coating solution was aspirated out from the 
wells, and 200µl of 1x blocking solution (solution 5) was added to each well, 
covered with adhesive plate and incubated for 30 minutes at RT. Blocking solution 
was removed from the wells and plate was washed using 300µl 1x wash solution 
(solution 4).  
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After transferring the lysed cells into the microplate, plate was covered and 
incubated for 90 minutes at RT. After incubation, the wells were emptied out by 
inverting the plate and tapping on a layer of absorbent papers. The wells were 
washed three times using 300µl of wash solution. After the last wash, 200µl of wash 
solution was added to each well and plate was placed in a microwave for 5 minutes 
to irradiate at 500W. A beaker containing 500ml of water was also placed in the 
microwave to prevent dehydration. The plate was placed in -20
o
C freezer for 10 
minutes for cooling and the contents were aspirated out. 100µl of anti-BrdU-POD 
conjugate solution (solution 6) was added to each well. The plate was covered using 
an adhesive plate cover and incubated for further 90 minutes at RT. The plates were 
washed three times using 300µl of wash solution. 100µl of substrate solution was 
added to each well and plate was covered in foil and incubated on a shaker for 5 
minutes. 25µl of stop solution (solution 8) was added to each well and incubated for 
10 minutes on a shaker. The absorbance was recorded at 450nm within 5 minutes of 
adding the stop solution using a colorimetric plate reader. 
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2.4.7 NF-κB Luciferase Activity Assay 
Dr Raghu Adya carried out NF-κB Luciferase Activity Assay.  
For each sample transfection, 5µl of pcDNA3.1-NF-κB-Luc [0.35µg/µl] was 
added to 125µl of Opti-MEM
®
 medium in an eppendorf tube (Solution 1). Solution 2 
was prepared in a separate eppendorf tube by adding 5µl of Lipofectamine and 125µl 
of Opti-MEM
®
 medium. Both solution 1 and solution 2 were mixed and allowed to 
stand at RT for 15 minutes. 250µl of the resultant solution was added to each well 
and incubated for 12 hours in a humidified incubator at 37
o
C at 5% CO2 
environment. Opti-MEM
®
 medium was added to some wells which served as un-
transfected control wells. A control plasmid, TK-plasmid, with a luciferase gene 
insert was also transfected and used as a control in measuring luciferase activity. 
Following 12 hours incubation, the cell medium was replaced with MCDB medium 
containing 10% FCS and further incubated for 12 hours. Cells were treated with 
different chemerin (21-157) concentrations [0-10nM] and TNF-α [10ng/ml] for a 
maximum of 24 hours. Following cell treatments, cell lysates were collected and 
luminescence was measured using a dual luciferase reporter assay system 
(Luminometer, Promega, UK). 
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2.4.8 Endothelial-Monocyte Cell Adhesion Assay 
Dr Raghu Adya carried out endothelial-monocyte cell adhesion assay. 
Endothelial-Monocyte cell adhesion assay was performed using BD BioCoat 
Endothelial Cell Adhesion Assay kit (BD Biosciences, San Jose, CA, USA). THP-1 
monocytes, a human acute monocytic leukaemia cell line, were labelled with 2.5µM 
Calcein AM. The cells were mixed gently by inverting and the cell suspension was 
incubated at 37
o
C for 30 minutes. An excess of Calcein from the cells was removed 
by repeated washing with PBS. The Calcein labelled cell suspension was prepared to 
a final concentration of 2x10
6
 cells/ml. Alongside, HMEC-1 cells were also 
trypsinised and a cell suspension containing 1.5x10
6
 cells/ml in a specific cell 
medium was prepared. 100µl of HMEC-1 cell suspension was added to each 96-well 
tissue culture plate (included in the kit) and incubated for 2-3 hours to allow 
attachment of cells to the plate surface. Post incubation, cell medium was aspirated 
out and 100µl of Cycloheximide solution was added to the control wells, and 100µl 
of fresh 10% FCS MCDB cell medium in rest of the wells. Endothelial cells were 
activated by adding 10µl of TNF-α [20ng/ml] (Calbiochem, UK) to respective wells 
and cells were stimulated with chemerin (21-157) [0-10nM] with and without 
inhibitors and incubated for 2-6 hours. 75µl of medium was aspirated out  from the 
plate wells and were gently washed using 200µl of Assay Buffer solution. After the 
last wash, fresh 50µl of Assay Buffer solution was added to each well. 100µl of 
Calcein AM labelled THP-1 monocytes (~50,000 to 200,000 cells) were added to 
each well and incubated at 37
o
C for 30 minutes. Approximately, 120µl solution was 
removed from the plate wells and two 200µl cell washes were performed using 
Assay Buffer solution. An additional wash was performed to remove any remaining 
unbound cells in order to eliminate non-specific binding. 100µl of Assay Buffer was 
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added to each well and the plate reading was performed using a fluorescent plate 
reader with an excitation/emission filter at 485/530nm. 
2.4.9  Quantification of sE-selectin, sICAM-1, sVCAM-1 and sPAI-1 in EC 
Supernatants 
Adhesion molecules (sE-selectin, sICAM-1 and VCAM-1) and sPAI-1 levels 
were quantified using multiplex assay kit (Millipore, UK). This kit allows 
simultaneous quantification of various different analytes in combination. Before 
using, pre-wet the microtitre plate by adding 200µl of 1x wash solution to each well, 
cover the plate using adhesive film and incubate for 10 minutes on a plate shaker at 
RT. Wash buffer was removed by vacuum and by placing the plate on a blotting 
paper to remove excess of wash buffer. 25μl of assay buffer was added to 0 standard 
and the sample wells. 25μl of each standard or control solution was added to each 
well, followed by 25μl of matrix solution and 25μl of each sample solution was 
added to the wells. 25μl of Mixed Beads were added to each well, sealed with 
adhesive plate cover, wrapped in aluminium foil and incubated overnight at 2-8
o
C 
with shaking. After overnight incubation, the contents were removed by vacuuming 
the plate and washed twice using 300µl/well 1x wash buffer. The wash solution was 
removed using vacuum filtration and excess by placing the plate on an absorbent 
paper. 25μl of detection antibody cocktail was added to each well, sealed and 
covered the plate with aluminium foil and incubated with shaking for 2 hours at RT. 
Following the incubation, 25μl of Streptavidin-Phycoerythrin detection antibody was 
added to each well, sealed and covered in aluminium foil and incubated for 30 
minutes at RT on a shaking incubator. After incubation, contents were gently 
removed by vacuuming and plate was washed two times using 300μl of 1x wash 
buffer, removing the wash buffer using vacuum filtration and excess by placing the 
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plate on an absorbent paper or tissue. 100μl of Sheath Fluid was added to each well, 
sealed and covered in aluminium foil and incubated for 5 minutes on a shaker. Plate 
was run on Luminex® 100 instrument and 50 beads per bead set in 50µl of sample 
were read. 
2.4.10 Assessment of Nitrites and Nitrates in Endothelial Cell Lysates and 
Supernatants 
Nitrates and nitrites were measured using Griess reagent assay. This assay is 
the most commonly used method for indirect measurement of Nitric Oxide (NO) 
(Miranda et al., 2001) and was used to determine the nitrite only, and combined 
amount of nitrite and nitrates (NOx) in cell culture lysates and supernatants. HMEC-
1 cells were plated in 6-well plates in MCDB cell medium containing 10% FCS and 
were serum starved in the same medium before performing different chemerin (21-
157) treatments. Cell medium was removed and cells were washed with pre-warmed 
PBS twice. 1ml of PBS was added to the wells and different chemerin (21-157) 
treatments were performed for 15 minutes. Cell supernatants were collected in pre-
labelled eppendorf tubes for NOx and nitrite analyses. 500µl of dH2O was added to 
the wells, cells were lysed and collected for both NOx and nitrite analysis. Both cell 
supernatants and lysates were centrifuged at 8,000rpm for 5 minutes and stored at 
4
o
C until analysis. 100mM sodium nitrite stock solution was prepared by adding 
1.725g of sodium nitrite (Sigma Aldrich, Dorset, UK) in 250ml of PBS and dH2O; 
and 100mM sodium nitrate (Sigma Aldrich, Dorset, UK) standard solution was 
prepared by adding 2.125g sodium nitrate in 250ml of PBS and dH2O. Vanadium 
chloride (Sigma Aldrich, Dorset, UK) was prepared by adding 400mg in 50ml 1M 
HCL solution (Sigma Aldrich, Dorset, UK). N-(1-Naphthyl) ethylenediamine 
dihydrochloride (NEDD) (Sigma Aldrich, Dorset, UK) was prepared by dissolving 
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0.1g in 100ml dH2O. Sulphanilamide (SULF) (Sigma Aldrich, Dorset, UK) was 
prepared by adding 2g in 100ml 5% 1M HCL solution. Standard solutions for both 
sodium nitrite and nitrate was serially diluted from 800µM to 0.75µM. For NOx 
assessment, 100µl of each standard or sample (both cell lysates and supernatants) 
solution was added to each well in a 96-well plate. 100µl of Vanadium chloride 
solution was added to each standard or sample followed by 100µl of Griess reagent 
mix (50µl of NEDD + 50µl SULF) and the plates were incubated for 45 minutes. 
The absorbance was recorded at 550nm. For nitrite only analysis, 300µl of a standard 
or sample (both cell lysates and supernatants) solution was added to pre-labelled 1.5 
ml eppendorf tubes. Equal volume of Griess reagent mix (150µl of NEDD + 150µl 
SULF) was added to the standard or sample and mixed thoroughly. 300µl of each 
standard or sample was transferred to 96-well plate and incubated for 10 minutes. 
The absorbance was recorded at 550nm.  
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2.5 Statistics and Software Used 
Western blotting protein band intensities were determined using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). All results were 
normalised as a ratio of expression of specific proteins to β-actin loading control, or 
as a ratio of phosphorylated protein to total protein; and results were expressed as a 
fold increase relative to basal. The results were expressed as mean ± Standard Errors 
of Mean (SEM) of three independent experiments. Single-factor one-way Analysis 
of variance (ANOVA) (non-parametric) was performed for each treatment and 
results were reported to be significant when  p  < 0.05.  
 
 
 
 
 
 
 
 
  74 
3.1 Introduction   
The initial aims of this project were to; (1) identify and confirm the presence of 
chemerin gene and protein expression in human microvascular (HMEC-1) and 
macrovascular (EA.hy926) EC lines, (2) identify and confirm the presence of 
chemerin receptor, CMKLR1 at gene and protein levels in HMEC-1, EA.hy926 cell 
lines as well as in primary HUVEC cells, and finally, (3) study the role of known 
inflammatory cytokines such as Tumour Necrosis Factor (TNF)-alpha (α), 
Interleukin (IL)-6 and IL-1β in CMKLR1 receptor regulation in HMEC-1 cell line. 
Chemerin, as mentioned previously, is a product of TIG-2 gene [also known as 
Retinoic Acid Receptor Responder 2 (RARRES2)] and is synthesised as a 164 amino 
acids long protein, known as prochemerin (Meder et al., 2003, Zabel et al., 2006b). 
Prochemerin undergoes C-terminus cleavage to form various active and inactive 
chemerin fragments at the sites of inflammation (Fig. 1.2.3a.1, page number 16). 
Chemerin (21-157) is the most active and abundant circulating chemerin form in the 
human body. Chemerin binds to its natural GPCR, CMKLR1, which is primarily 
expressed on the cells of the immune system. In addition, chemerin also acts as a 
ligand to two other orphan GPCRs, CCRL2 (Zabel et al., 2008) and GPR1 (Zabel et 
al., 2008, Barnea et al., 2008). Chemerin is expressed in a number of body tissues 
including liver, white and brown adipose tissue, heart and placenta (Bozaoglu et al., 
2007), and plays an important role in various immunological and metabolic 
functions (Goralski et al., 2007, Wittamer et al., 2003). CMKLR1 is mainly 
expressed in the cells of immune system and in lower levels in a number of other 
body tissues including lungs, heart and adipose tissue (Goralski et al., 2007, Roh et 
al., 2007). First of all, the main aim of this project was to identify the presence of 
chemerin and its receptors in both microvascular and macrovascular EC lines. 
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Endothelial cells form a protective barrier between the circulating blood and the 
surrounding organs. Microvascular (HMEC-1) and macrovascular (EA.hy926) EC 
lines, as well as primary HUVECs cells were cultured to study gene and protein 
expressions of chemerin and its receptors. In addition, CMKLR1 receptor expression 
regulation by known inflammatory mediators such as Tumour Necrosis Factor 
(TNF)-α, Interleukin (IL)-6 and IL-1β was determined in HMEC-1 cell line. 
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3.2 Materials and Methods  
HMEC-1 and EA.hy926 cells were cultured in 6-well plates in MCDB and 
DMEM cell media respectively. Primary HUVECs were cultured in M199 medium. 
Cells were plated in 6-well plates in specific cell media and were serum starved. 
Cells were lysed in RNA lysis solution or protein lysis solution (1x RIPA) for RNA 
isolation and protein sample preparations. RNA was isolated using GenElute
™
 
Mammalian Total RNA Miniprep Kit (Qiagen, Crawley, UK), and RNA 
concentrations were quantified using NanoDrop spectrophotometer (Labtech 
International, Ringmer, UK). RNA concentrations were normalised and were reverse 
transcribed into cDNA using Reverse-Transcription Polymerase Chain Reaction 
(RT-PCR). Using specific gene primers (Table 3.2.1b), PCR reactions were carried 
out using different PCR components (Table 3.2.1a). For human chemerin gene, the 
following PCR conditions were used: 95
o
C for 1 minute; 95
o
C for 45sec, 55
o
C for 
30sec, 72
o
C for 1 minute in a total of 40 cycles with a final extension step at 72
o
C 
for 10 minute. For all three different human chemerin receptors, CMKLR1, CCRL2 
and GPR1, 45 cycles were performed under similar conditions. PCR products were 
separated using agarose gel electrophoresis, were excised from the agarose gel and 
DNA was isolated and purified. DNA samples for each gene were sequence analysed 
at the Molecular Biology Laboratories at The University of Warwick (Coventry, UK). 
The cellular protein expressions of chemerin, CMKLR1, CCRL2 and GPR1 were 
detected using SDS-PAGE (Chapter 2, section 2.3.7, page numbers 57-60) using 
different percentages of polyacrylamide gels to separate different proteins (Table 
3.2.1b).  
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Table 3.2.1a 
The chemical components of PCR reactions used per sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical 
components 
Concentrations Volume used per 
reaction 
 
10x PCR buffer 1x 5µl 
MgCl2 1.5mM 1.5µl 
Taq polymerase 0.5 U/µl 2µl 
10 dNTP 0.2mM 1µl 
R and F primers 100ng/ml 1µl 
cDNA 200ng 2µl 
H2O n/a 37.5µl 
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Table 3.2.1b 
The sense (forward) and anti-sense (reverse) primer sequences for human 
chemerin, CMKLR1, CCRL2, GPR1 and β-actin genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemerin 
CMKLR1 
GPR1 
CCRL2 
CAA CCT GGC AGT GGC AGA TT AGC AGG AAG ACG CTG GTG AA 
TCA GGC ACC ATG TTC TGA CT AGG ATG CTT CGC TTC TTC AC 
GCT GGC ACC AGA GGA TGA AT GTC CAG GAC ACC GAT CAC AA 
β-actin AAG AGA GGC ATC CTC ACC CT TAC ATG GCT GGG GTC TTG AA 
Gene Forward primer Reverse primer 
AGA CAA GCT GCC GAA GA CG TGG AGA AGG CGA ACT  TCC AA 
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Table 3.2.1c 
The molecular weights of proteins and gel percentages used for SDS-PAGE 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein name Molecular weight (kDa) Percentage gels used 
Chemerin 16 15 
CCRL2 40 12 
CMKLR1 42 12 
GPR1 60 10 
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3.3 Data Presentation and Analyses 
3.3.1 Identification of Human Chemerin mRNA Expression in HMEC-1 Cell 
Line 
HMEC-1 cells were cultured in 6-well plates in MCDB medium containing 10% 
FCS, and were serum starved overnight in cell medium containing 1% FCS. Cells 
were lysed in RNA lysis solution and RNA was isolated. mRNA was reverse 
transcribed into cDNA using specific primers (Table 3.2.1a). Conventional PCR was 
carried out to identify the presence of human chemerin mRNA expression in ECs. 
Chemerin PCR products were separated and visualised as a 252bp product by 
agarose gel electrophoresis (Fig. 3.3.1a). DNA product was purified and sequenced 
for sequence authenticity. BLAST search confirmed chemerin gene sequence.  
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Figure 3.3.1a Human chemerin mRNA expression identification in HMEC-1 
cell line 
HMEC-1 cells were cultured in 6-well plates in MCDB medium. Cells were lysed 
using RNA lysis solution and RNA was isolated and quantified using NanoDrop 
spectrophotometer (Labtech International, Ringmer, UK). PCR analysis identified 
human chemerin gene as a 252bp DNA product. The PCR products were resolved on 
1% agarose gel, purified and sequenced to confirm the authenticity of the product. 
Three independent experiments were performed and identical results were obtained. 
GeneRuler
TM
 1kb DNA ladder was used as a marker.  
 
 
 
 
 
 
 
 
 
 
250 
  Marker                HMEC-1 
252bp 
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3.3.2 Chemerin Protein Expression in HMEC-1 and EA.hy926 Cell Lines 
 
HMEC-1 and EA.hy926 cells were cultured in 6-well plates in specific cell 
media containing 10% FCS and were serum starved overnight in respective cell 
media containing 1% FCS. Cells were lysed in 1x RIPA buffer and protein lysates 
were separated using SDS-PAGE. Chemerin protein was identified as a 16kDa 
product in both HMEC-1 and EA.hy926 cell lines (Fig. 3.3.2a). 
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Figure 3.3.2a Chemerin protein expression in HMEC-1 and EA.hy926 cell line 
Both HMEC-1 and EA.hy926 cells were lysed in 1x RIPA buffer and amount of 
proteins were quantified using BCA method. Samples were prepared by mixing 
equal volumes of cell lysates with 1x Laemmili buffer solution, and the proteins 
were separated using 15% polyacrylamide gels, and transferred to PVDF membranes  
at 100V for 1 hour. Membranes were incubated with goat anti-chemerin antibody 
[(1:1000); R and D systems, UK] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with HRP-conjugated rabbit anti-
goat antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. The corresponding 
bands for chemerin were detected as a 16kDa product. 
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3.3.3 Identification of Human CMKLR1, CCRL2 and GPR1 mRNA 
Expression in ECs 
 
HMEC-1, EA.hy926 cell lines and primary HUVEC cells were cultured in 6-
well plates in specific cell media containing 10% FCS and were serum starved 
overnight in respective cell media containing 1% FCS. The cells were lysed, RNA 
was isolated and  reverse transcribed into cDNA. Using specific primers for all three 
different receptors and other PCR components (Table 3.2.1a), conventional PCR was 
performed to identify the presence of chemerin receptors in ECs. Human CMKLR1 
gene was identified as a 153bp DNA product in HMEC-1, EA.hy926 and HUVEC 
cells (Fig. 3.3.3a). Both human CCRL2 and GPR1 mRNA expression was also 
identified in HMEC-1 cell line (Fig. 3.3.3b), EA.hy926 cell line (Fig. 3.3.3c), as well 
as in primary HUVEC cells (Fig. 3.3.3d). DNA products were separated using 2% 
agarose gel and were visualised using UV illuminator. All three receptor PCR 
products were purified and sequenced for sequence authenticity. BLAST search 
confirmed the gene sequences for all three receptors.  
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Figure 3.3.3a Human CMKLR1 receptor identification in HMEC-1 and 
EA.hy926 cell lines and in primary HUVEC cells  
HMEC-1, EA.hy926 cell lines and primary HUVEC cells were cultured in specific 
cell media. Cells were lysed using RNA lysis solution and RNA was isolated and 
quantified using NanoDrop spectrophotometer (Labtech International, Ringmer, UK). 
PCR analysis identified human CMKLR1 as a 153bp DNA product in all three 
different EC types. The PCR products were resolved on 2% agarose gel, purified and 
sequenced to confirm the authenticity of the products. Three independent 
experiments were performed and identical results were obtained. GeneRuler
TM
 50bp 
DNA ladder was used as a marker. 
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Figure 3.3.3b  Human CMKLR1, GPR1 and CCRL2 mRNA expression in 
HMEC-1 cell line 
HMEC-1 cells were cultured in specific cell medium. Cells were lysed using RNA 
lysis solution and RNA was isolated and quantified using NanoDrop 
spectrophotometer (Labtech International, Ringmer, UK). Specific primers identified 
human CMKLR1, GPR1 and CCRL2 as a 153bp, 115bp and 151bp DNA products in 
HMEC-1 cell line respectively. The PCR products were resolved on 2% agarose gel, 
purified and sequenced to confirm the authenticity of the products. Three 
independent experiments were performed and identical results were obtained. 
GeneRuler
TM
 50bp DNA ladder was used as a marker.  
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Figure 3.3.3c  Human CMKLR1, GPR1 and CCRL2 mRNA expression in 
EA.hy926 cell line 
EA.hy926 cells were cultured in specific cell medium. Cells were lysed using RNA 
lysis solution and RNA was isolated and quantified using NanoDrop 
spectrophotometer (Labtech International, Ringmer, UK). Specific primers identified 
human CMKLR1, GPR1 and CCRL2 as a 153bp, 115bp and 151bp DNA products in 
EA.hy926 cell line respectively. The PCR products were resolved on 2% agarose gel, 
purified and sequenced to confirm the authenticity of the products. Three 
independent experiments were performed and identical results were obtained. 
GeneRuler
TM
 50bp DNA ladder was used as a marker.  
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Figure 3.3.3d  Human CMKLR1, GPR1 and CCRL2 mRNA expression levels 
in primary HUVEC cells 
Primary HUVEC cells were cultured in specific cell medium. Cells were lysed using 
RNA lysis solution and RNA was isolated and quantified using NanoDrop 
spectrophotometer (Labtech International, Ringmer, UK). Specific primers identified 
human CMKLR1, GPR1 and CCRL2 as a 153bp, 115bp and 151bp DNA products in 
HUVEC cells respectively. The PCR products were resolved on 2% agarose gel, 
purified and sequenced to confirm the authenticity of the products. Three 
independent experiments were performed and identical results were obtained. 
GeneRuler
TM
 50bp DNA ladder was used as a marker.  
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3.3.4 CMKLR1 Receptor Sequence Analysis 
 
DNA was isolated and purified from CMKLR1 PCR products separated by 
agarose gel electrophoresis. DNA was sequence analysed to confirm the authenticity 
of the product. The sequence analysis for CMKLR1 receptor using Basic Local 
Alignment Search Tool (BLAST) confirmed the authenticity of the product (Fig. 
3.3.4a). 
NM_001142345.1 Homo sapiens chemokine-like receptor 1 (CMKLR1) 
Gene ID: 1240 CMKLR1 
Score = 171 bits (92), Expect = 4e-42 
Identities = 93/94 (99%), Gaps 0/94 (0%) 
Strand = Plus/Plus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  90 
 
 
 
 
 
 
 
 
 
Figure 3.3.4a   Part of human CMKLR1 sequence analysis 
Subject sequence is obtained from NM_001142345.1 (BLAST Nucleic Acid 
Database), and the Query sequence is cloned from CMKLR1.  
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3.3.5 Identification of CMKLR1, GPR1 and CCRL2 Protein Expression in 
HMEC-1, EA.hy926 Cell Lines and Primary HUVEC Cells 
 
HMEC-1, EA.hy926 cell lines and primary HUVEC cells were cultured in 6-
well plates in specific cell media containing 10% FCS and were serum starved 
overnight in respective cell media containing 1% FCS. Cells were lysed in 1x RIPA 
buffer and protein lysates were separated using SDS-PAGE. CMKLR1 protein was 
detected both in HMEC-1 and EA.hy926 cell lines as well as in primary HUVEC 
cells as a 42kDa product (Fig. 3.3.5a). Both orphan chemerin GPCRs, CCRL2 and 
GPR1 were identified as 40kDa and 60kDa protein products in HMEC-1 and 
EA.hy926 cell lines (Fig. 3.3.5b). 
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Figure 3.3.5a  CMKLR1 protein expression in HMEC-1 and EA.hy926 cell lines 
and in primary HUVEC cells 
Both HMEC-1 and EA.hy926 cell lines, and primary HUVEC cells were cultured in 
6-well plates and lysed in a cell lysis solution (1x RIPA). For sample preparations, 
equal volumes of cell lysates were mixed with 1x Laemmli buffer, and the proteins 
were separated using 15% polyacrylamide gels and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with mouse anti-CMKLR1 antibody 
[(1:500); Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with HRP-conjugated anti-mouse antibody 
[(1:1500); Sigma, UK] for 1 hour at RT. Protein complexes were visualised using 
ECL plus detection reagent on X-ray films. Membranes were re-probed with rabbit 
β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for CMKLR1 and β-actin were detected as 
42kDa and 45kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA).  
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Figure 3.3.5b Chemerin orphan receptors, CCRL2 and GPR1 protein 
expressions in HMEC-1 and EA.hy926 cell lines 
Both HMEC-1 and EA.hy926 cell lines were cultured in 6-well plates and lysed in a 
cell lysis solution (1x RIPA). For sample preparations, equal volumes of cell lysates 
were mixed with 1x Laemmli buffer, and the proteins were separated using 12% 
(CCRL2) and 10% (GPR1) polyacrylamide gels and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with rabbit anti-CCRL2 
antibody [(1:1000); Abcam, Cambridge, UK] and mouse anti-GPR1 [(1:1000); Santa 
Cruz, California, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with HRP-conjugated anti-rabbit antibody 
[(1:2000); Dako, Ely, UK] and anti-mouse antibody [(1:1500); Sigma, UK] for 
CCRL2 and GPR1 for 1 hour at RT respectively. Protein complexes were visualised 
using ECL plus detection reagent on X-ray films. The corresponding bands for 
CCRL2 and GPR1 were detected as 40kDa and 60kDa products. 
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3.3.6 Known Inflammatory Mediators; Tumour Necrosis Factor (TNF)-α, 
Interleukin (IL)-6 and IL-1β Increased CMKLR1 Receptor Protein 
Expression in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB medium containing 10% 
FCS and were serum starved overnight in cell medium containing 1% FCS before 
performing different treatments. HMEC-1 cells were treated with different 
concentrations of TNF-α [0-20ng/ml], IL-1β [0-100ng/ml] and IL-6 [0-100ng/ml] for 
12 and 24 hours. Cells were lysed in 1x RIPA buffer and protein lysates were 
separated using SDS-PAGE. TNF-α significantly upregulated CMKLR1 receptor 
protein expression in HMEC-1 cell line in a concentration-dependent manner (p < 
0.001) both at 12 (Fig. 3.3.6a) and 24 hours (Fig. 3.3.6b). IL-6 upregulated 
CMKLR1 receptor expression significantly at [100ng/ml] after 12 (Fig. 3.3.6c) and 
24 hours of incubation (p < 0.001) (Fig. 3.3.6d). IL-1β significantly upregulated 
CMKLR1 receptor expression in HMEC-1 cells in a concentration-dependent 
manner at 12 hours  (p < 0.001) (Fig. 3.3.6e) and 24 hours (Fig. 3.3.6f). 
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Figure 3.3.6a TNF-α increased CMKLR1 receptor protein expression in 
HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with different TNF-α concentrations [0-20 ng/ml] for 12 
hours. Following cell lysis and sample preparations, protein lysates were separated 
using 12% polyacrylamide gels and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with mouse anti-CMKLR1 antibody [(1:500); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with HRP-conjugated anti-mouse antibody [(1:1500); 
Sigma, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for CMKLR1 and β-actin were detected as 42kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 and **p < 0.01 
compared to basal.  
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Figure 3.3.6b TNF-α increased CMKLR1 receptor protein expression in 
HMEC-1 cell line after 24 hours 
HMEC-1 cells were treated with different TNF-α concentrations [0-20 ng/ml] for 12 
and 24 hours. Following cell lysis and sample preparations, protein lysates were 
separated using 12% polyacrylamide gels and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with mouse anti-CMKLR1 antibody 
[(1:500); Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with HRP-conjugated anti-mouse antibody 
[(1:1500); Sigma, UK] for 1 hour at RT. Protein complexes were visualised using 
ECL plus detection reagent on X-ray films. Membranes were re-probed with rabbit 
β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for CMKLR1 and β-actin were detected as 
42kDa and 45kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates ***p < 0.001 and 
**p < 0.01 compared to basal. 
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Figure 3.3.6c IL-6 increased CMKLR1 receptor protein expression in HMEC-1 
cell line after 12 hours 
HMEC-1 cells were treated with different IL-6 concentrations [0-100 ng/ml] for 12 
hours. Following cell lysis and sample preparations, protein lysates were separated 
using 12% polyacrylamide gels and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with mouse anti-CMKLR1 antibody [(1:500); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with HRP-conjugated anti-mouse antibody [(1:1500); 
Sigma, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for CMKLR1 and β-actin were detected as 42kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 compared to basal. 
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Figure 3.3.6d IL-6 increased CMKLR1 receptor protein expression in HMEC-1 
cell line after 24 hours 
HMEC-1 cells were treated with different IL-6 concentrations [0-100 ng/ml] for 24 
hours. Following cell lysis and sample preparations, protein lysates were separated 
using 12% polyacrylamide gels and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with mouse anti-CMKLR1 antibody [(1:500); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with HRP-conjugated anti-mouse antibody [(1:1500); 
Sigma, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for CMKLR1 and β-actin were detected as 42kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 compared to basal. 
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Figure 3.3.6e  IL-1β increased CMKLR1 receptor protein expression in HMEC-
1 cell line after 12 hours 
HMEC-1 cells were treated with different IL-1β concentrations [0-100 ng/ml] for 12 
hours. Following cell lysis and sample preparations, protein lysates were separated 
using 12% polyacrylamide gels and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with mouse anti-CMKLR1 antibody [(1:500); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with HRP-conjugated anti-mouse antibody [(1:1500); 
Sigma, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for CMKLR1 and β-actin were detected as 42kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates  ***p < 0.001 and **p < 0.01 
compared to basal. 
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Figure 3.3.6f  IL-1β increased CMKLR1 receptor protein expression in HMEC-
1 cell line after 24 hours 
HMEC-1 cells were treated with different IL-1β concentrations [0-100 ng/ml] for 24 
hours. Following cell lysis and sample preparations, protein lysates were separated 
using 12% polyacrylamide gels and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with mouse anti-CMKLR1 antibody [(1:500); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with HRP-conjugated anti-mouse antibody [(1:1500); 
Sigma, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for CMKLR1 and β-actin were detected as 42kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates  ***p < 0.001 and **p < 0.01 
compared to basal. 
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3.4 Summary of Results 
In these preliminary set of experiments, human chemerin gene and protein 
expression levels were identified in both human microvascular and macrovascular 
EC lines. All three different chemerin receptors – CMKLR1, CCRL2 and GPR1 
receptors were also identified and confirmed in human EC lines both at gene and 
protein levels. PCR analysis identified chemerin gene as a 252bp product in HMEC-
1 cell line (Fig. 3.3.1a). Chemerin proteins levels were detected in both HMEC-1 and 
EA.hy926 cell lines as a 16kDa product (Fig. 3.3.2a).    
PCR analysis identified CMKLR1 gene in all three different types of ECs as a 
153bp product (Fig. 3.3.3a), and the product authenticity was confirmed using 
BLAST search (Fig. 3.3.4a). In addition to CMKLR1, two other chemerin orphan 
GPCRs, CCRL2 and GPR1 gene levels were also identified and confirmed in 
HMEC-1 (Fig. 3.3.3b), EA.hy926 (Fig. 3.3.3c) cell lines and in primary HUVEC 
cells (Fig. 3.3.3d). Western blotting confirmed the protein expression levels of both 
CCRL2 and GPR1 receptors in both microvascular and macrovascular ECs (Fig. 
3.3.5b). Throughout the rest of this project, only HMEC-1 cell line was used to 
perform different experiments, unless otherwise stated. Microvascular ECs line most 
of the vascularised organs in the human body alongwith macrovascular ECs. Both 
these cell types possess different functional, morphogenetic, and functional 
characteristics (Dye et al., 2004), and are known to secrete varied range of 
vasoactive substances. Different cell types are also known to respond differently to a 
variety of external stimuli, which are likely to affect the activities and functionality 
of different proteins in the cell, alter the transcriptional regulation of various 
different transcription factors, hence regulating the expression of different genes, and 
finally altering the overall biological responses.  
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4.1 Introduction  
The specific aims of this part of the project were to explore the role (s) of 
chemerin (21-157) in; (1) the phosphorylation of important signalling kinases 
including Extracellular Kinases (ERK) 1/2 Mitogen-activated Protein Kinases 
(MAPK), ERK5 MAPK, p38 MAPK and Akt/PKB kinases, (2) the protein 
expression of Vascular Endothelial Growth Factor 165 (VEGF165), a potent 
angiogenic molecule; and of VEGF165b, an anti-angiogenic VEGF isoform, (3) the 
transcriptional regulation of Hypoxia Inducible Factor (HIF)-1α, a transcription 
factor that regulates VEGF165 protein expression and secretion, (4) the 
phosphorylation of Vascular Endothelial Growth Factor Receptor (VEGFR) 2, the 
main signalling receptor for VEGF-mediated angiogenesis, (5) the activity of 
extracellular matrix degrading enzymes such as Matrix Metalloproteinase (MMP)-2 
and -9, and finally (6) inducing biological responses such as EC proliferation, 
migration and capillary tube formation in HMEC-1 cell line. 
Angiogenesis is the process of formation of new capillaries from pre-existing 
blood vessels, and is necessary during wound healing and tissue regeneration. In 
normo-physiological states, angiogenesis is a tightly-controlled process regulated by 
a fine balance between pro- and anti-angiogenic factors (Rangasamy et al., 2011, 
Klagsbrun and D'Amore, 1991). ERK1/2, ERK5 and p38 MAPK are important 
MAPKs which are activated by a number of different stimuli (Fig. 1.5.1a, page 
number 34). Various different cytokines and adipokine are known to activate these 
MAPKs and are implicated in various different cellular responses; for example 
ERK1/2 and ERK5 MAPK are important in cell proliferation (Zhang and Liu, 2002), 
whereas, p38 and SAPK/JNK MAPKs are known to mediate cell apoptosis (Xia et 
al., 1995, Henkart, 1996).  
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Akt/PKB kinase is an important kinase implicated in EC survival via 
VEGF/Akt/PI3K pathway and is known to regulate the expression of VEGF165, the 
most potent isoform of VEGF; which is specifically expressed in the endothelium 
and is implicated in EC angiogenesis, vasodilation and microvascular permeability 
(Semenza et al., 2011, Senger et al., 1983, Dvorak et al., 1995a). VEGF gene 
undergoes alternative splicing and results in the formation of anti-angiogenic 
isoforms of VEGF, which are collectively grouped in VEGFxxxb family – xxx 
representing the number of amino acids (Appendix 5, Fig. 5.1a, page number 248). 
VEGF165b is the most abundant anti-angiogenic, and opposite counterpart of 
VEGF165 which is reported to exert anti-angiogenic functions (Craine et al., 1995). 
Different VEGF isoforms bind and signal via two different Receptor Tyrosine 
Kinases (RTKs), VEGFR1 and VEGFR2. Upon ligand stimulation, both receptors 
dime rise and undergo trans-autophosphorylation, however, VEGFR2 is the main 
functional receptor for VEGF-dependent angiogenesis and vascular permeability 
(Okamoto et al., 1997). Under hypoxic conditions, Hypoxia Inducible Factor (HIF)-1, 
a heterodimer transcription factor composed of an α and a β subunit, regulates the 
expression and secretion of VEGF protein (Shimaoka et al., 2001). VEGF induces 
the expression of matrix degrading enzymes such as MMP-2 and -9, which further 
promote EC proliferation, migration and capillary tube formation (Hagemann et al., 
2004). 
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4.2 Materials and Methods Used 
The cellular protein expression and phosphorylation were determined using 
SDS-PAGE (Chapter 2, section 2.3.7, page numbers 57-60) using different 
percentage polyacrylamide gels for separating different proteins (Table 4.2.1a). The 
gelatinolytic activity of secreted MMP-2 and -9 in EC culture supernatants was 
studied using gelatin zymography (Chapter 2, section 2.3.9, page numbers 61). 
Endothelial cell proliferation was determined using CellTiter
®
 96 AQueous One 
Solution cell proliferation assay (MTS) (Chapter 2, section 2.4.2, page number 63). 
EC migration was studied by using both Wound-healing Cell Motility Assay 
(Chapter 2, section 2.4.3, page numbers 63-4), and also by using in vitro Cell 
Invasion Assay (Chapter 2, section 2.4.4, page numbers 64-5). Chemerin (21-157) 
and EC capillary tube formation was studied using Growth Factor Reduced Matrigel 
(Chapter 2, section 2.4.5, page number 65-6). EC death was studied using Cellular 
DNA Fragmentation ELISA kit (Chapter 2, section 2.4.6,  page numbers 66). 
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Table 4.2.1a  
The molecular weights of different proteins and gel percentages used for SDS-
PAGE analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein  Molecular weight (kDa) Percentage gels used 
Akt/PKB Kinase 60 10 
ERK1/2 MAPK 44/42 12 
ERK5 MAPK 110 8 
HIF-1α 93 10 
MMP-2 and -9 68 and 88 10 
p38 MPAK 38 12 
VEGFR2 230 6 
VEGF165 45 12 
VEGF165b 22 15 
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4.3 Data Presentation and Analyses 
4.3.1 Chemerin (21-157) Lead to ERK1/2 MAPK Phosphorylation in a Time- 
and Concentration-dependent manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
ERK1/2 MAPK phosphorylation, HMEC-1 cells were treated with [0.1nM] 
chemerin (21-157) at different time-points for a maximum of 30 minutes. For 
concentration-dependent ERK1/2 MAPK phosphorylation, HMEC-1 cells were 
treated with different chemerin (21-157) [0-30nM] concentrations for 5 minute. Cells 
were lysed in 1x RIPA buffer and protein lysates were separated using SDS-PAGE. 
Chemerin (21-157) increased ERK1/2 (Thr202/Tyr204) MAPK phosphorylation in a 
time-dependent manner with a significant increase at 5 minutes (p < 0.001) 
compared to basal and decreasing at 30 minutes (Fig. 4.3.1a). Chemerin (21-157) at 
[0.1nM] significantly increased phosphorylation of ERK1/2 (Thr202/Tyr204) 
MAPK (p < 0.001), and decreasing at 1, 10 and 30nM concentrations compared to 
basal (Fig. 4.3.1b). 
 
 
 
 
 
 
  107 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1a Chemerin (21-157) lead to ERK1/2 MAPK phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [0.1nM] chemerin (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the proteins were separated using 12% 
polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 hour. 
Membranes were incubated with specific phospho-ERK1/2 (Thr202/Tyr204) 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After 
removing the primary antibody complexes, membranes were incubated with anti-
rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total ERK1/2 MAPK antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both phospho-ERK1/2 and total ERK1/2 MAPK were detected as 
44/42kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 and **p < 0.01 
compared to basal. 
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Figure 4.3.1b Chemerin (21-157) lead to ERK1/2 MAPK phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 5 minutes. Following cell lysis and sample preparations, the proteins were 
separated using 12% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific phospho-ERK1/2 
(Thr202/Tyr204) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight 
at 4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at 
RT. Protein complexes were visualised using ECL plus detection reagent on X-ray 
films. Membranes were re-probed with total ERK1/2 antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both phospho-ERK1/2 and total ERK1/2 MAPK were detected as 
44/42kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 and **p < 0.01 
compared to basal. 
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4.3.2 Chemerin (21-157) Lead to ERK5 MAPK Phosphorylation in a Time- 
and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
ERK5 MAPK phosphorylation, HMEC-1 cells were treated with [10nM] chemerin 
(21-157) at different time-points for a maximum of 30 minutes. For concentration-
dependent ERK5 MAPK phosphorylation, HMEC-1 cells were treated with different 
chemerin (21-157) [0-10nM] concentrations for 15 minute. Cells were lysed in 1x 
RIPA buffer and protein lysates were separated using SDS-PAGE. Chemerin (21-
157) increased ERK5 (Thr218/Tyr220) MAPK phosphorylation both in a time-
dependent manner with significant increase at 15 minutes (p < 0.01) (Fig. 4.3.2a), 
and also in a concentration-dependent manner significantly at [0.01-10nM] chemerin 
(21-157) concentrations compared to basal (Fig. 4.3.2b).  
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Figure 4.3.2a  Chemerin (21-157) lead to ERK5 MAPK in a time-dependent 
manner in HMEC-1 cell line 
HMEC-1 cells were treated with [10nM] chemerin (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the proteins were separated using 8% 
polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 hour. 
Membranes were incubated with specific phospho-ERK5 (Thr218/Tyr220) MAPK 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After 
removing the primary antibody complexes, membranes were incubated with anti-
rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with ERK5 MAPK antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for both 
phospho-ERK5 and total ERK5 MAPK were detected as 115kDa products. The band 
intensities were measured using Scion Image™ densitometer (Scion Corporation, 
Maryland, USA). The data are presented as mean ± SEM of three independent 
experiments in duplicates **p < 0.01 and *p < 0.05 compared  to basal.  
 
 
P
h
o
s
p
h
o
/T
o
ta
l 
E
R
K
5
 M
A
P
K
 
(R
e
la
ti
v
e
 t
o
 b
a
s
a
l)
 
Time (minutes) 
* 
** 
** 
* 
   B             2              5             10            15            30 
0
1
2
3
4
5
6 
 
4 
3 
2 
 
 
 Time (minutes) B             2             5           10            15          30 
115 kDa 
115 kDa ERK 5 MAPK 
ph-ERK5 MAPK 
(Thr218/Tyr220) 
  111 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2b Chemerin (21-157) lead to ERK5 MAPK phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 15 minutes. Following cell lysis and sample preparations, the proteins 
were separated using 8% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific phospho-ERK5 
(Thr218/Tyr220) MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
overnight at 4
o
C. After removing the primary antibody complexes, membranes were 
incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 
1 hour at RT. Protein complexes were visualised using ECL plus detection reagent 
on X-ray films. Membranes were re-probed with ERK5 MAPK antibody [(1:1500); 
Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-ERK5 and total ERK5 MAPK were detected 
as 115kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001, **p < 0.01 and 
*p < 0.05 compared to basal.  
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4.3.3 Chemerin (21-157) Lead to p38 MAPK Phosphorylation in a Time- and 
Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent p38 
MAPK phosphorylation, HMEC-1 cells were treated with [0.1nM] chemerin (21-157) 
at different time-points for a maximum of 30 minutes. For concentration-dependent 
p38 MAPK phosphorylation, HMEC-1 cells were treated with different chemerin 
(21-157) [0-30nM] concentrations for 15 minute. Cells were lysed in 1x RIPA buffer 
and protein lysates were separated using SDS-PAGE. Chemerin (21-157) increased 
p38 (Thr180/Tyr182) MAPK phosphorylation in a time-dependent manner with a 
significant increase at 10 and 15 minutes (p < 0.001) and decreasing at 30 minutes 
compared to basal (Fig. 4.3.3a). Chemerin (21-157) significantly increased p38 
(Thr180/Tyr182) MAPK phosphorylation at lower concentrations (p < 0.001) which 
then decreased at 10 and 30nM chemerin (21-157) concentrations compared to basal 
(Fig. 4.3.3b).  
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Figure 4.3.3a Chemerin (21-157) lead to p38 MAPK phosphorylation in a time-
dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [0.1nM] chemerin (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the proteins lysates were separated 
using 12% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with specific phospho-p38 (Thr180/Tyr182) 
MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total p38 MAPK [(1:1500); Cell signalling, Beverly, 
MA, USA] and used as a loading control. The corresponding bands for both 
phospho-p38 (Thr180/Tyr182) and total p38 MAPK were detected as 38kDa 
products. The band intensities were measured using Scion Image™ densitometer 
(Scion Corporation, Maryland, USA). The data are presented as mean ± SEM of 
three independent experiments in duplicates ***p < 0.001 and *p < 0.05 compared to 
basal.  
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Figure 4.3.3b Chemerin (21-157) lead to p38 MAPK phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with chemerin (21-157) [0-30nM] for 10 minutes. 
Following cell lysis and sample preparations, the proteins lysates were separated 
using 12% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with specific phospho-p38 (Thr180/Tyr182) 
MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total p38 MAPK [(1:1500); Cell signalling, Beverly, 
MA, USA] and used as a loading control. The corresponding bands for both 
phospho-p38 (Thr180/Tyr182) and total p38 MAPK  were detected as 38kDa 
products. The band intensities were measured using Scion Image™ densitometer 
(Scion Corporation, Maryland, USA). The data are presented as mean ± SEM of 
three independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared 
to basal.  
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4.3.4 Chemerin (21-157) Lead to Akt/PKB Kinase Phosphorylation in a Time- 
and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent Akt 
phosphorylation, HMEC-1 cells were treated with [10nM] chemerin (21-157) at 
different time-points for a maximum of 30 minutes. For concentration-dependent 
Akt phosphorylation, HMEC-1 cells were treated with different chemerin (21-157) 
concentrations [0-30nM] for 5 minute. Cells were lysed in 1x RIPA buffer and 
protein lysates were separated using SDS-PAGE. Chemerin (21-157) increased Akt 
(Ser473) phosphorylation in a time-dependent manner with a significant increase at 5 
minutes (p < 0.001) compared to basal (Fig. 4.3.4a). Chemerin (21-157) significantly 
increased Akt (Ser473) phosphorylation at lower concentrations (p < 0.001 and p < 
0.01), decreasing  at [30nM] compared to basal (Fig. 4.3.4b). 
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Figure 4.3.4a Chemerin (21-157) lead to Akt/PKB kinase phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with chemerin [10nM] (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the proteins lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with specific phospho-Akt (Ser473) antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-rabbit IgG-HRP 
labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes 
were visualised using ECL plus detection reagent on X-ray films. Membranes were 
re-probed with total Akt [(1:1500); Cell signalling, Beverly, MA, USA] and used as 
a loading control. The corresponding bands for both phospho-Akt and total Akt were 
detected as 60kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates ***p < 0.001, **p < 
0.01 and *p < 0.05 compared  to basal.  
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Figure 4.3.4b Chemerin (21-157) lead to Akt/PKB kinase phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 10 minutes. Following cell lysis and sample preparations, the proteins 
were separated using 10% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific phospho-Akt (Ser473) 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After 
removing the primary antibody complexes, membranes were incubated with anti-
rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total Akt [(1:1500); Cell signalling, Beverly, MA, 
USA] and used as a loading control. The corresponding bands for both phospho-Akt 
and total Akt protein were detected as 60kDa products. The band intensities were 
measured using Scion Image™ densitometer (Scion Corporation, Maryland, USA). 
The data are presented as mean ± SEM of three independent experiments in 
duplicates ***p < 0.001, **p < 0.01 and *p < 0.05 compared  to basal.  
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4.3.5 Chemerin (21-157)  Decreased VEGF165 Protein Expressions in HMEC-
1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. HMEC-1 cells were treated 
with different chemerin (21-157) [0-30nM] concentrations for 12 and 24 hours. Cells 
were lysed in 1x RIPA buffer and protein lysates were separated using SDS-PAGE. 
After 12 hours, chemerin (21-157) decreased VEGF165 protein expression levels in 
HMEC-1 cells in a concentration-dependent manner with the most significant 
decrease at [30nM] (p < 0.001) (Fig. 4.3.5a). Also, at 24 hours, chemerin (21-157) 
decreased VEGF165 protein expression levels in a concentration-dependent manner 
compared to basal (Fig. 4.3.5b).  
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Figure 4.3.5a Chemerin (21-157) decreased VEGF165 protein expression in 
HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 12 hours. Following cell lysis and sample preparations, the proteins were 
separated using 12% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific mouse anti-VEGF165 
antibody [(1:1000); Santa Cruz, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-mouse IgG-HRP labelled 
antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membranes were re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both VEGF165 and β-
actin were detected as 45kDa products. The band intensities were measured using 
Scion Image™ densitometer (Scion Corporation, Maryland, USA). The data are 
presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.001, **p < 0.01 and *p < 0.05 compared to basal.  
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Figure 4.3.5b Chemerin (21-157) decreased VEGF165 protein expression in 
HMEC-1 cell line after 24 hours 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 24 hours. Following cell lysis and sample preparations, the proteins were 
analysed using 12% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific mouse anti-VEGF165 
antibody [(1:1000); Santa Cruz, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-mouse IgG-HRP labelled 
antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membranes were re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both VEGF165 and β-
actin were detected as 45kDa products. The band intensities were measured using 
Scion Image™ densitometer (Scion Corporation, Maryland, USA). The data are 
presented as mean ± SEM of three independent experiments in duplicates **p < 0.01 
and *p < 0.05 compared to basal.  
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4.3.6 Chemerin (21-157) Increased VEGF165b Protein Expression in HMEC-
1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. HMEC-1 cells were treated 
with different chemerin (21-157) [0-30nM] concentrations for 12 and 24 hours. Cells 
were lysed in 1x RIPA buffer and protein lysates were separated using SDS-PAGE. 
In both 12 and 24 hours treated HMEC-1 cells, chemerin (21-157) significantly 
increased VEGF165b protein expression levels in HMEC-1 cells in a concentration-
dependent manner with significant increase at [10nM] and [30nM] concentrations (p 
< 0.001) (Fig. 4.3.6a and b respectively).  
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Figure 4.3.6a Chemerin (21-157) increased VEGF165b protein expression in 
HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 12 hours. Following cell lysis and sample preparations, the proteins were 
separated using 15% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific mouse anti-VEGF165b 
antibody [(1:1000); R and D Systems, UK] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-mouse IgG-HRP 
labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein 
complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for 
VEGF165b and β-actin were detected as 22kDa and 45kDa products. The band 
intensities were measured using Scion Image™ densitometer (Scion Corporation, 
Maryland, USA). The data are presented as mean ± SEM of three independent 
experiments in duplicates ***p < 0.001 and *p < 0.05 compared to basal.  
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Figure 4.3.6b Chemerin (21-157) increased VEGF165b protein expression in 
HMEC-1 cell line after 24 hours  
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 24 hours. Following cell lysis and sample preparations, the proteins were 
separated using 15% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific mouse anti-VEGF165b 
antibody [(1:1000); R and D Systems, UK] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-mouse IgG-HRP 
labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein 
complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for 
VEGF165b and β-actin were detected as 22kDa and 45kDa products. The band 
intensities were measured using Scion Image™ densitometer (Scion Corporation, 
Maryland, USA). The data are presented as mean ± SEM of three independent 
experiments in duplicates ***p < 0.001, **p < 0.01 and  *p < 0.05 compared to basal.  
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4.3.7 Chemerin (21-157) Lead to VEGFR2 Phosphorylation in a Time- and 
Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
VEGFR2 phosphorylation, HMEC-1 cells were treated with [10nM] chemerin (21-
157) at different time-points for a maximum of 30 minutes. For concentration-
dependent VEGFR2 phosphorylation, HMEC-1 cells were treated with different 
chemerin (21-157) [0-30nM] concentrations for 1 minute. Cells were lysed in 1x 
RIPA buffer and protein lysates were separated using SDS-PAGE. Chemerin (21-
157) increased VEGFR2 receptor phosphorylation both in a time-dependent manner 
with a significant increase at 0.5 minutes (p < 0.001) (Fig. 4.3.7a), and also in a 
concentration-dependent manner at [1.0nM], [10nM] and [30nM] chemerin (21-157) 
concentrations (p < 0.001 and p < 0.01) compared to basal (Fig. 4.3.7b). VEGF 
[10ng/ml] was used as a positive control.  
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Figure 4.3.7a Chemerin (21-157) lead to VEGFR2 phosphorylation in a time-
dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [10nM] chemerin (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the proteins were separated using 6% 
polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 hour. 
Membranes were incubated with specific phospho-VEGFR2 (Tyr1175) antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-rabbit IgG-HRP 
labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes 
were visualised using ECL plus detection reagent on X-ray films. Membranes were 
re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for phospho-VEGFR2 
(Tyr1175) protein and β-actin were detected as 230kDa and 45kDa products. The 
band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared to 
basal. VEGF [10ng/ml] was used as a positive control. 
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Figure 4.3.7b Chemerin (21-157) lead to VEGFR2 phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 1 minute. Following cell lysis and sample preparations, the proteins were 
separated using 6% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific phospho-VEGFR2 
(Tyr1175) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membrane was re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for 
phospho-VEGFR2 (Tyr1175) protein and β-actin were detected as 230kDa and 
45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 and **p < 0.01 
compared to basal. VEGF [10ng/ml] was used as a positive control. 
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4.3.8 Chemerin (21-157) Increased MMP-2 and -9 Gelatinolytic Activity in a 
Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. HMEC-1 cells were 
treated with different chemerin (21-157) concentrations [0-30nM] for 24 hours and 
cell supernatants were collected. Gelatin zymography was used to determine the 
gelatinolytic activity of secreted MMP-2 and -9 in cell supernatants. Chemerin (21-
157) significantly increased the activities of both MMP-2 and -9 in a concentration-
dependent manner with a peak response at [10nM] and [30nM] concentrations (p < 
0.001) (Fig. 4.3.8a and b respectively). VEGF [10ng/ml] was used as a positive 
control. 
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Figure 4.3.8a Chemerin (21-157) increased MMP-2 gelatinolytic activity in a 
concentration-dependent manner in HMEC-1 cell supernatants 
10μl of cell culture supernatant sample was mixed with 10μl zymography sample 
buffer and resolved on 10% SDS-PAGE containing 1 mg/ml of gelatin (Sigma, St. 
Louis, USA) under non-reducing conditions. Following electrophoresis at 4
o
C, gels 
were washed twice for 30 minutes with denaturation buffer (2.5% Triton X-100) at 
RT, and incubated overnight in incubation buffer (50mM Tris-HCl pH 7.5, 200mM 
NaCl, 10mM CaCl2, 1μM ZnCl2) at 37oC. Characterisation of MMPs activity was 
determined by inhibition with EDTA [10mM]. Following incubation, gels were 
stained for 1 hour (0.25% Coomassie brilliant blue R-250 in 45% methanol, 10% 
acetic acid), and de-stained in the same buffer without Coomassie. The white bands 
against a blue background were observed following de-staining of gels. The 
corresponding bands for MMP-2 were detected as a 68kDa products. The band 
intensities were measured using Gel Pro image analysis [Gel Pro image analysis (Gel 
Pro 4.5, Media Cybernetics, USA)]. The data are represented as mean ± SEM of 
three independent experiments in duplicates ***p < 0.001 and *p < 0.05 compared to 
basal. VEGF [10ng/ml] used as a positive control. 
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Figure 4.3.8b Chemerin (21-157) increased MMP-9 gelatinolytic activity in a 
concentration-dependent manner in HMEC-1 cell supernatants 
10μl of cell culture supernatant sample was mixed with 10μl zymography sample 
buffer and resolved on 10% SDS-PAGE containing 1 mg/ml of gelatin (Sigma, St. 
Louis, USA) under non-reducing conditions. Following electrophoresis at 4
o
C, gels 
were washed twice for 30 minutes with denaturation buffer (2.5% Triton X-100) at 
RT, and incubated overnight in incubation buffer (50mM Tris-HCl pH 7.5, 200mM 
NaCl, 10mM CaCl2, 1μM ZnCl2) at 370C. Characterisation of MMPs activity was 
determined by inhibition with EDTA [10mM]. Following incubation, gels were 
stained for 1 hour (0.25% Coomassie brilliant blue R-250 in 45% methanol, 10% 
acetic acid), and de-stained in the same buffer without Coomassie. The white bands 
against a blue background were observed following de-staining of gels. The 
corresponding bands for MMP-9 were detected as a 68kDa product. The band 
intensities were measured using Gel Pro image analysis [Gel Pro image analysis (Gel 
Pro 4.5, Media Cybernetics, USA)]. The data are represented as mean ± SEM of 
three independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared 
to basal. VEGF [10ng/ml] used as a positive control. 
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4.3.9  Chemerin (21-157) Increased HMEC-1 Cell Proliferation in a 
Concentration-dependent Manner 
 
HMEC-1 cell proliferation was determined using CellTiter 96 AQueous One 
Solution cell proliferation assay (Chapter 2, section 2.4.2, page number 60). HMEC-
1 cells were trypsinised and cultured in 96-well plate (provided in the kit) at the cell 
density of 2.5x10
5 
cells/well for 24 hours in a humidified incubator at 37
o
C at 5% 
CO2 environment. Cells were serum-starved overnight and treated with different 
chemerin (21-157) [0-30nM] concentrations for a maximum of 24 hours. After 24 
hours of incubation, the cell medium was replaced with 100μl of fresh culture 
medium, 20μl MTS reagent was added to each well, and incubated for 1 hour. The 
absorbance was recorded at 490nm using an ELISA plate reader (EL800, Bio-Tek 
Instruments, Inc., Winooski, VT, USA). Chemerin (21-157) significantly increased 
HMEC-1 cell proliferation at the concentrations of [0.1nM] and [1.0nM] (p < 0.01), 
and decreasing at higher chemerin (21-157) concentrations compared to basal (Fig. 
4.3.9a). VEGF [10ng/ml] was used as a positive control. 
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Figure 4.3.9a Chemerin (21-157) induced HMEC-1 cell proliferation in a 
concentration-dependent manner  
HMEC-1 cells were plated at the cell density of 2.5x10
5
 in a 96-well culture for 24 
hours in a humidified incubator at 37
o
C at 5% CO2 environment. Serum-starved 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-30 
nM] for 24 hours. Following chemerin treatments, 20μl MTS reagent was added to 
100μl of cell culture medium per well. After 1 hour at 37oC in a humidified, 5% CO2 
atmosphere, the absorbance was recorded at 490nm using an ELISA plate reader 
(EL800, Bio-Tek Instruments, Inc., Winooski, VT, USA). The percentage increase in 
absorbance was calculated against untreated cells. The results are presented as 
percentage of cells in relation to basal (untreated), and represents the mean of 
triplicates in duplicates **p < 0.01 and *p < 0.05 compared to basal. VEGF [10ng/ml] 
was used as a positive control. 
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4.3.10 Chemerin (21-157) Increased HMEC-1 Cell Migration in a 
Concentration-dependent Manner 
 
HMEC-1 cell migration was studied using Wound-healing Motility Assay as 
well as In Vitro Cell Invasion Assay. For Wound-healing Motility Assay (Chapter 2, 
section 2.4.3, page numbers 64-5), HMEC-1 cells were trypsinised and plated in 6-
well plates at the final cell density of 1x10
5 
cells/ml in MCDB cell medium 
containing 10% FCS and incubated overnight. In 75-80% confluent cells, a single 
scratch wound was created using a sterile p10 micropipette tip. Cell medium was 
replaced with MCDB medium containing 1% FCS and incubated overnight. Cells 
were treated with different chemerin (21-157) [0-30nM] concentrations and 
incubated for a maximum of 24 hours. Chemerin (21-157) increased the number of 
migrated ECs in a concentration-dependent manner (Fig. 4.3.10a). VEGF [10ng/ml] 
was used as a positive control. In Vitro Cell Invasion Assay was performed using BD 
BioCoat™ Matrigel™ Invasion Chamber. 750μl of 1% FCS containing MCDB 
medium treated with different chemerin (21-157) [0-30nM] concentrations was 
added to the BD Falcon™ TC Companion Plate. The rehydrated Culture Inserts were 
placed in the plates, and 250µl of HMEC-1 cell suspension containing approximately 
3x10
4
 cells/ml was added, and incubated for 24 hours in a humidified incubator at 
37
o
C at 5% CO2 environment. After incubations, the non-invading cells were 
scrubbed off using a cotton-tipped swab from the Culture Inserts, and cells invaded 
through the Matrigel™ Matrix were labelled with 4µg/ml Calcein-AM for 90 
minutes. Fluorescence of migrated cells was read at 494/517nm (excitation/emission) 
using a fluorescence plate reader. Chemerin (21-157) significantly increased the 
number of migrating endothelial cells in a concentration-dependent manner (p < 0.01) 
(Fig. 4.3.10b). VEGF [10ng/ml] was used as a positive control. 
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Figure 4.3.10a Chemerin (21-157) induced EC migration in HMEC-1 cell line in 
a concentration-dependent manner 
HMEC-1 cells were trypsinised and plated in 6-well plates at the final cell density of 
1x10
5 
cells/ml in MCDB cell medium containing 10% FCS and incubated overnight. 
In 75-80% confluent cells, a single scratch wound was created using a sterile p10 
micropipette tip, and markings were created to serve as reference points in order to 
eliminate any possible variation caused by the difference in the width of the 
scratches. Cell medium was replaced with MCDB medium containing 1% FCS and 
incubated overnight. Cells were treated with different human recombinant chemerin 
(21-157) concentrations [0-30nM] (R and D systems, Abingdon, UK)  and incubated 
for a maximum of 24 hours. VEGF [10ng/ml] (Sigma Aldrich, Dorset, UK) was used 
as a positive control. Images were captured using invert phase microscope. 
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Figure 4.3.10b Chemerin (21-157) induced EC migration in a concentration-
dependent manner in HMEC-1 cell line 
HMEC-1 cells were trypsinised and final cell suspension of 3x10
4
 cell/ml was 
prepared. 250µl of resultant cell suspension was added to each Culture Inserts 
suspended in 750µl of chemerin (21-157) treated starvation medium in the lower 
chamber and incubated overnight in a humidified incubator at 37
o
C at 5% CO2 
environment. After incubations, the non-invading cells were scrubbed off using a 
cotton-tipped swab from the Culture Inserts, and cells invaded through the 
Matrigel™ Matrix were labelled with 4µg/ml Calcein-AM (BD Biosciences, UK) for 
90 minutes. Fluorescence of migrated cells was read at 494/517nm 
(excitation/emission) using a fluorescence plate reader. The migrated cells were 
expressed as the ratio of the fluorescence value compared to the basal. This figure 
shows graphical representation of migratory distance (expressed as a percentage 
difference relative to basal). The data are presented as mean ± SEM of three 
independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared to 
basal. VEGF [10ng/ml] was used as a positive control. 
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4.3.11 Chemerin (21-157) and Capillary Tube Formation in HMEC-1 Cell Line 
Endothelial cell capillary tube formation was studied using Growth Factor 
Reduced Matrigel Matrix (Chapter 2, section 2.4.5, page number 65-6). HMEC-1 
cells were trypsinised in MCDB cell medium and cell suspension containing 2x10
4
 
cells/well was prepared and added to pre-coated Matrigel plate, and incubated for 2 
hours to encourage cell attachment. Post incubation, cell medium was carefully 
removed from the wells avoiding any damage to the coated gel, and was replaced 
with cell medium containing 1% FCS and incubated for 4 hours. Cells were treated 
with different chemerin (21-157) [0-30nM] concentrations for 24 hours, and 
capillary tube formation images were captured with a digital microscope camera 
system (Olympus, Tokyo, Japan) under 100x magnification using invert phase 
microscope (Fig.4.3.11a). The tube lengths in 3-4 randomly selected fields in each of 
the wells were measured and compared against untreated groups using Image-Pro 
Plus software. Chemerin (21-157) significantly increased capillary tube length in a 
concentration-dependent manner, with a maximum tube length formation at higher 
chemerin (21-157) concentrations (p < 0.001) (4.3.11b). VEGF [10ng/ml] was used 
as a positive control. 
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Figure 4.3.11a Chemerin (21-157) induced capillary tube formation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were trypsinised and seeded onto the Matrigel coated plates at the cell 
density of 2x10
3
cells/well in the fresh medium and incubated for 2 hours. Cell 
medium was replaced with MCDB medium containing 1% FCS and incubated for 4 
hours. Post incubations, HMEC-1 cells were treated with different chemerin (21-157) 
concentrations [0-30nM] and VEGF [0.5nM] and incubated for a maximum of 24 
hours. Capillary tube formation images were captured using a digital microscope 
camera system (Olympus, Tokyo, Japan) under 100x magnification. Image-Pro Plus 
software was used to quantify the tube length formation. The tube lengths in 3-4 
randomly selected fields in each of the wells were measured and compared against 
untreated groups. VEGF [10ng/ml] was used as a positive control. 
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Figure 4.3.11b Graphical presentation of chemerin (21-157)-induced capillary 
tube formation in HMEC-1 cell line 
This figure represents the capillary tube length measurement, expressed as relative to 
basal; HMEC-1 cells were incubated with different chemerin (21-157) 
concentrations [0-30nM] for a maximum of 24 hours. Image-Pro Plus software was 
used to quantify the tube length. The length of tubes in 3-4 randomly selected fields 
in each of the treatment group was compared with the untreated groups. The data are 
presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.001, **p < 0.01 and *p < 0.05 compared to basal. VEGF [10ng/ml] was used as a 
positive control.  
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4.3.12 Chemerin (21-157) Increased HMEC-1 Cell Apoptosis in a 
Concentration-dependent Manner  
 
Endothelial cell apoptosis assay was studied using Cellular DNA 
Fragmentation ELISA kit (Chapter 2, section 2.4.6, page numbers 66-7). HMEC-1 
cells were trypsinised and plated in 96-well plates at the cell density of 1x10
3 
cells/ml and incubated overnight in a humidified incubator at 37
o
C at 5% CO2 
environment. Cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 24 hours. Following incubations, cell supernatants were carefully 
removed and 200µl of 1x incubation solution (solution 5) was added to each well 
and incubated for 30 minutes at RT. Cells were centrifuged at 250g for 10 minutes 
and 100µl of the cell supernatants from lysed cells were transferred to pre-coated 
anti-DNA antibody microplates, ELISA was performed, and the absorbance was 
recorded at 450 nm using a plate reader. Chemerin (21-157) significantly increased 
EC death in a concentration-dependent manner (p < 0.001) (Fig. 4.3.12a). 
Camptothecin [2µM] was used as a positive control. 
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Figure 4.3.12a  Chemerin (21-157) and cell apoptosis in HMEC-1 cell line 
HMEC-1 cells were trypsinised and plated in 96-well plate at the cell density of 
1x10
3 
cells/ml and incubated overnight in a humidified incubator at 37
o
C at 5% CO2 
environment. Cells were labelled with anti-BrdU solution (solution 7) at the final 
concentration of [10µM] and incubated for 24 hours before treating with different 
chemerin (21-157) concentrations [0-30nM] for another 24 hours. After incubation, 
cell supernatants were carefully removed and 200µl of 1x incubation solution 
(solution 5) was added to each well for cell lysis and incubated for 30 minutes at RT. 
Cells were centrifuged at 250g for 10 minutes and 100µl of the cell supernatants 
were transferred to pre-coated ELISA microplates and absorbance was measured  
using a spectrophotometer (Beckman Instruments Inc., California, USA). The data 
are presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.001 compared to basal. Camptothecin [2µM] was used as a positive control. 
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4.4 Summary of Results 
Chemerin (21-157) lead to ERK1/2 MAPK and ERK5 MAPKs 
phosphorylation in a time- and concentration-dependent manner (Fig. 4.3.1a (time 
response) and b (concentration response), and Fig. 4.3.2a and b respectively). 
Chemerin (21-157) also resulted in p38 MAPK phosphorylation in a time- and 
concentration-dependent manner (Fig. 4.3.3a and b respectively) which is an 
important MAPK implicated in cell apoptosis. SAPK/JNK is another important 
MAPK known to play crucial role in cell death, and was phosphorylated by chemerin 
(21-157) in a time- and concentration-dependent manner (Appendix 11, Fig. 11.1a 
and b respectively, page numbers 277-79). 
Chemerin (21-157) also lead to the phosphorylation of Akt/PKB kinase at 
Ser473 phosphorylation site in a time- and concentration-dependent manner (Fig. 
4.3.4a and b respectively). Akt/PKB kinase phosphorylation at Ser473 site is known 
to increase EC angiogenesis upstream of VEGF protein and regulates the production 
of endothelium NO (Michell et al., 1999). Akt/PKB kinase regulates protein 
expression of VEGF, which is the most potent angiogenic molecule known to 
promote angiogenesis; and Akt/PKB kinase activation is suggested to be sufficient 
for angiogenesis to take place (Ackah et al., 2005).   
Chemerin (21-157) treated HMEC-1 cells showed an increased expression of 
HIF-1α protein in a concentration-dependent manner (Appendix 3, Fig. 3.1a, page 
numbers 245-6). HIF-1α is a transcription factor that is known to regulate mRNA 
expression of a number of genes under normal and hypoxic conditions. Essentially, 
under hypoxic conditions, increased HIF-1α activity is reported to increase VEGF 
protein expression; however, quite interestingly, chemerin (21-157) decreased 
VEGF165 protein expression in a concentration-dependent manner both at 12 and 24 
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hours in HMEC-1 cell line (Fig. 4.3.5a and b respectively). An anti-angiogenic form 
of VEGF, VEGF165b, which is formed upon alternative splicing of VEGF gene at 
exon 8b (Appendix 5, Fig. 5.1a, page number 248); was significantly increased with 
increasing chemerin (21-157) concentrations in HMEC-1 cell line (Fig. 4.3.6a and b 
respectively). VEGF165b is an opposite counterpart of VEGF165, and competes 
with VEGF165 for the binding site (s) on tyrosine kinase receptor, VEGFR2 – the 
main signalling receptor involved in VEGF-dependent angiogenesis and exerts anti-
angiogenic properties (Neufeld et al., 1999, Nowak et al., 2008).  
Chemerin (21-157) lead to VEGFR2 phosphorylation at Tyr1175 site both in a 
time- and concentration-dependent manner (Fig. 4.3.7a and b respectively). 
VEGFR2 receptor phosphorylation at Tyr1175 is suggested to be the key tyrosine 
residue involved in VEGF-dependent angiogenesis (Koch et al., 1995, Palframan et 
al., 2001). Waltenberger and colleagues reported that, in porcine aortic ECs although 
both VEGFR2 and VEGFR1 receptors undergo phosphorylation, only VEGFR2 
transfected cells displayed migratory and proliferative responses (Waltenberger et al., 
1994). VEGFR2 receptor activation is also known to recruit adaptor proteins such as 
PI3K and many other protein tyrosine phosphatases, ultimately resulting in 
promoting angiogenesis (Kroll and Waltenberger, 1997).  
Chemerin (21-157) increased the activities of MMP-2 and -9 in a 
concentration-dependent manner (4.3.8a and b respectively). A number of cytokines 
and growth factors are reported to regulate the MMPs balance in the vasculature 
(Kobayashi et al., 1997), which when disturbed is known to cause diseases of the 
endothelial-barrier function. Chemerin (21-157) promoted EC proliferation (Fig. 
4.3.9a), migration (4.3.10a and b), and capillary tube formation (Fig. 4.3.11a and b) 
in HMEC-1 cell line in a concentration-dependent manner which further suggests 
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angiogenic chemerin (21-157) properties. The angiogenic chemerin (21-157) 
behaviour in the presence of decreased VEGF165, and increased VEGF165b 
proteins protein expressions, suggests the involvement of angiogenic pathways 
independent of VEGF, for example Notch/DLL4 (Appendix 4, Fig. 4.1a, page 
number 247).  
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Figure 4.4.1a  Schematic representation of the findings in this chapter 
This picture shows the schematic representation of involvement and localisation of 
different MAPKs and Akt/PKB kinases in a cell. The transcription factor, HIF-1α 
and the expression regulation of VEGF165 and VEGF165b proteins, resulting in 
altering the activities of MMP-2 and MMP-9 enzymes, and ultimately, affecting the 
biological responses in a cell; for example EC proliferation, migration and capillary 
tube formation. This picture also shows the RTKs, VEGFR1 and VEGFR2 on the 
EC wall and their involvement in endothelial cell angiogenesis. 
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5.1 Introduction 
 
The specific aims of this part of the project were to study the role (s) of 
chemerin (21-157) in; (1) endothelial Cell Adhesion Molecules (CAMs) such as E-
selectin, Vascular Cell Adhesion Molecule (VCAM)-1 and Intracellular Cell 
Adhesion Molecule (ICAM)-1 protein expression and secretion in both HMEC-1 cell 
lysates and supernatants, (2) CAM protein expression in HMEC-1 cells when co-
treated with chemerin (21-157) and a known pro-inflammatory mediator, Interleukin 
(IL)-1β, (3) mediating the activity of Nuclear Factor (NF)-κB pathway, (4) 
Monocyte Chemoattractant protein (MCP)-1 protein expression, when treated with 
chemerin (21-157) alone, and in combination with IL-1β, and finally (5) Endothelial 
(HMEC-1) and monocyte (THP-1) cell adhesion. 
Endothelium possess cell-surface glycoproteins, such as E-selectin, VCAM-1, 
and ICAM-1 which are upregulated in response to different inflammatory stimuli. 
These inflammatory stimuli encourage leukocyte recruitment and adherence to the 
endothelium surface at very early stages of vascular inflammation, that ultimately 
leads to vascular inflammatory disease initiation and progression such as 
atherosclerosis (Blankenberg et al., 2003). Upon chronic cell activation, selectin 
molecules and other adhesion molecules including ICAM-1 and VCAM-1 are 
rapidly cleaved off from the cell surface by a number of different mechanisms and 
circulate freely in the bloodstream. Soluble isoforms of these molecules are 
detectable in blood and plasma and are considered as an independent markers of 
endothelial cell dysfunction and diseases of cardiovascular system (Blankenberg et 
al., 2003, Ridker et al., 1998, Ingelsson et al., 2008, Soro-Paavonen et al., 2006, 
Hwang et al., 1997, Tardif et al., 2006).  
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Activation of Nuclear Factor (NF)-κB pathway in an injured endothelium is 
known to play a significant role in the early development of inflammatory responses 
in diseased states such as atherosclerosis (Collins et al., 1995, Savoia and Schiffrin, 
2007, Read et al., 1997, Hu et al., 2000, Blankenberg et al., 2003). Several 
inflammatory cytokines secreted by the adipose tissue cause EC activation and 
inflammation, causing the diseases of cardiovascular system such (Karkkainen et al., 
2000a, Karkkainen et al., 2000b, Fiumara et al., 1989).   
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5.2 Materials and Methods 
 
The cellular protein expression and phosphorylation was determined by SDS-
PAGE (Chapter 2, section 2.3.7, page numbers 57-60) using different percentage 
polyacrylamide gels for separating different proteins (Table 5.2.1a). NF-κB activity 
was studied using Luciferase activity assay (Chapter 2, section 2.4.7, page number 
68). Endothelial-Monocyte cell adhesion was studied using BD BioCoat Endothelial 
Cell Adhesion Assay kit (Chapter 2, section 2.4.8, page numbers 69-70). 
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Table 5.2.1a  
The molecular weights of different proteins and gel percentages used for SDS-
PAGE analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein name Molecular weight (kDa) Percentage gels used 
E-selectin 115 8 
ICAM-1 85 10 
MCP-1 11 15 
VCAM-1 110 8 
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5.3 Data Presentation and Analyses 
5.3.1 Chemerin (21-157) and E-selectin Protein Expression and Secretion in 
HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study cellular protein 
expression of E-selectin, HMEC-1 cells were treated with different chemerin (21-
157) [0-10nM] concentrations for 12 and 24 hours. Cells were lysed in 1x RIPA 
buffer and protein lysates were separated using SDS-PAGE. To study secreted levels 
of E-selectin protein in ECs, HMEC-1 cells were treated with different chemerin 
(21-157) [0-30nM] concentrations for 4, 12 and 24 hours. Cell supernatants were 
collected and soluble E-selectin (see-selectin) protein levels were determined using 
Luminex® 100 instrument in all three different treatment groups. In addition, in 24 
hours cell supernatants, sE-selectin protein expression was studied using SDS-PAGE. 
Chemerin (21-157) significantly increased cellular E-selectin protein expression in a 
concentration-dependent manner in both 12 hours (Fig. 5.3.1a) and 24 hours (Fig. 
5.3.1b) HMEC-1 cell lysates (p < 0.001, p < 0.01 and p < 0.05).  In 24  hours treated 
cell supernatants, chemerin (21-157) significantly increased sE-selectin expression in 
a concentration-dependent manner (p < 0.01 and p < 0.05) (Fig. 5.3.1c). In contrast, 
no sE-selectin proteins were detected in HMEC-1 cell supernatants in multiplex 
ELISA, and also, different chemerin (21-157) treatments failed to show any change 
in sE-selectin protein secretion in all different treatment groups (Appendix 7.1, Table 
7.1a, b and c respectively; page numbers 253-56). TNF-α [10ng/ml] and IL-1β 
[10ng/ml] were used as positive controls. 
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Figure 5.3.1a Chemerin (21-157) increased E-selectin protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 12 hours. Following cell lysis and sample preparations, the protein lysates 
were separated using 8% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific mouse E-selectin 
antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-mouse IgG-HRP labelled 
antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membrane was re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both E-selectin and β-
actin were detected as 115kDa and 45kDa products. The band intensities were 
measured using Scion Image™ densitometer (Scion Corporation, Maryland, USA). 
The data are presented as mean ± SEM of three independent experiments in 
duplicates ***p < 0.001, **p < 0.01 and *p < 0.05 compared to basal. 
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Figure 5.3.1b Chemerin (21-157) increased E-selectin protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 24 hours 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 24 hours. Following cell lysis and sample preparations, the protein lysates 
were separated using 8% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific mouse E-selectin 
antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-mouse IgG-HRP labelled 
antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membrane was re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both E-selectin and β-
actin were detected as 115kDa and 45kDa products. The band intensities were 
measured using Scion Image™ densitometer (Scion Corporation, Maryland, USA). 
The data are presented as mean ± SEM of three independent experiments in 
duplicates ***p < 0.001, **p < 0.01 and *p < 0.05 compared to basal. 
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Figure 5.3.1c Chemerin (21-157) increased sE-selectin protein secretion in 
HMEC-1 cell supernatants in a concentration-dependent manner after 24 hours 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 24 hours and cell supernatants were collected. Samples were prepared by 
mixing equal volumes of cell supernatants with 1x Laemmili buffer solution. 
Following sample preparations, the proteins were separated using 8% 
polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 hour. 
Membranes were incubated with specific mouse E-selectin antibody [(1:800); Santa 
Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-mouse IgG-HRP labelled antibody [(1:8000); 
Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised using ECL 
plus detection reagent on X-ray films. The corresponding band for sE-selectin was 
detected as a 115kDa product. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates **p < 0.01 and *p < 
0.05 compared to basal. 
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5.3.2 Chemerin (21-157) and VCAM-1 Protein Expression and Secretion in 
HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. To study cellular 
protein expression of VCAM-1, HMEC-1 cells were treated with different chemerin 
(21-157) [0-10nM] concentrations for 12 and 24 hours. Cells were lysed in 1x RIPA 
buffer and protein lysates were separated using SDS-PAGE. To study secreted levels 
of VCAM-1 protein in EC supernatants, HMEC-1 cells were treated with different 
chemerin (21-157) [0-30nM] concentrations for 4, 12 and 24 hours. Cell 
supernatants were collected and soluble VCAM-1 (sVCAM-1) levels were 
determined using Luminex® 100 instrument in all three different treatment groups. 
In addition, in 24 hours cell supernatants, sVCAM-1 protein expression was studied 
using SDS-PAGE. Chemerin (21-157) significantly upregulated cellular VCAM-1 
protein expression in a concentration-dependent manner in both 12 hours (Fig. 5.3.2a) 
and 24 hours (Fig. 5.3.2b) cell lysates (p < 0.01, p < 0.01 and p < 0.05). In 24  hours 
treated cell supernatants, chemerin (21-157) significantly increased sVCAM-1 
protein expression in a concentration-dependent manner (p < 0.01, p < 0.01 and p < 
0.05) (Fig. 5.3.2c). In contrast, sVCAM-1 proteins were not detected in HMEC-1 
cell supernatants in all chemerin (21-157) treated cell supernatants in all treatment 
groups by multiplex ELISA (Appendix 7.2, Table 7.2a, b and c; page numbers 257-
60). TNF-α [10ng/ml] and IL-1β [10ng/ml] were used as positive controls. 
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Figure 5.3.2a Chemerin (21-157) increased VCAM-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 12 hours. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 8% polyacrylamide gels, and transferred to PVDF membranes  at 100V for 1 
hour. Membranes were incubated with specific mouse anti-VCAM-1 antibody 
[(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with anti-mouse IgG-HRP labelled antibody 
[(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised 
using ECL plus detection reagent on X-ray films. Membrane was re-probed with 
rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for VCAM-1 and β-actin were detected as 
110kDa and 45kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates ***p < 0.001, **p < 
0.01 and *p < 0.05 compared to basal. 
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Figure 5.3.2b  Chemerin (21-157) increased VCAM-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 24 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 24 hours. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 8% polyacrylamide gels, and transferred to PVDF membranes  at 100V for 1 
hour. Membranes were incubated with specific mouse anti-VCAM-1 antibody 
[(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with anti-mouse IgG-HRP labelled antibody 
[(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised 
using ECL plus detection reagent on X-ray films. Membrane was re-probed with 
rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for VCAM-1 and β-actin were detected as 
110kDa and 45kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates ***p < 0.001 and 
**p < 0.01 compared to basal. 
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Figure 5.3.2c Chemerin (21-157) increased VCAM-1 protein secretion in 
HMEC-1 supernatants a concentration-dependent manner after 24 hours   
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 24 hours and cell 
supernatants were collected. Samples were prepared by mixing equal volumes of cell 
supernatants and 1xLaemmili buffer solution. Following sample preparations, the 
proteins were separated using 8% polyacrylamide gels, and transferred to PVDF 
membranes  at 100V for 1 hour. Membranes were incubated with specific mouse 
anti-VCAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. After 
removing the primary antibody complexes, membranes were incubated with anti-
mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
The corresponding band for sVCAM-1 was detected as a 110kDa product. The band 
intensities were measured using Scion Image™ densitometer (Scion Corporation, 
Maryland, USA). The data are presented as mean ± SEM of three independent 
experiments in duplicates ***p < 0.001, **p < 0.01 and **p < 0.05 compared to 
basal. 
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5.3.3 Chemerin (21-157) and ICAM-1 Protein Expression and Secretion in 
HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in specific cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. To study cellular 
protein expression of ICAM-1, HMEC-1 cells were treated with different chemerin 
(21-157) concentrations [0-10nM] for 12 and 24 hours. Cells were lysed in 1x RIPA 
buffer and protein lysates were separated using SDS-PAGE. To study secreted levels 
of ICAM-1 in endothelial cells, HMEC-1 cells were treated with different chemerin 
(21-157) concentrations [0-30nM] for 4, 12 and 24 hours. Cell supernatants were 
collected and soluble ICAM-1 (sICAM-1) levels were determined using Luminex® 
100 instrument in all three different treatment groups. In addition, in 24 hours cell 
supernatants, sVCAM-1 protein expression was studied using SDS-PAGE. 
Chemerin (21-157) significantly increased cellular ICAM-1 protein expression in a 
concentration-dependent manner in both 12 hours (Fig. 5.3.3a) and 24 hours (Fig. 
5.3.3b) cell lysates (p < 0.001, p < 0.01 and p < 0.05).  In 24  hours treated cell 
supernatants, chemerin (21-157) significantly increased sICAM-1 protein expression 
in a concentration-dependent manner (p < 0.01, p < 0.01 and p < 0.01) (Fig. 5.3.3c). 
Multiplex ELISA failed to detect any sICAM-1 protein levels, and different 
chemerin (21-157) treatments failed to show any change in sICAM-1 protein levels 
in HMEC-1 cell supernatants in all three different treatment groups (Appendix 7.3, 
Table 7.3a, b and c; page numbers 261-64). TNF-α [10ng/ml] and IL-1β [10ng/ml] 
were used as positive controls. 
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Figure 5.3.3a Chemerin (21-157) increased ICAM-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 12 hours. 
Following cell lysis and sample preparations, protein lysates were separated using 10% 
polyacrylamide gels and transferred to PVDF membranes  at 100V for 1 hour. 
Membranes were incubated with specific mouse anti-ICAM-1 antibody [(1:800); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-mouse IgG-HRP labelled antibody [(1:8000); 
Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised using ECL 
plus detection reagent on X-ray films. Membrane was re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for ICAM-1 and β-actin were detected as 85kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001 and **p < 0.01 
compared to basal. 
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Figure 5.3.3b Chemerin (21-157) increased ICAM-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 24 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 12 hours. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes  at 100V for 1 
hour. Membranes were incubated with specific mouse anti-ICAM-1 antibody 
[(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with anti-mouse IgG-HRP labelled antibody 
[(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised 
using ECL plus detection reagent on X-ray films. Membrane was re-probed with 
rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for ICAM-1 and β-actin were detected as 
85kDa and 45kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates **p < 0.01 and *p < 
0.05 compared to basal. 
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Figure 5.3.3c Chemerin (21-157) increased ICAM-1 protein secretion in 
HMEC-1 cell supernatants in a concentration-dependent manner after 24 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 24 hours and cell 
supernatants were collected. Samples were prepared by mixing equal volumes of cell 
supernatants and 1x Laemmili buffer solution. Following sample preparations, the 
proteins were separated using 10% polyacrylamide gels and transferred to PVDF 
membranes  at 100V for 1 hour. Membranes were incubated with specific mouse 
anti-ICAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing 
the primary antibody complexes, membranes were incubated with anti-mouse IgG-
HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein 
complexes were visualised using ECL plus detection reagent on X-ray films. The 
corresponding band for sICAM-1 was detected as a 85kDa product. The band 
intensities were measured using Scion Image™ densitometer (Scion Corporation, 
Maryland, USA). The data are presented as mean ± SEM of three independent 
experiments in duplicates **p < 0.01 and *p < 0.01 compared to basal. 
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5.3.4 Combined Chemerin (21-157) and Interleukin-1β Treatments Resulted 
in Altered E-selectin, VCAM-1 and ICAM-1 Protein Expression in 
HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and cells were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. HMEC-1 cells were incubated 
with IL-1β [10ng/ml] at different time-points for a maximum of 18 hours. At 6 hours 
incubation, IL-1β [10ng/ml] showed maximum VCAM-1 and ICAM-1 protein 
expressions (Appendix 6, Fig. 6.1a and b respectively, page numbers 249-51). To 
study the combined effects of chemerin (21-157) and IL-1β on E-selectin, VCAM-1 
and ICAM-1 protein expressions, HMEC-1 cells were pre-incubated with IL-1β 
[10ng/ml] for 6 hours, and then treated with [3.0nM] chemerin (21-157) for further 
12 hours. Cells were lysed in 1x RIPA buffer and protein lysates were separated 
using SDS-PAGE. Combined IL-1β and chemerin (21-157) treatments in HMEC-1 
cells resulted in altered protein expression levels of E-selectin (p < 0.01 and p < 0.05) 
(Fig. 5.3.4a), VCAM-1 (p < 0.001 and p < 0.01) ( Fig. 5.3.4b) and ICAM-1 (p < 
0.001 and p < 0.01) compared to chemerin (21-157) and IL-1β alone (relative to 
basal) (Fig. 5.3.4c). For all three different adhesion molecules, same β-actin loading 
control was used and was run separately using 10% gels. 
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Figure 5.3.4a Combined chemerin (21-157) and interleukin-1β treatments 
resulted in altered E-selectin protein expression in HMEC-1 cell line after 12 
hours 
HMEC-1 cells were pre-treated with IL-1β [10ng/ml] for 6 hours followed by 
chemerin (21-157) [3.0nM] stimulation for 12 hours. Following cell lysis and sample 
preparations, the protein lysates were separated using 8% polyacrylamide gels, and 
transferred to PVDF membranes  at 100V for 1 hour. Membranes were incubated 
with specific mouse E-selectin antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at 
RT. Protein complexes were visualised using ECL plus detection reagent on X-ray 
films. Membrane was re-probed with rabbit β-actin antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both E-selectin and β-actin were detected as 115kDa and 45kDa products. 
The band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates **p < 0.01 and *p < 0.05 compared to basal. 
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Figure 5.3.4b Combined chemerin (21-157) and interleukin-1β treatments 
resulted in altered VCAM-1 protein expression in HMEC-1 cell line after 12 
hours 
HMEC-1 cells were pre-treated with IL-1β [10ng/ml] for 6 hours followed by 
chemerin [3.0nM] stimulation for 12 hours. Following cell lysis and sample 
preparations, the protein lysates were separated using 8% polyacrylamide gels, and 
transferred to PVDF membranes  at 100V for 1 hour. Membranes were incubated 
with specific mouse anti-VCAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 
4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 
hour at RT. Protein complexes were visualised using ECL plus detection reagent on 
X-ray films. Membrane was re-probed with rabbit β-actin antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for VCAM-1 and β-actin were detected as 110kDa and 45kDa products. The 
band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared to 
basal. 
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Figure 5.3.4c Combined chemerin (21-157) and interleukin-1β treatments 
resulted in altered ICAM-1 protein expression in HMEC-1 cell line after 12 
hours 
HMEC-1 cells were pre-treated with IL-1β [10ng/ml] for 6 hours followed by 
chemerin [3.0nM] stimulation for 12 hours. Following cell lysis and sample 
preparations, the protein lysates were separated using 10% polyacrylamide gels, and 
transferred to PVDF membranes  at 100V for 1 hour. Membranes were incubated 
with specific mouse anti-ICAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 
4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 
hour at RT. Protein complexes were visualised using ECL plus detection reagent on 
X-ray films. Membrane was re-probed with rabbit β-actin antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for ICAM-1 and β-actin were detected as 85kDa and 45kDa products. The 
band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared to 
basal. 
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5.3.5 Chemerin (21-157) and MCP-1 Protein Expression in HMEC-1 Cell Line 
 
 HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study cellular protein 
expression of MCP-1, HMEC-1 cells were treated with different chemerin (21-157) 
concentrations [0-10nM] for 12 and 24 hours. Cells were lysed in 1x RIPA buffer 
and protein lysates were separated using SDS-PAGE. Chemerin (21-157) 
significantly increased MCP-1 protein expression in a concentration-dependent 
manner at 12 hours and 24 hours (p < 0.001, p < 0.01 and p < 0.05) (Fig. 5.3.5a and 
b respectively). 
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Figure 5.3.5a Chemerin (21-157) increased MCP-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 12 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 12 hours. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 15% polyacrylamide gels, and transferred to PVDF membranes  at 100V for 1 
hour. Membranes were incubated with specific mouse anti-MCP-1 antibody [(1:800); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-mouse IgG-HRP labelled antibody [(1:8000); 
Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised using ECL 
plus detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for MCP-1 and β-actin were detected as 11kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates **p < 0.01 and *p < 0.05 
compared to basal. 
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Figure 5.3.5b Chemerin (21-157) increased MCP-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line after 24 hours 
HMEC-1 cells were treated with chemerin (21-157) [0-10nM] for 24 hours. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 15% polyacrylamide gels, and transferred to PVDF membranes  at 100V for 1 
hour. Membranes were incubated with specific mouse anti-MCP-1 antibody [(1:800); 
Santa Cruz, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-mouse IgG-HRP labelled antibody [(1:8000); 
Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised using ECL 
plus detection reagent on X-ray films. Membranes were re-probed with rabbit β-actin 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for MCP-1 and β-actin were detected as 11kDa 
and 45kDa products. The band intensities were measured using Scion Image™ 
densitometer (Scion Corporation, Maryland, USA). The data are presented as mean ± 
SEM of three independent experiments in duplicates ***p < 0.001, **p < 0.01 and 
**p < 0.05 compared to basal. 
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5.3.6 Combined Chemerin (21-157) and Interleukin-1β Treatments Resulted 
in Altered MCP-1 Protein Expression in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. To study the 
combined effects of chemerin (21-157) and IL-1β on MCP-1 protein expression, 
HMEC-1 cells were pre-incubated with IL-1β [10ng/ml] for 6 hours and then with 
[3.0nM] chemerin (21-157) for 12 hours. Combined IL-1β and chemerin (21-157) 
treatments resulted in significant increase in MCP-1 protein expression in HMEC-1 
cells compared to chemerin (21-157) and IL-1β alone (p < 0.001 and p < 0.01) (Fig. 
5.3.6a). 
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Figure 5.3.6a Combined chemerin (21-157) and interleukin-1β treatments 
resulted in altered MCP-1 protein expression in HMEC-1 cell line after 12 
hours 
HMEC-1 cells were pre-treated with IL-1β [10ng/ml] for 6 hours followed by 
chemerin [3.0nM] stimulation for 12 hours. Following cell lysis and sample 
preparations, the protein lysates were separated using 15% polyacrylamide gels, and 
transferred to PVDF membranes  at 100V for 1 hour. Membranes were incubated 
with specific mouse anti-MCP-1 antibody [(1:800); Santa Cruz, USA] overnight at 
4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 
hour at RT. Protein complexes were visualised using ECL plus detection reagent on 
X-ray films. Membranes were re-probed with rabbit β-actin antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for MCP-1 and β-actin were detected as 11kDa and 45kDa products. The band 
intensities were measured using Scion Image™ densitometer (Scion Corporation, 
Maryland, USA). The data are presented as mean ± SEM of three independent 
experiments in duplicates ***p < 0.01 and **p < 0.01 compared to basal. 
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5.3.7 Chemerin (21-157) Increased NF-κB Activity in a Concentration-
dependent Manner in HMEC-1 Cell Line 
 
NF-κB activity was measured using NF-κB Luciferase Activity Assay. 
pcDNA3.1-NF-κB-Luc [0.35µg/µl] plasmid was transfected into the HMEC-1 cells 
using Lipofectamine and Opti-MEM
®
 medium (Chapter 2, section 2.4.7, page 
number 68). Following 12 hours incubation, the cell medium was replaced with 
MCDB medium containing 10% FCS and further incubated for 12 hours. Cells were 
treated with different chemerin (21-157) [0-10nM] concentrations, and IL-1β 
[10ng/ml] for a maximum of 24 hours. Following cell treatments, cell lysates were 
collected and luminescence was measured using a dual luciferase reporter assay 
system (Luminometer, Promega, UK). Chemerin (21-157) significantly increased 
NF-κB activity in a concentration-dependent manner, showing an additive increase 
when co-stimulated with IL-1β and chemerin (21-157) together (p < 0.001 and p < 
0.01) (Fig. 5.3.7a). 
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Figure 5.3.7a  Chemerin (21-157) and NF-κB activity in HMEC-1 cell line 
The pcDNA3.1-NF-κB-Luc was transfected into HMEC-1 using Lipofectamine 
reagent (Invitrogen, Paisley, UK) and were cultured in 75 cm
2 
flask for 24 hours. 
Cells were trypsinised and cultured in a 6-well plates at the cell density of 3x10
5
 
cells/well in cell medium containing 10% FCS for 24 hours. Cells were treated with 
different chemerin (21-157) concentrations [0-10nM] for 24 hours. Following cell 
treatments, cell lysates were collected and luminescence was measured using a dual 
luciferase reporter assay system (Luminometer, Promega, UK). The data are 
presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.001 and **p < 0.01 compared to basal. 
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5.3.8 Chemerin (21-157)-induced VCAM-1 Protein Expression in the Presence 
of NF-κB Inhibitor in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. HMEC-1 cells were 
pre-incubated with BAY11-7085, a specific NF-κB inhibitor [10µM] for 1 hour and 
were treated with [3.0nM] chemerin (21-157) for 12 hours. Cells were lysed in 1x 
RIPA buffer and protein lysates were separated using SDS-PAGE. Chemerin  (21-
157) [3.0nM] treatment in BAY11-7085 pre-treated HMEC-1 cells resulted in 
decreased VCAM-1 protein expression compared to chemerin (21-157) and BAY11-
7085 alone (p < 0.01 and p < 0.01)  (relative to basal) (Fig. 5.3.8a). 
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Figure 5.3.8a Chemerin (21-157) decreased VCAM-1 protein expression in 
HMEC-1 cell line in the presence of BAY11-7085 after 12 hours 
HMEC-1 cells were pre-incubated with BAY 11-7085 [10 µM] for 1 hour and were 
treated with chemerin [3.0nM] for 12 hours. Following cell lysis and sample 
preparations, the protein lysates were separated using 8% polyacrylamide gels, and 
transferred to PVDF membranes  at 100V for 1 hour. Membranes were incubated 
with specific mouse anti-VCAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 
4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 
hour at RT. Protein complexes were visualised using ECL plus detection reagent on 
X-ray films. Membranes were re-probed with rabbit β-actin antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for VCAM-1 and β-actin were detected as 110kDa and 45kDa products. The 
band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates **p < 0.01 and *p < 0.05 compared to basal. 
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5.3.9 Chemerin (21-157) Induced Endothelial-Monocyte Cell Adhesion in a 
Concentration-dependent Manner in HMEC-1 Cell Line 
 
Endothelial-Monocyte cell adhesion assay was performed using BD BioCoat 
Endothelial Cell Adhesion Assay kit (BD Biosciences, San Jose, CA, USA). HMEC-
1 cells were trypsinised and a cell suspension containing 2x10
6
 cells/ml in a MCDB 
cell medium was prepared. 100µl of HMEC-1 cell suspension was added to each 96-
well tissue culture plate (included in the kit) and incubated for 3 hours to allow 
attachment of cells to the plate surface. Post incubation, cell medium was aspirated 
out and 100µl of Cycloheximide solution was added to the control wells, and 100µl 
of fresh 10% FCS MCDB cell medium. Endothelial cells were activated by adding 
10µl of TNF-α [20ng/ml] to respective wells. Cells were pre-treated with different 
inhibitors; BAY11-7085 [10µM]  for 1 hour, U0126 [10µM] for 1 hour, SB203580 
[10µM] for 30minutes, and LY294002 [10µM] for 1 hour; and were treated with 
different chemerin (21-157) [0-10nM] concentrations for 6 hours. 75µl of medium 
was aspirated out from the plate wells and washed gently with 200µl of Assay Buffer 
twice. After the last wash, 50µl of Assay Buffer solution was added to each well and 
100µl of Calcein AM labelled THP-1 monocytes (~50,000 to 200,000 cells) were 
added and incubated for 30 minutes at 37
o
C. Approximately, 120µl solution was 
aspirated out from the plate wells, and two 200µl cell washes were performed using 
Assay Buffer solution. An additional wash was performed to remove any remaining 
unbound cells in order to eliminate non-specific binding. 100µl of Assay Buffer was 
added to each well and the plate reading was performed using a fluorescent plate 
reader with an excitation/emission filter of 485/530nm. Chemerin (21-157) 
significantly increased monocyte-endothelial cell adhesion in a concentration-
dependent manner (p < 0.05 and p < 0.01), and was significantly afflicted in cells 
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pre-treated with U0126 (p < 0.05), SB203580 (p < 0.01) and LY294002 (p < 0.01) 
(Fig. 5.3.9a) inhibitors. 
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Figure 5.3.9a  Chemerin (21-157) increased Endothelial-Monocyte cell adhesion 
in a concentration-dependent manner 
HMEC-1 cells were trypsinised and a cell suspension containing 2x10
6
 cells/ml in a 
MCDB cell medium was prepared. 100µl of HMEC-1 cell suspension was added to 
each 96-well tissue culture plate (included in the kit) and incubated for 3 hours to 
allow attachment of cells to the plate surface. Post incubation, cell medium was 
aspirated out and 100µl of Cycloheximide solution was added to the control wells, 
and 100µl of fresh 10% FCS MCDB cell medium. Endothelial cells were activated 
by adding 10 µl of TNF-α [20ng/ml] to respective wells. Cells were pre-treated with 
different inhibitors; BAY11-7085 [10µM]  for 1 hour, U0126 [10µM] for 1 hour, 
SB203580 [10µM] for 30minutes and LY294002 [10µM] for 1 hour, and were 
treated with different chemerin (21-157) concentrations [0-10nM] for 6 hours. 75µl 
of medium was aspirated out  from the plate wells and washed gently with 200µl of 
Assay Buffer twice. After the last wash, 50µl of Assay Buffer solution was added to 
each well and 100µl of Calcein AM labelled THP-1 monocytes (~50,000 to 200,000 
cells) were added and incubated for 30 minutes at 37
o
C. Approximately, 120µl 
solution was aspirated out from the plate wells and two 200µl cell washes were 
performed using Assay Buffer solution. An additional wash was performed to 
remove any remaining unbound cells in order to eliminate non-specific binding. 
100µl of Assay Buffer was added to each well and the plate reading was performed 
using a fluorescent plate reader with an excitation/emission filter of 485/530nm. The 
data are presented as mean ± SEM of three independent experiments in duplicates 
**p < 0.01 and *p < 0.05 compared to basal. 
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5.4 Summary of Results 
 
Chemerin (21-157) significantly upregulated the cellular protein expression 
levels of E-selectin (Fig. 5.3.1a and b), VCAM-1 (Fig. 5.3.2a and b) and ICAM-1 
(Fig. 5.3.3a and b) adhesion molecules in a concentration-dependent manner at 12 
and 24 hours (respectively). In addition, chemerin (21-157) also increased secreted 
levels of E-selectin (sE-selectin), VCAM-1 (sVCAM-1) and ICAM-1 (sICAM-1) 
adhesion molecules in a concentration-dependent manner (Fig. 5.3.1c, 5.3.2c and 
5.3.3c respectively). The protein expression levels of E-selectin, VCAM-1 and 
ICAM-1 were altered in HMEC-1 cell line, when combined chemerin (21-157) and 
known inflammatory mediator IL-1β treatments were performed, compared to 
chemerin (21-157) and IL-1β alone (5.3.4a, b and c respectively). 
Chemerin (21-157) significantly upregulated the protein expression of MCP-1 
in a concentration-dependent manner after 12 and 24 hours of incubation (Fig. 5.3.5a 
and 5.3.5b respectively). Also, combined HMEC-1 cells treatments with chemerin 
(21-157) and IL-1β resulted in additive increase in MCP-1 protein expression, 
compared to chemerin (21-157) and IL-1β alone (Fig. 5.3.6a). 
Chemerin (21-157) increased NF-κB pathway activity, a well studied 
inflammatory pathway in a concentration-dependent manner, showing an additive 
increase when co-stimulated with chemerin (21-157) and IL-1β together in HMEC-1 
cell line (Fig. 5.3.7a). HMEC-1 cell treatments with BAY11-7085, a specific NF-κB 
inhibitor, prior to stimulating with chemerin (21-157) resulted in VCAM-1 protein 
expression down-regulation compared to chemerin (21-157) and BAY11-7085 alone 
(Fig. 5.3.8b). NF-κB modulates a number of genes regulating inflammatory and 
acute phase responses (Vereecke and Carmeliet, 2000), as well as play an important 
role in body’s immune responses and other process such as thymus development, 
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apoptosis, embryonic development, growth regulation, malignant transformation and 
viral mRNA expression (Baes et al., 2000, Bautch et al., 2000). The NF-κB activity 
is stimulated by a number of stimuli including various bacterial and viral stimuli, and 
other cellular and environmental stressors such as irradiation, osmotic shock, 
osmotic stress, hyperglycaemia and haemorrhage also stimulate NF-κB activity 
(Dvorak et al., 1995b).  
Chemerin (21-157) dose-dependently encouraged monocyte cell adhesion to 
ECs in a concentration-dependent manner, and was inhibited when pre-incubated 
with a specific NF-κB inhibitor; BAY11-7085, a MAPK inhibitor; U0126, a p38 
MAPK inhibitor, SB203580; and an Akt/PI3K inhibitor, LY294002 (Fig. 5.3.9a).  
CAM expression is kept under check by the endothelium NO, a molecule 
produced by endothelial Nitric Oxide Synthase (eNOS), which is an enzyme 
constitutively expressed on the walls of ECs and regulates NO production. The final 
aim of this project explored the role of chemerin (21-157) in the activity of eNOS 
enzyme (chapter 6); the key signalling pathways involved, and finally, in the 
production of NO in HMEC-1 cell line.  
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Figure 5.4.1a  Schematic representation of the findings in this chapter 
This picture shows the schematic representation of the role of chemerin (21-157) in 
E-selectin, ICAM-1 and VCAM-1 endothelial cell adhesion molecules protein 
expression inside a cell. This picture also shows the involvement of NF-κB pathway 
in regulating the expression of these adhesion molecules, which finally results in 
endothelial-monocyte cell adhesion resulting in vascular inflammation. The role and 
implication of increased Reactive Oxygen Species (ROS) and decreased Nitric Oxide 
(NO) levels in the expression of endothelial cell adhesion molecules, consequently 
resulting in vascular pathology.  
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6.1 Introduction  
The specific aims of this part of the project were to explore the role (s) of 
chemerin (21-157) in; (1) the activity of endothelial Nitric Oxide Synthase (eNOS) 
by studying eNOS phosphorylation at Ser1177, and dephosphorylation at Thr495 
sites both in a time- and concentration-dependent manner, (2) the involvement of 
Akt/PI3 kinase, Protein Kinase A (PKA) and Protein Kinase C (PKC) signalling 
pathways in the regulation of eNOS activity, (3) the levels of nitrites and nitrates; the 
end products of Nitric Oxide (NO) catabolism, and finally (4) the inducible Nitric 
Oxide Synthase (iNOS) protein expression in HMEC-1 cell line. 
NO is secreted by the vascular endothelium and acts as a potent vasodilator, 
promotes angiogenesis, and reduces the expression of adhesion molecules on the EC 
surface. NO production is regulated by endothelial specific enzyme, endothelial 
Nitric Oxide Synthase (eNOS) which is constitutively expressed on EC surfaces. 
eNOS activity is regulated by phosphorylation and dephosphorylation on a number 
of different sites, however, eNOS phosphorylation at Ser1177 and dephosphorylation 
at Thr495 sites contribute as the two most significant sites of eNOS regulatory 
activity. In this project, eNOS phosphorylation at Ser1177, and dephosphorylation at 
Thr495 sites were studied in relation to the activity of eNOS enzyme. A number of 
different upstream pathways may be involved in regulating the activity of eNOS (Fig. 
6.4.1a, page number 199). However, in relation to chemerin (21-157), involvement 
of three pathways including Akt/PI3K, PKA and PKC pathways was studied in 
inducing eNOS phosphorylation at Ser1177 site only. Nitrites and nitrates are end 
products of NO metabolism, which are detectable in cell supernatants and lysates. 
Inducible Nitric Oxide Synthase (iNOS) is induced during injury or inflammation 
and secretes 100- to 1000-fold more NO compared to eNOS (Morris and Billiar, 
1994, Nathan and Xie, 1994). 
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6.2 Materials and Methods 
 
The protein expression levels and phosphorylation were determined by SDS-
PAGE (Chapter 2, section 2.3.7, page numbers 57-60) using different percentage 
polyacrylamide gels for separating different proteins (Table 6.2.1a). Amount of 
nitrites and nitrates was determined using Griess reagent test (Chapter 2, section 
2.4.10, page numbers 71-2). 
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Table 6.2.1a  
The molecular weights of different proteins and gel percentages used for SDS-
PAGE analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein name Molecular weight (kDa) Percentage gels used 
eNOS 120 8 
iNOS 130 8 
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6.3 Data Presentation and Analyses 
6.3.1 Chemerin and endothelial Nitric Oxide Synthase (eNOS) Activity in 
HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
eNOS phosphorylation, HMEC-1 cells were treated with [3.0nM] chemerin (21-157) 
at different time-points for a maximum of 30 minutes. For concentration-dependent 
eNOS phosphorylation, HMEC-1 cells were treated with different chemerin (21-157) 
[0-30nM] concentrations for 3 minutes. Cells were lysed in 1x RIPA buffer and 
protein lysates were separated using SDS-PAGE. Chemerin (21-157) increased 
eNOS activity by phosphorylating at Ser1177 [eNOS (Ser1177)] in a time-dependent 
manner with a significant increase at 3 minutes (p < 0.01) (Fig. 6.3.1a), and by 
dephosphorylation at Thr495 [eNOS(Thr495)] (p < 0.001 and p < 0.01) (Fig. 6.3.1b). 
Chemerin (21-157) increased eNOS activity in a concentration-dependent manner by 
phosphorylating at Ser1177 [eNOS (Ser1177)] with a significant increase at [10nM] 
(p < 0.001) (Fig. 6.3.1c), and by dephosphorylation at Thr495 [eNOS(Thr495)]  (p < 
0.001  and p < 0.01) (Fig. 6.3.1d).  
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Figure 6.3.1a Chemerin (21-157) lead to eNOS (Ser1177) phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [3.0nM] chemerin (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 8% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with specific eNOS (Ser1177) antibody [(1:1500); 
Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-rabbit IgG-HRP labelled 
antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membrane was re-
probed with total eNOS [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for both phospho-eNOS (Ser1177) and 
total eNOS were observed as 120kDa products. The band intensities were measured 
using Scion Image™ densitometer (Scion Corporation, Maryland, USA). The data 
are presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.001, **p < 0.01 and *p < 0.05 compared to basal. VEGF was [10ng/ml] used as a 
positive control. 
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Figure 6.3.1b  Chemerin (21-157) lead to eNOS (Thr495) dephosphorylation in 
a time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [3.0nM] chemerin (21-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 8% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with specific eNOS (Thr495) antibody [(1:1500); 
Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-rabbit IgG-HRP labelled 
antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membrane was re-
probed with total eNOS [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for both phospho-eNOS (Thr495) and total 
eNOS were observed as 120kDa products. The band intensities were measured using 
Scion Image™ densitometer (Scion Corporation, Maryland, USA). The data are 
presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.01 and **p < 0.01 compared to basal. H2O2 was [0.3µM] used as a positive control. 
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Figure 6.3.1c Chemerin (21-157) lead to eNOS (Ser1177) phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 3 minutes. Following cell lysis and sample preparations, the 
protein lysates were separated using 8% polyacrylamide gels, and transferred to 
PVDF membranes at 100V for 1 hour. Membranes were incubated with specific 
eNOS (Ser1177) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight 
at 4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at 
RT. Protein complexes were visualised using ECL plus detection reagent on X-ray 
films. Membrane was re-probed with total eNOS [(1:1500); Cell signalling, Beverly, 
MA, USA] and used as a loading control. The corresponding bands for both 
phospho-eNOS (Ser1177) and total eNOS were observed as 120kDa products. The 
band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates ***p < 0.01 and **p < 0.01 compared to 
basal. VEGF [10ng/ml] was used as a positive control. 
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Figure 6.3.1d  Chemerin (21-157) lead to eNOS (Thr495) dephosphorylation in 
a concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 3 minutes. Following cell lysis and sample preparations, the 
protein lysates were separated using 8% polyacrylamide gels, and transferred to 
PVDF membranes at 100V for 1 hour. Membranes were incubated with specific 
eNOS (Thr495) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 
4
o
C. After removing the primary antibody complexes, membranes were incubated 
with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at 
RT. Protein complexes were visualised using ECL plus detection reagent on X-ray 
films. Membrane was re-probed with total eNOS [(1:1500); Cell signalling, Beverly, 
MA, USA] and used as a loading control. The corresponding bands for both 
phospho-eNOS (Thr495) and total eNOS were observed as 120kDa products. The 
band intensities were measured using Scion Image™ densitometer (Scion 
Corporation, Maryland, USA). The data are presented as mean ± SEM of three 
independent experiments in duplicates ***p < 0.001 and **p < 0.01 compared to 
basal. H2O2 was [0.3µM] used as a positive control. 
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6.3.2  Chemerin (21-157) Induced eNOS (Ser1177) Phosphorylation via 
Akt/PI3K, PKA and PKC Pathways in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. HMEC-1 cells were 
pre-treated with LY294002 [30µmol/L] for 1 hour, H-89 [10µmol/L] and BIS II 
[10µmol/L] for 40 minutes, and were treated with [3.0nM] chemerin (21-157) for 3 
minutes. Cells were lysed in 1x RIPA buffer and protein lysates were separated using 
SDS-PAGE. Chemerin (21-157) increased eNOS activity by phosphorylating at 
Ser1177 [eNOS (Ser1177)] which was inhibited significantly by Akt/PI3K inhibitor, 
LY294002 [30µmol/L] (Fig. 6.3.2a); PKA inhibitor, H-89 [10µmol/L] (Fig. 6.3.2b); 
and PKC inhibitor, BIS II [10µmol/L] (Fig. 6.3.2c) treatments (p < 0.001, p < 0.01 
and p  < 0.05) compared to basal. 
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Figure 6.3.2a Chemerin (21-157) induced eNOS (Ser1177) phosphorylation via 
Akt/PKB kinase pathway in HMEC-1 cell line 
HMEC-1 cells were pre-incubated with LY294002 [30µmol/L] for 1 hour and were 
treated with [3.0nM] chemerin (21-157) for 3 minutes. Following cell lysis and 
sample preparations, the protein lysates were separated using 8% polyacrylamide 
gels, and transferred to PVDF membranes at 100V for 1 hour. Membranes were 
incubated with specific eNOS (Ser1177) antibody [(1:1500); Cell signalling, Beverly, 
MA, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); 
Dako, Ely, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membrane was re-probed with total eNOS 
[(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-eNOS (Ser1177) and total eNOS were 
observed as 120kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates ***p < 0.001 and 
**p < 0.01 compared to basal. 
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Figure 6.3.2b  Chemerin (21-157) induced eNOS (Ser1177) phosphorylation via 
PKA pathway in HMEC-1 cell line 
HMEC-1 cells were incubated with H-89 [10µmol/L] for 40 minutes and were 
treated with [3.0nM] chemerin (21-157) for 3 minutes. Following cell lysis and 
sample preparations, the protein lysates were separated using 8% polyacrylamide 
gels, and transferred to PVDF membrane at 100V for 1 hour. Membranes were 
incubated with specific eNOS (Ser1177) antibody [(1:1500); Cell signalling, Beverly, 
MA, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); 
Dako, Ely, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membrane was re-probed with total eNOS 
[(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-eNOS (Ser1177) and total eNOS were 
observed as 120kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates **p < 0.01 and *p < 
0.05 compared to basal. 
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Figure 6.3.2c  Chemerin (21-157) induced eNOS (Ser1177) phosphorylation via 
PKC pathway in HMEC-1 cell line 
HMEC-1 cells were incubated with BIS II [10µmol/L] for 40 minutes and were 
treated with [3.0nM] chemerin (21-157) for 3 minutes. Following cell lysis and 
sample preparations, the protein lysates were separated using 8% polyacrylamide 
gels, and transferred to PVDF membranes at 100V for 1 hour. Membranes were 
incubated with specific eNOS (Ser1177) antibody [(1:1500); Cell signalling, Beverly, 
MA, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); 
Dako, Ely, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membrane was re-probed with total eNOS 
[(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-eNOS (Ser1177) and total eNOS were 
observed as 120kDa products. The band intensities were measured using Scion 
Image™ densitometer (Scion Corporation, Maryland, USA). The data are presented 
as mean ± SEM of three independent experiments in duplicates ***p < 0.001 and 
**p < 0.01 compared to basal. 
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6.3.3 Chemerin (21-157) Increased inducible Nitric Oxide Synthase (iNOS) 
Protein Expression in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. For studying time-point 
response, HMEC-1 cells were treated with [10nM] chemerin (21-157) at different 
time-points for a maximum of 12 hours. For concentration-dependent response, 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 6 hours. Cells were lysed in 1x RIPA buffer and protein lysates 
were separated using SDS-PAGE. Chemerin (21-157) increased iNOS protein 
expression in HMEC-1 cell line in a time-dependent manner showing a peak 
response at 6 hours (Fig. 6.3.3a). Chemerin (21-157) increased iNOS protein 
expression in a concentration-dependent manner showing maximum response at 
[10nM] chemerin (21-157) (Fig. 6.3.3b).  
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Figure 6.3.3a  Chemerin (21-157) increased iNOS protein expression in a time-
dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [10nM] chemerin (21-157) for a maximum of 12 
hours. Following cell lysis and sample preparation, the protein lysates were 
separated using 8% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific iNOS antibody [(1:1500); 
Abcam Cambridge, UK] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with anti-mouse IgG-HRP labelled antibody 
[(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised 
using ECL plus detection reagent on X-ray films. The corresponding bands for iNOS 
were detected  as 130kDa products.  
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Figure 6.3.3b  Chemerin (21-157)  increased iNOS protein expression in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 6 hours. Following cell lysis and sample preparation, the protein 
lysates were separated using 8% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with specific iNOS 
antibody [(1:1500); Abcam Cambridge, UK] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-mouse IgG-HRP 
labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein 
complexes were visualised using ECL plus detection reagent on X-ray films. The 
corresponding bands for iNOS were detected  as 130kDa products.  
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6.3.4 Chemerin and Nitrites and Nitrates in HMEC-1 Cell Lysates and  
Supernatants 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. Cell  medium was aspirated 
out, washed with PBS, and was replaced with 1ml fresh PBS. HMEC-1 cells were 
treated with different chemerin (21-157) [0-30nM] concentrations for 15 minutes and 
cell supernatants were collected. Cells were washed with ice cold PBS twice, and 
500µl of dH2O was added to the wells, lysed, and cell lysates were collected in 
eppendorf tubes. Amounts of combined nitrite and nitrate (NOx), as well as nitrite 
(NO2–) only were determined using Griess reagent method. Griess reagent failed to 
detect any NOx levels in chemerin (21-157) treated HMEC-1 cell supernatants (data 
not shown), and remained unchanged in EC lysates with increasing chemerin (21-
157) concentrations (Fig. 6.3.4a). Different chemerin (21-157) [0-30nM] 
concentrations significantly down-regulated NO2
–
 levels in a concentration-
dependent manner (p < 0.001) (Fig. 6.3.4b) in EC supernatants, and were not 
detected in EC lysates (data not shown). 
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Figure 6.3.4a  Chemerin (21-157) and NOx levels in HMEC-1 cell lysates 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 15 minutes. Cell lysates were collected in 500µl of dH2O and NOx levels 
were determined using Griess reagent test. 100µl of each standard or sample was 
added into a 96-well plate, followed by 100µl of Vanadium chloride solution. Griess 
reagent mix (50µl of NEDD + 50µl SULF) was prepared and 100µl of the mixture 
was added to each well and incubated for 45 minutes. The absorbance was recorded 
at 550nm. The data are presented as mean ± SEM of three independent experiments 
in duplicates. 
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Figure 6.3.4b  Chemerin (21-157) and NO2
–
 levels in HMEC-1 cell supernatants 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 15 minutes. Cell supernatants were collected and nitrite levels were 
determined using Griess reagent test. 300µl of each standard or sample solution 
(both cell lysates and supernatants) was added to the pre-labelled 1.5ml eppendorf 
tubes. Griess reagent mix (150µl of NEDD+150µl SULF) was prepared and resultant 
300µl of mix was added to each standard or sample, mixed gently and 300µl was 
transferred to 96-well plate and incubated for 10 minutes. The absorbance was 
recorded at 550nm. The data are presented as mean ± SEM of three independent 
experiments in duplicates ***p < 0.001 compared to basal. 
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6.4 Summary of Results 
 
Chemerin (21-157) increased eNOS enzyme activity in a time-dependent 
manner by causing eNOS phosphorylation at Ser1177 [eNOS (Ser1177)] (Fig. 
6.3.1a), and dephosphorylation at Thr495 site [eNOS (Thr495)] (Fig. 6.3.1b). 
Chemerin (21-157) increased eNOS activity in a concentration-dependent manner by 
causing eNOS phosphorylation at Ser1177 [eNOS (Ser1177)] (Fig. 6.3.1c), and 
dephosphorylation at Thr495 [eNOS (Thr495)] (Fig. 6.3.1d). [eNOS (Ser1177)] and 
[eNOS (Thr495)] sites are the main regulatory sites that are reported to regulate the 
activity of eNOS enzyme in the endothelium. 
Upstream signalling kinases such as Akt/PI3K, PKA and PKC pathways were 
found to be involved in chemerin (21-157)-mediated activity of eNOS enzyme. In 
HMEC-1 cells, chemerin (21-157)-induced eNOS activity at Ser1177 [eNOS 
(Ser1177)] site was inhibited significantly when pre-incubated with an Akt/PI3K 
inhibitor, LY294002 (Fig. 6.3.2a); a PKA inhibitor, H-89 (Fig. 6.3.2b) and a PKC 
inhibitor, BIS II (Fig. 6.3.2c).  
Chemerin (21-157) increased iNOS protein expression in a time- and 
concentration-dependent manner in HMEC-1 cell line (Fig. 6.3.4a and b 
respectively).  
Chemerin (21-157) increased caveolin-1 protein expression in a time- and 
concentration-dependent manner (Appendix 8, Fig. 8.1a and 8.1b respectively, page 
numbers 265-7).  
Chemerin (21-157) increased HSP90 protein expression in a time- and 
concentration-dependent manner in HMEC-1 cell line (Appendix 9, Fig. 9.1a and 
9.1b respectively, page numbers 268-70).  
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Interestingly, Griess reagent test failed to detect any change in NOx levels in 
chemerin (21-157)-treated HMEC-1 cell supernatants (data not shown), and amount 
of NOx in cell lysates remain unchanged with increasing chemerin (21-157) 
concentrations (Fig. 6.3.3a). Different chemerin (21-157) [0-30nM] concentrations 
significantly down-regulated NO2
–
 levels in a concentration-dependent manner in 
HMEC-1 cell supernatants (Fig. 6.3.3b); however, NO2
–
 levels remained undetected 
in cell supernatants (data not shown).  
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Figure 6.4.1a  Schematic representation of the findings in this chapter 
The figure shows the eNOS monomer and the two main phosphorylation sites – 
eNOS (Thr495) and eNOS (Ser1177), and the involvement of different kinases in 
eNOS (Ser1177) phosphorylation. This figure also shows the NO production, L-
arginine acting as a precursor molecule, ROS involvement, and formation of 
peroxynitrite (OONO
–
). 
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7.1 Identification of chemerin and its receptors in human microvascular and 
macrovascular ECs: CMKLR1 receptor regulation by inflammatory 
cytokines 
 
Both human chemerin and its natural GPCR receptor, CMKLR1 were 
identified and confirmed at gene and protein levels in both microvascular (HMEC-1) 
and macrovascular (EA.hy926) endothelial cell lines, as well as in primary HUVEC 
cells. In addition to CMKLR1, two human orphan chemerin GPCRs, CCRL2 and 
GPR1 receptors were also identified in ECs at both gene and protein levels. 
Chemerin mainly functions via CMKLR1 receptor, CCRL2 is known to act as a non-
functional decoy receptor (Cash et al., 2008), whereas, the functional effects of 
chemerin upon GPR1 receptor binding still remain unknown (Barnea et al., 2008). 
Chemerin is a newly identified cytokine and is expressed in a number of body tissues, 
however, adipose tissue acts as a major source of chemerin expression and secretion 
in the human body (Roh et al., 2007, Bozaoglu et al., 2007, Goralski et al., 2007). 
Chemerin functions via its natural GPCR, CMKLR1 and is known to mediate 
adipogenesis, adipocyte metabolism (Roh et al., 2007, Goralski et al., 2007) and 
recruitment of cells of immune system to the sites of inflammation (Wittamer et al., 
2005, Wittamer et al., 2003). Chemerin expression is reported to be upregulated in 
inflammatory diseases such as psoriatic skin lesions (Albanesi et al., 2009) and 
rheumatoid arthritis (Kaneko et al., 2011). Circulating chemerin levels positively 
correlate with various facets of metabolic syndrome such as high circulating glucose 
levels, triglycerides, high blood pressure and low levels of HDL and high LDL levels 
(Bozaoglu et al., 2007, Bozaoglu et al., 2009). Abnormal circulating metabolites in 
the bloodstream are implicated in the development and progression of diseases 
associated with chronic inflammation, EC injury, T2D and related cardiovascular 
complications (Kukk et al., 1996b, Grundy et al., 2004). In HMEC-1 cells, known 
  201 
inflammatory cytokines such as TNF-α, IL-6 and IL-1β treatments resulted in 
increased protein expression of CMKLR1 which suggests that under inflammatory 
conditions, CMKLR1 receptor availability is increased (Kaur et al., 2010), hence 
encouraging the participation of chemerin/CMKLR1 axis in causing inflammatory 
responses in a cell, and mediating the occurrence of inflammation-related 
pathologies in the body. CMKLR1, is primarily expressed on cells of the immune 
system, and under inflammatory conditions, the receptor expression is reported to be 
increased. A number of other molecules such as Lipopolysaccharide (LPS), an 
endotoxin, is also reported to increase CMKLR1 receptor expression in lower 
concentrations, however, is down-regulated when treated with higher LPS 
concentrations (Luangsay et al., 2009). In macrophages, Transforming Growth 
Factor-β (TGF-β), an anti-inflammatory protein, decreased CMKLR1 receptor 
protein expression (Zabel et al., 2006a). CMKLR1 receptor protein expression is also 
reported to change upon maturation of immature plasmacytoid dendritic cells (pDCs) 
into mature pDCs suggesting that chemerin may play an important role in pDCs 
trafficking (Vermi et al., 2005).  
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7.2 Chemerin (21-157) lead to ERK1/2, ERK5, p38 and SAPK/JNK MAPKs 
and Akt/PKB Kinases phosphorylation: role in EC proliferation, 
migration and capillary tube formation in HMEC-1 cell line 
 
It is well documented that a number of MAPKs mediate critical cellular 
processes such as cell proliferation, apoptosis and differentiation depending on the 
type of stimuli involved and certain cell types. The Ras-Raf-MEK-ERK and 
MEK2/3-MEK5-ERK5 MAPKs signalling cascades are activated by a number of 
external stimuli (Fig. 1.5.1a, page number 35). These MAPK are known to play 
important roles in cell proliferation and differentiation (Nishimoto and Nishida, 
2006), the key processes implicated in biological responses such as vasculogenesis 
and angiogenesis. ERK1/2 MAPK is known to play an important role from cell 
morphogenesis to whole organism development (Nishimoto and Nishida, 2006).  
Mice lacking ERK2 and MEK1 showed defects in embryo development, whereas, 
mice lacking ERK1 and MEK2 showed normal development (Hatano et al., 2003). 
Activation of ERK2 MAPK is of particular importance as mice deficient in ERK2 
showed abnormal mesoderm differentiation, suggesting that ERK2 plays a crucial 
role in mesoderm formation (Yao et al., 2003). ERK5 MAPK is essential in the 
processes of cell proliferation, migration and angiogenesis as mice embryos deficient 
in ERK5 MAPK are reported to die due to lack of angiogenesis and failure to 
develop fully functional cardiovascular system. Also, mice lacking ERK5
-/-
 showed 
decreased VEGF/VEGF165 expression, altered expression and secretion of other 
mitogenic factors, hence, leading to defective angiogenic responses (Sohn et al., 
2002). A number of adipose-tissue derived hormones such as leptin, TNF-α and IL-
1β are known to cause ERK1/2 MAPK phosphorylation and promote angiogenesis 
(Bouloumie et al., 1998), however, the roles of these MAPK in cell death remain to 
be fully understood (Mebratu and Tesfaigzi, 2009). p38 and SAPK/JNK MAPKs are 
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important MAPK known to play crucial roles in a number of biological processes 
including inflammation, cell cycle and death, development, and cell differentiation.  
Akt/PKB kinase phosphorylation at Ser473 site is known to increase EC 
angiogenesis upstream of VEGF protein and regulates the production of NO by the 
vascular endothelium (Michell et al., 1999). Akt/PKB kinase regulate protein 
expression of VEGF, which is the most potent angiogenic molecule known to 
promote angiogenesis, and activation of Akt/PKB kinase is suggested to be sufficient 
for angiogenesis to take place (Ackah et al., 2005). EC angiogenesis is a tightly 
regulated process in normo-physiological and pathological conditions and involves 
EC proliferation, migration and elongation of the EC tips to form capillary-like 
structures, such as embryo development and wound healing (Klagsbrun and 
D'Amore, 1991), and is balanced by a number of pro- and anti-angiogenic molecules 
(Folkman, 2006). Dysregulated angiogenesis in diseased states such as ischaemia, 
chronic inflammation, diabetes, and atherosclerosis is initiated by a number of risk 
factors affecting the normal EC functioning. Abnormal fat-cell secreted adipokines 
or chemokines circulating in the blood stream cause cell injury or inflammation of 
the endothelium vessel wall. Increased circulating chemerin levels in obese patients 
with metabolic disease risk factors suggest a role of chemerin in mediating EC injury, 
initiation, progression and pathogenesis of diseases such as dysregulated 
angiogenesis in tumour formation; atherosclerosis and causing diseases including 
heart attack and myocardial infarction by disrupting the functions of a number of 
different enzymes and proteins leading to defective functional outcome. VEGF also 
plays an important role in mediating pathological angiogenesis, such as that 
associated with tumour growth (Ferrara and Davis-Smyth, 1997). VEGF is supported 
heavily as a mitogen known to induce angiogenic responses in different animal 
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models (Zhang et al., 2011), and is a survival factor for ECs both in vivo and in vitro 
(Ohuchi et al., 1997b, Semenza et al., 2001). Many studies focussed on the actions of 
VEGF in ECs, and is demonstrated to be a potent stimulator of EC proliferation 
(Yamane et al., 1994, Ferrara and Henzel, 1989, Plouet et al., 1989, Connolly et al., 
1989) and migration (Rousseau et al., 1997). Also, Watanabe and colleagues 
suggested that VEGF promotes endothelial survival by encouraging scaffold 
formation and cell attachment in microvascular ECs (Watanabe and Dvorak, 1997). 
Chemerin (21-157) upregulated the protein expression of HIF-1α, a transcription 
factor that regulates the mRNA expression of a number of genes including VEGF 
under normal and hypoxic conditions. Under hypoxic conditions, HIF-1α is known 
to increase VEGF protein expression, however, chemerin (21-157) down-regulated 
VEGF165 protein expression in a concentration-dependent manner. VEGF165b, 
which is formed upon alternative splicing of VEGF gene at exon 8 is an anti-
angiogenic form of VEGF. VEGF165b is the opposite counterpart of VEGF165, and 
is the most abundant anti-angiogenic form of VEGFxxxb family (xxx representing 
the number of amino acids) (Appendix 5, Fig. 5.1a, page number 248), and competes 
for the binding site on tyrosine kinase receptor, VEGFR2, which is the main 
signalling receptor involved in VEGF-dependent angiogenesis and known to exert 
anti-angiogenic properties (Neufeld et al., 1999, Nowak et al., 2008). VEGF165b is 
reported to inhibit VEGF165-induced EC proliferation, migration and vasodilation 
(Bates et al., 2002). VEGF165b is implicated in the inhibition of VEGF165-induced 
EC proliferation, migration and vasodilation (Bates et al., 2002). VEGF165b is also 
reported to inhibit physiological angiogenesis and tumour growth (Woolard et al., 
2004). In comparison to VEGF165, VEGF165b is down-regulated in cancers 
including renal-cell carcinoma (Bates et al., 2002), prostate (Woolard et al., 2004), 
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colon carcinoma (Varey et al., 2008) and malignant melanoma (Pritchard-Jones et al., 
2007). VEGF165b contains the receptor-binding domain in its structure and acts as a 
competitive inhibitor of VEGF165 for VEGF receptor binding, however, failing to 
induce the full tyrosine phosphorylation of the receptor (Woolard et al., 2004). 
Increased VEGF165b protein expression in HMEC-1 cell line after Chemerin (21-
157) treatments suggests that chemerin (21-157) may activate pathways independent 
of VEGF to promote EC angiogenesis, for example Notch/DLL4 (Appendix 4, page 
number 247). The balance between the pro- and anti-angiogenic VEGFR2 is the 
main signalling receptor for VEGF-dependent angiogenesis and was phosphorylated 
by chemerin (21-157) at Tyr1175 site both in a time- and concentration-dependent 
manner. VEGFR2 receptor phosphorylation at Tyr1175 is reported to be the key 
tyrosine residue involved in VEGF-dependent angiogenesis (Koch et al., 1995, 
Palframan et al., 2001). Waltenberger and colleagues reported that in porcine aortic 
ECs, although both VEGFR2 and VEGFR1 receptors undergo phosphorylation, only 
VEGFR2 transfected cells displayed migratory and proliferative responses 
(Waltenberger et al., 1994). VEGFR2 receptor activation further resulted in the 
recruitment of adaptor proteins such as PI3K and many other protein tyrosine 
phosphatases (Kroll and Waltenberger, 1997). VEGF is the most important and 
specific isoform of VEGF (Ferrara and Henzel, 1989) and is also known to initiate 
and accelerate other inflammatory diseases such as atherogenesis (Miura et al., 1997, 
Tabuchi et al., 1997) via activating VEGFR2 receptor (Terman et al., 1992). 
Chemerin (21-157) increased the activity of MMP-2 and -9 in a concentration-
dependent manner in ECs. MMP-2 and MMP-9 are important metalloproteinases 
that are known to degrade the extracellular matrix and facilitate cell proliferation, 
migration and resulting capillary tube formation. A number of cytokines and growth 
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factors are reported to regulate the MMPs balance in the vasculature (Kobayashi et 
al., 1997) which when disturbed caused disease of endothelial-barrier function. 
Chemerin (21-157) also induced EC proliferation and capillary tube formation in a 
concentration-dependent manner. Cell proliferation and capillary tube formation are 
critically controlled processes in the normal and pathological angiogenesis.  
In this project, HMEC-1 cell treatments with different chemerin (21-157) 
concentrations resulted in delayed ERK5 activity as compared with ERK1/2 MAPK, 
and could be due to the involvement of GPCR signalling pathways acting 
independent of GPCR receptors without the involvement of intracellular G-proteins, 
for example G Protein-Coupled Receptor Kinases (GRKs) and β-arrestins. 
Concentration-dependent biphasic response in the activities of p38 MAPK, ERK1/2 
MAPK and Akt/PKB kinases; and also in HMEC-1 cell proliferation, in the presence 
of linear concentration-response observed in cell apoptosis assay, when treated with 
different chemerin (21-157) concentrations could be owing to the involvement of 
neighbouring receptors, either GPCR or non-GPCR receptors, for example Receptor 
Tyrosine Kinases (RTKs) or Epidermal Growth Factor Receptors (EGFRs). In order 
to eliminate the assumption if higher chemerin (21-157) concentrations prove to be 
toxic to the endothelial cells, performing a cell count before treatments with desired 
chemical could help to determine the limitation of endothelial cell apoptosis used in 
this project. 
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In conclusion, the role of chemerin (21-157) in sFlt-1 (soluble form of 
VEGFR1) secretion and production, VEGFR1 phosphorylation, and most 
importantly, the question of how the VEGF receptor signalling network is integrated 
and co-ordinated with other receptor tyrosine kinases in the ECs, such as 
angiopoietins and Tie receptors (Gale and Yancopoulos, 1999) must be addressed. 
Also, the involvement of different MAPKs and other signalling kinases in chemerin 
(21-157)-mediated angiogenesis and cell death remains to be elucidated. Bozaoglu 
and colleagues reported the involvement of ERK1/2 MAPK in angiogenesis 
(Bozaoglu et al., 2010), however, the role of other important MAPK such as p38, 
SAPK/JNK, ERK5 MAPK and Akt/PKB kinases needs to be understood. Role of 
chemerin (21-157) in mediating angiogenesis via pathways which are independent of 
VEGF such as Notch/DLL4 remains to be explored. Involvement of different MAPK 
in mediating the activities of MMPs enzymes, and also elucidate the role of Tissue 
Inhibitors of Metalloproteinases (TIMPs) in angiogenesis. In order to fully 
appreciate the role of chemerin (21-157) in mediating important biological responses 
such as angiogenesis, the finding must be carried out in in vivo models. 
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7.3 Chemerin (21-157) increased cell adhesion molecules protein expression 
and Nuclear Factor (NF)-κB activity: role in endothelial-monocyte cell 
adhesion in HMEC-1 cell line 
 
Chemerin (21-157) significantly upregulated the cellular protein expression 
levels of cell adhesion molecules including E-selectin, VCAM-1, and ICAM-1 in a 
concentration-dependent manner at 12 and 24 hours. In addition, chemerin (21-157) 
also increased soluble protein expression of E-selectin (sE-selectin), VCAM-1 
(sVCAM-1) and ICAM-1 (sICAM-1) adhesion molecules in a concentration-
dependent manner. Combined treatments of HMEC-1 cells with chemerin (21-157) 
alone and in combination with IL-1β resulted in altered protein expression levels of   
E-selectin, VCAM-1 and ICAM-1. Adhesion molecules expression is known to 
increase in inflammatory states, for example ICAM-1 protein expression is induced 
by inflammatory cytokines and is highly expressed on the activated endothelium 
which is particularly important in mediating the firm adhesion of neutrophils on ECs 
as well as trans-endothelial migration. Under transcriptional regulation, VCAM-1 
protein expression is considered as one of the earliest markers of lesions in animal 
model of atherogenesis (Cybulsky and Gimbrone, 1991). VCAM-1 is a key adhesion 
molecule expressed on the ECs that mediates monocyte recruitment to early lesions 
in an experimental model of atherogenesis (Cybulsky et al., 2001). Chemerin (21-
157) increased NF-κB pathway activity, a well studied inflammatory pathway in a 
concentration-dependent manner, showing an additive increase when co-stimulated 
with chemerin (21-157) and IL-1β together in HMEC-1 cell line. HMEC-1 pre-
treatments with BAY11-7085, a specific NF-κB inhibitor, prior to stimulating with 
chemerin (21-157) resulted in the down-regulation of VCAM-1 protein expression 
compared to chemerin (21-157) only treatments. Interestingly, BAY11-7085 only 
treatments in HMEC-1 cells resulted in increased VCAM-1 protein expression, 
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however, no current explanation is supported in the literature at present. Chemerin 
(21-157) significantly upregulated the protein expression of the chemoattractant 
protein, MCP-1 in a concentration-dependent manner after 12 and 24 hours of 
incubation; also showing an additive increase when co-stimulated with chemerin 
(21-157) and IL-1β, in comparison to chemerin (21-157) and IL-1β alone. MCP-1 is 
a chemoattractant protein and is implicated in the recruitment of monocytes to the 
inflamed endothelium (Gerszten et al., 1999, Luscinskas et al., 2000). Low 
molecular weight cytokines such as MCP-1 are capable of crossing the epithelial cell 
barriers such as EC, and establish a chemokine gradient across the cell wall, and 
attract monocytes to the extravascular spaces. Chemerin (21-157) encouraged 
monocyte cell adhesion to ECs in a concentration-dependent manner, and was 
inhibited when pre-incubated with specific inhibitors for NF-κB, p38 MAPK, 
ERK1/2 MAPK and Akt/PI3K pathways; suggesting the involvement of NF-κB 
transcription factor, and other mentioned key MAPKs, and kinases such as Akt/PKB 
in monocyte-endothelial cell adhesion respectively. MCP-1 is a chemoattractant 
protein and is primarily implicated in the recruitment of monocytes to the inflamed 
endothelium (Gerszten et al., 1999, Luscinskas et al., 2000). Leukocyte adhesion to 
EC involves initial leukocyte cell adhesion to the EC, rolling and tethering on the EC 
surface, followed by firm adhesion and trans-endothelial migration. In particular, 
recruitment and transmigration of monocyte cells to the extravascular spaces and 
formation of foam cells after the ingestion of lipids results in the production of 
inflammatory cytokines, recruiting smooth muscle cells to the inflammatory site and 
promoting cell proliferation; which again results in the formation of more unstable 
and complex plaques leading to complications associated with CVDs. 
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In conclusion, involvement of important kinases such as ERK1/2, p38 and 
ERK5 MAPKs in inducing NF-κB pathway activation remains to be elucidated. As 
different chemerin fragments are reported to show different functional effects, for 
example murine chemerin 15 (140-154) is reported to show anti-inflammatory 
properties (Cash et al., 2008). Therefore, not only the role of other chemerin 
fragments in inducing EC inflammation and pathology must be explored, but also  
the involvement of one or more chemerin receptors in mediating those effects must 
be understood (Fig. 1.3.1a, page number 26). In addition, finding must be carried out 
in in vivo animal models in order to fully understand the pro- or anti-inflammatory 
chemerin (21-157) behaviour. 
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7.4 Chemerin (21-157) increased endothelial Nitric Oxide Synthase (eNOS) 
activity via Akt/PI3 Kinase, PKA and PKC Pathways in ECs: role in 
nitrite and nitrate production in HMEC-1 cell line 
 
Chemerin (21-157) increased eNOS activity by phosphorylating eNOS at 
Ser1177 [eNOS (Ser1177)] and dephosphorylating at Thr 495 [eNOS (Thr495)] in a 
time- and concentration-dependent manner; which are reported to be the main sites 
that regulate the activity of eNOS enzyme. In addition to Ser1177 and Thr495, eNOS 
is reported to be phosphorylated on a number of different sites that are known to 
increase the activity of eNOS; including Ser116 and Ser617, where the consequences 
of Ser116 phosphorylation remain unclear. More recently, eNOS phosphorylation or 
dephosphorylation at Thr495 site has been suggested as an intrinsic switch 
mechanism that determines whether eNOS enzyme results in the generation of NO or 
O2
–
 (Lin et al., 2003). eNOS, which is an enzyme constitutively expressed on the 
cells of the endothelium, is the main enzyme that regulates the production of 
vascular NO, which maintains vascular homeostasis. ED marks early stages of 
vascular disease and is suggested as a direct result of NO deficiency (Cooke, 2004). 
NO inhibits key processes in atherogenesis such as down-regulating the expression 
of cell adhesion molecules (De Caterina et al., 1995, Khan et al., 1996, Biffl et al., 
1996), monocyte adhesion, platelet aggregation, and vascular smooth muscle 
proliferation (Garg and Hassid, 1989). A variety of stimuli such as shear stress 
(Marsden et al., 1993), chronic exercise (Kojda et al., 2001), VEGF (Bouloumie et 
al., 1999), TGF-β (B et al., 2002); and a number of other cytokines are reported to 
alter eNOS expression and activity (Chen et al., 2003, Lu et al., 1996). Chemerin 
(21-157) increased the activity of eNOS at Ser1177 [eNOS (Ser1177)] via Akt/PI3, 
PKA, and PKC pathways. Chemerin (21-157)-induced eNOS (Ser1177) 
phosphorylation is reduced in ECs when pre-incubated with Akt/PI3 kinase, PKA 
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and PKC inhibitors, which suggests the involvement of these pathways in chemerin 
(21-157)-induced eNOS activity. Moreover, both PKA and PKC inhibitor pre-
incubations in HMEC-1 cells, in the absence of chemerin (21-157), lead to eNOS 
phosphorylation at Ser1177, however, no current explanation is supported in the 
literature at present. Akt/PKB kinase phosphorylation at Ser473 site is crucial as it 
then phosphorylates eNOS at Ser1177 site resulting in the release of  NO (Dimmeler 
et al., 1999, Fulton et al., 1999, Luo et al., 2000). In addition, AMPKα kinase 
phosphorylation at Thr172 (Appendix 12, Fig. 12.1a and b respectively, page 
numbers 280-82) is also known to increase the activity of eNOS by directly 
phosphorylating at Ser1177 [eNOS(Ser1177)]. VEGF, in addition to its mitogenic 
and chemotactic activities, is also known to release NO in primary HUVEC cells 
(van der Zee et al., 1997, Ahmed et al., 1997). Chemerin (21-157) increased the 
protein expression of caveolin-1 in a time- and concentration-dependent manner 
(Appendix 8, Fig. 8.1a and b respectively, page numbers 265-67). eNOS interaction 
with caveolin proteins including caveolin-1 and -3 is known to inhibit the activity of 
eNOS thus interfering with the production of NO (Bucci et al., 2000). Also, 
chemerin (21-157) increased HSP90 protein expression in a time- and concentration-
dependent manner (Appendix 9, Fig. 9.1a and b respectively, page numbers 268-70). 
eNOS interaction with HSP90 is suggested to result in increased eNOS activity 
(Garcia-Cardena et al., 1998). Chemerin (21-157) increased iNOS protein expression 
in a time- and concentration-dependent manner; which is known to produce 100- to 
1000- times more NO compared to that of eNOS (Nathan and Xie, 1994). In 
atherosclerosis, iNOS expression is increased, whereas, eNOS expression is low 
(Fukuchi and Giaid, 1999). iNOS protein expression is also increased in response to 
ischaemia (Azadzoi et al., 2004) and due to involvement of ROS (Aliev et al., 1998). 
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However, chemerin (21-157) failed to induce any changes in NOx levels in HMEC-1 
cells, and caused decrease in NO2– levels. No or reduced availability of NO 
metabolites, in the presence of increased eNOS activity and iNOS expression, 
suggests the involvement of ROS. Although chemerin (21-157) increased eNOS 
activity, and also increased iNOS protein expression in a time- and concentration-
dependent manner in HMEC-1 cell line, unfortunately, the assessment of NO 
metabolites in this project remained inconclusive. 
Hence, in conclusion, in order to fully understand the role of chemerin (21-157) 
in EC functioning and NO production in the endothelium, better NO assessment 
method must be considered. Involvement of ROS in endothelium NO production and 
depletion needs to be elucidated; as ROS are known to act as signalling molecules in 
the vascular endothelium and activate a number of downstream signalling molecules 
such as MAPKs and different ion channels; which in turn are implicated in a number 
of different biological processes such as EC proliferation, migration, extracellular 
matrix degradation and expression of various different pro-inflammatory cytokines. 
In addition to ROS-mediated NO reduced bioavailability, oxidative stress is also 
known to inhibit eNOS activity via a number of different mechanisms such as 
depletion or toxicity of eNOS substrates, eNOS uncoupling and involvement of 
different endogenous inhibition of eNOS. One of these important mechanisms that is 
increasingly becoming popular is the involvement of endogenous inhibitors of eNOS. 
Asymmetrical N
G
, N
G
-dimethyl-L-arginine (ADMA), first characterised by Vallance 
P and colleagues (1991), is reported to act as a competitive inhibitor of eNOS, and 
its accumulation is reported to cause increased blood pressure and reduced blood 
flow (Vallance et al., 1992a). N
G
-monomethyl-L-arginine (MMA) is reported to be 
another endogenous inhibitor of eNOS (Vallance et al., 1992b). Similar to ADMA 
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and MMA, Symmetric Dimethylarginine (SDMA) competes with eNOS substrate, 
L-arginine; however, is inactive and does not inhibit eNOS activity (Teerlink et al., 
2009). Therefore, role of chemerin (21-157) in all above mentioned processed must 
be accounted for, and again in vivo animal models must be developed to fully 
understand the role of chemerin in different aspects of EC biology. 
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As previously mentioned, a number of active and inactive chemerin fragments 
are formed upon proteolytic cleavage of precursor protein, pre-prochemerin (Fig. 
1.2.3a.1, page number 16). Chemerin (149-157) is the shortest chemerin fragment 
known to retain most of the activity of full length chemerin (21-157) in vitro, and 
binds to CMKLR1 in micromolar concentrations (Wittamer et al., 2004, Wong et al., 
2011). The future work will be focussed on studying the role of chemerin (149-157) 
in EC biology. So far, similar to chemerin (21-157), chemerin (149-157) induced the 
phosphorylation of important MAPKs including ERK1/2, p38, SAPK/JNK MAPKs, 
and Akt/PKB and AMPKα kinases in a time- and concentration-dependent manner in 
HMEC-1 cell line. In addition, chemerin (149-157) also induced EC capillary tube 
formation in a concentration-dependent manner in HMEC-1 cell line. 
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8.1 Chemerin (149-157) Lead to ERK1/2 MAPK Phosphorylation in a Time- 
and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
ERK1/2 MAPK phosphorylation, HMEC-1 cells were treated with [3.0µM] 
chemerin (149-157) at different time-points for a maximum of 30 minutes. For 
concentration-dependent ERK1/2 MAPK phosphorylation, HMEC-1 cells were 
treated with different chemerin (149-157) [0-1000nM] concentrations for 15 minutes, 
however, failed to show ERK1/2 MAPK phosphorylation in nanomolar 
concentrations (Appendix 13, Fig. 13.1a, page numbers 283). HMEC-1 cells were 
then treated with different, micromolar chemerin (149-157) [0-30µM] concentrations 
for 15 minute. Cells were lysed in 1x RIPA buffer and protein lysates were separated 
using SDS-PAGE. Chemerin (149-157) phosphorylated ERK1/2 MAPK in a time- 
and concentration-dependent manner (Fig. 8.1a and b respectively). 
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Figure 8.1a Chemerin (149-157) lead to ERK1/2 MAPK phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [3.0µM] chemerin (149-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the proteins were separated using 12% 
polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 hour. 
Membranes were incubated with specific phospho-ERK1/2 (Thr202/Tyr204) MAPK 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After 
removing the primary antibody complexes, membranes were incubated with anti-
rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total ERK1/2 MAPK antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both phospho-ERK1/2 and total ERK1/2 MAPK were detected as 
44/42kDa products. 
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Figure 8.1b Chemerin (149-157) lead to ERK1/2 MAPK phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (149-157) concentrations [0-
30µM] for 15 minutes. Following cell lysis and sample preparations, the proteins 
were separated using 12% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific phospho-ERK1/2 
(Thr202/Tyr204) MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
overnight at 4
o
C. After removing the primary antibody complexes, membranes were 
incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 
1 hour at RT. Protein complexes were visualised using ECL plus detection reagent 
on X-ray films. Membranes were re-probed with total ERK1/2 MAPK antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-ERK1/2 and total ERK1/2 MAPK were 
detected as 44/42kDa products. 
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8.2 Chemerin (149-157) Lead to  p38 MAPK Phosphorylation in a Time- 
and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent p38 
MAPK phosphorylation, HMEC-1 cells were treated with [3.0µM] chemerin (149-
157) at different time-points for a maximum of 30 minutes. For concentration-
dependent p38 MAPK phosphorylation, HMEC-1 cells were treated with different 
chemerin (149-157) [0-30µM] concentrations for 15 minute. Cells were lysed in 1x 
RIPA buffer and protein lysates were separated using SDS-PAGE. Chemerin (149-
157) phosphorylated p38 MAPK in a time- and concentration-dependent manner 
(Fig. 8.2a and b respectively). 
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Figure 8.2a Chemerin (149-157) lead to p38 MAPK phosphorylation in a time-
dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [3.0µM] chemerin (149-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 12% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with specific phospho-p38 (Thr180/Tyr182) 
MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total p38 MAPK antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both phospho-p38 and total p38 were detected as 38kDa products. 
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Figure 8.2b Chemerin (149-157) lead to p38 MAPK phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (149-157) concentrations [0-
30µM] for 15 minutes. Following cell lysis and sample preparations, the protein 
lysates were separated using 12% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with specific phospho-
p38 (Thr180/Tyr182) MAPK antibody [(1:1500); Cell signalling, Beverly, MA, 
USA] overnight at 4
o
C. After removing the primary antibody complexes, membranes 
were incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, 
UK] for 1 hour at RT. Protein complexes were visualised using ECL plus detection 
reagent on X-ray films. Membranes were re-probed with total p38 MAPK antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-p38and total p38 were detected as 38kDa 
products. 
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8.3 Chemerin (149-157) lead to SAPK/JNK MAPK Phosphorylation in a 
Time- and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
SAPK/JNK MAPK phosphorylation, HMEC-1 cells were treated with [1.0µM] 
chemerin (149-157) at different time-points for a maximum of 30 minutes. For 
concentration-dependent SAPK/JNK MAPK phosphorylation, HMEC-1 cells were 
treated with different chemerin (149-157) [0-30µM] concentrations for 30 minute. 
Cells were lysed in 1x RIPA buffer and protein lysates were separated using SDS-
PAGE. Chemerin (149-157) phosphorylated SAPK/JNK MAPK in a time- and 
concentration-dependent  manner (Fig. 8.3a and b respectively). 
.  
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Figure 8.3a Chemerin (149-157) lead to SAPK/JNK MAPK phosphorylation in 
a time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [1.0µM] chemerin (149-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with phospho-SAPK/JNK (Thr183/Tyr185) 
MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total SAPK/JNK MAPK antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both phospho-SAPK/JNK and total SAPK/JNK were detected as 54/46kDa 
products.  
 
 
 
 
 
 
 Time (minutes)      B            2          5           10         15          30 
54 kDa 
46 kDa 
54 kDa 
46 kDa 
ph-SAPK/JNK 
(Thr183/Tyr185) 
SAPK/JNK 
  224 
 
 
 
 
 
 
 
 
Figure 8.3b Chemerin (149-157) lead to SAPK/JNK MAPK phosphorylation in 
a concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (149-157) concentrations [0-
30µM] for 30 minutes. Following cell lysis and sample preparations, the protein 
lysates were separated using 10% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with phospho-
SAPK/JNK (Thr183/Tyr185) MAPK antibody [(1:1500); Cell signalling, Beverly, 
MA, USA] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); 
Dako, Ely, UK] for 1 hour at RT. Protein complexes were visualised using ECL plus 
detection reagent on X-ray films. Membranes were re-probed with total SAPK/JNK 
MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a 
loading control. The corresponding bands for both phospho-SAPK/JNK and total 
SAPK/JNK were detected as 54/46kDa products. 
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8.4 Chemerin (149-157) Lead to Akt/PKB Kinase Phosphorylation in a 
Time- and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. To study time-
dependent Akt/PKB kinase phosphorylation, HMEC-1 cells were treated with 
[3.0µM] chemerin (149-157) at different time-points for a maximum of 30 minutes. 
For concentration-dependent Akt/PKB kinases phosphorylation, HMEC-1 cells were 
treated with different chemerin (149-157) [0-30µM] concentrations for 15 minute. 
Cells were lysed in 1x RIPA buffer and protein lysates were separated using SDS-
PAGE. Chemerin (149-157) phosphorylated Akt/PKB Kinase in a time- and 
concentration-dependent manner (Fig. 8.4a and b respectively). 
. 
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Figure 8.4a Chemerin (149-157) lead to Akt/PKB Kinase phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [3.0µM] chemerin (149-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with phospho-Akt (Ser473) antibody [(1:1500); 
Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-rabbit IgG-HRP labelled 
antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membranes were re-
probed with total Akt antibody [(1:1500); Cell signalling, Beverly, MA, USA] and 
used as a loading control. The corresponding bands for both phospho-Akt and total 
Akt were detected as 60kDa products. 
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Figure 8.4b Chemerin (149-157) lead to Akt/PKB Kinase phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (149-157) concentrations [0-
30µM] for 15 minutes. Following cell lysis and sample preparations, the protein 
lysates were separated using 10% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with phospho-Akt 
(Ser473) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total Akt antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for both 
phospho-Akt and total Akt were detected as 60kDa products. 
 
 
 
 
 
 
 
 
 
 
Chemerin (149-157) [µM]  B           0.1        1.0         3.0         10           30 
60 kDa 
Akt 
ph-Akt 
(Ser473) 
60 kDa 
  228 
8.5 Chemerin (149-157) Lead to AMPKα Kinase Phosphorylation in a Time- 
and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
AMPKα kinases phosphorylation, HMEC-1 cells were treated with [10µM] 
chemerin (149-157) at different time-points for a maximum of 30 minutes. For 
concentration-dependent AMPKα kinase phosphorylation, HMEC-1 cells were 
treated with different chemerin (149-157) [0-30µM] concentrations for 10 minute. 
Cells were lysed in 1x RIPA buffer and protein lysates were separated using SDS-
PAGE. Chemerin (149-157) phosphorylated AMPKα kinase in a time- and 
concentration-dependent manner (Fig. 8.5a and b respectively). 
. 
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Figure 8.5a Chemerin (149-157) lead to AMPKα kinase phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [10µM] chemerin (149-157) for 0-30 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with phospho-AMPKα (Thr172) antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-rabbit IgG-HRP 
labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes 
were visualised using ECL plus detection reagent on X-ray films. Membranes were 
re-probed with total AMPKα antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both phospho-AMPKα 
and total AMPKα were detected as 68kDa products. 
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Figure 8.5b Chemerin (149-157) lead to AMPKα kinase phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (149-157) concentrations [0-
30µM] for 10 minutes.  Following cell lysis and sample preparations, the protein 
lysates were separated using 10% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with phospho-AMPKα 
(Thr172) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membranes were re-probed with total AMPKα antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for both 
phospho-AMPKα and total AMPKα were detected as 68kDa products. 
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8.6 Chemerin (149-157) Induced Capillary Tube Formation in HMEC-1 Cell 
Line 
 
Chemerin (149-157) induced capillary tube formation in a concentration-
dependent manner in HMEC-1 cell line. VEGF [10ng/ml] was used as a positive 
control (Fig. 8.6a). 
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Figure 8.6a Chemerin (149-157) induced capillary tube formation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were trypsinised and seeded onto the Matrigel coated plates at the cell 
density of 2x10
3
cells/well in the fresh medium and incubated for 2 hours. Cell 
medium was replaced with MCDB medium containing 1% FCS and incubated for 4 
hours. Post incubations, HMEC-1 cells were treated with different chemerin (149-
157) concentrations [0-30µM] and VEGF [10ng/ml] and incubated for a maximum 
of 24 hours. Capillary tube formation images were captured using a digital 
microscope camera system (Olympus, Tokyo, Japan) under 100x magnification. 
VEGF [10ng/ml] was used as a positive control. 
 
Basal Chemerin 149-157 [0.01µM] Chemerin 149-157 [0.1µM] 
Chemerin 149-157 [3.0 µM] Chemerin 149-157 [10µM] 
Chemerin 149-157 [30µM] VEGF [10ng/ml] 
Chemerin 149-157 [1.0µM] 
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1. Materials Used 
 
1.1 List of buffers and cell media solution 
 
List of Buffers and Cell Media Solution 
 
Blocking solution – 5% Bovine Serum Albumin 
 
DMEM medium – Invitrogen, Paisley, UK 
 
HMEC-1 cell line  - CDC, Atlanta, Georgia, USA 
 
MCDB medium  - Sigma-Aldrich, Dorset, UK 
 
Medium 199 (M199) cell medium – Invitrogen, Paisley, UK L-glutamine 
Membrane Stripping Buffer 
Opti-MEM
® 
medium  - Invitrogen, Paisley, UK) 
 
SDS-PAGE Transfer Buffer – 10% Tris/Glycine solution, 20% methanol and 
water 
SDS-PAGE Running Buffer (10x) 
30.3g Tris base, 144g glycine, 10g SDS – total volume 1000ml with distilled 
water 
PBS containing 0.01% Triton X-100 (PBS-T) 
Phosphate Buffer Solution (PBS) 
 
Tris Borate-EDTA (TBE) 
 
Tris Buffered Saline (TBS) wash buffer 
Tris Buffered Saline-0.1% Tween-20 (TBS-T) wash buffer 
 
Trypan Blue solution - Invitrogen, Paisley, UK 
 
Trypsin EDTA  
 
 
All the buffer solutions were prepared by Media Preparation Laboratory, Department 
of Life Sciences, The University of Warwick, UK; unless otherwise stated. 
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1.2 DNA and protein markers 
 
Markers 
 
Supplier name 
GeneRuler
TM
 1kb DNA ladder 
 
Fermentas, UK 
GeneRuler
TM
 50bp DNA ladder Fermentas, UK 
 
PageRulerTM Prestained Protein 
 
Fermentas, UK 
SpectraTM Multicolour Broad Range 
Protein Ladder 
Fermentas, UK 
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1.3 List of chemicals and reagents 
 
Chemicals/Reagents Supplier name 
 
Ammonium  Persulphate (APS) 
 
Sigma Aldrich, Dorset, UK 
Chemerin (21-157) R and D systems, Abingdon, 
UK 
Chemerin 149-157  
 
AnaSpec, Cambridge, UK 
β-Mercaptoethanol Sigma Aldrich, Dorset, UK 
Dimethylsulphoxide (DMSO) Sigma Aldrich, Dorset, UK 
Endothelial Cell Growth Supplement 
(ECGS)  
BD Biosciences, Bedford, MA, 
UK 
Epidermal Growth Factor (EGF)  Invitrogen, Paisley, UK 
Ethidium Bromide Sigma Aldrich, Dorset, UK 
Fetal Calf Serum (FCS) 
 
Sigma Aldrich, Dorset, UK 
Glacial Acetic Acid Sigma Aldrich, Dorset, UK 
Glutamine 
 
Sigma Aldrich, Dorset, UK 
Heparin  
 
Aventis Pharma, Milan, Italy 
H2O2 
 
Sigma Aldrich, Dorset, UK 
Interleukine-1 beta (IL-1β) Abcam, Cambridge, UK 
Interleukine-6 NBS Biologicals, 
Cambridgeshire, UK 
Lipofectamine Invitrogen, Paisley, UK 
MgCl2 Biogene, Kimbolton, UK 
(M-MuLV) reverse transcriptase Fermentas, York, UK 
N-(1-Naphthyl) ethylenediamine 
dihydrochloride  
Sigma Aldrich, Dorset, UK 
NF-κB binding sites (pcDNA3.1-NF-
κB-Luc)  
Stratagene, La Jolla, CA 
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N, N, N’, N’- tetramethyl-
ethylenediamine  
Sigma Aldrich, Dorset, UK 
Penicillin 
 
Sigma Aldrich, Dorset, UK 
Protogel [30% Acrylamide: 
Bisacrylamide (37.5:1) 
GENEFLOW, Limited, UK 
Poly-L-lysine Sigma Aldrich, Dorset, UK 
Sodium nitrite Sigma Aldrich, Dorset, UK 
Sodium nitrate Sigma Aldrich, Dorset, UK 
Streptomycin 
 
Sigma Aldrich, Dorset, UK 
Sulfanilamide  Sigma Aldrich, Dorset, UK 
Tumour Necrosis factor (TNF)-alpha 
 
Calbiochem, UK 
Trypsin/EDTA 
 
Sigma Aldrich, Dorset, UK 
Vanadium chloride Sigma Aldrich, Dorset, UK 
VECTASHIELD mounting medium 
with DAPI 
Vector Laboratories, Inc Orton 
Southgate, Peterborough, UK 
VEGF Sigma Aldrich, Dorset, UK 
1M HCL solution Sigma Aldrich, Dorset, UK 
4´,6-Diamidino-2-phenylindole 
dihydrochloride 
Sigma-Aldrich, Dorset, UK 
70% Ethanol Sigma Aldrich, Dorset, UK 
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1.4 Inhibitors  
 
Inhibitors 
 
Supplier name 
 
BAY11-7085 Calbiochem, UK 
LY294002 Calbiochem, san Diego, CA, 
USA 
Pertussis toxin 
 
Sigma-Aldrich, UK 
PKA inhibitor - H-89 Calbiochem, san Diego, CA, 
USA 
PKC inhibitor - BIS II Sigma-Aldrich, UK 
SB203580  Calbiochem, san Diego, CA, 
USA 
U0126  Calbiochem, san Diego, CA, 
USA 
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1.5 Lab apparatus and glass and plastic ware 
 
Lab apparatus and glass and plastic ware 
Gilson pipettes 
Glassware – cylinders, beakers, conical flasks, storage bottles and funnels 
Filters 
Gloves  
Liquid Broth (LB) plates 
Petri dishes 
Pipette tips 
Syringes 
0.5, 1 and 1.5ml eppendorf tubes 
6, 12, 24 and 96 well plates 
5, 10 and 20ml eppendorf tubes 
Tissue culture flasks 
Universal containers 
 
Liquid Broth (LB) plates were prepared by Media Preparation Laboratory, 
Department of Life Sciences, The University of Warwick, UK. 
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1.6 Lab equipment 
 
 
 
 
 
 
Lab apparatus 
Automated analyser – Abbott Architect, Abbott Laboratories, Abbott Park, IL, 
USA 
Digital microscope camera – Olympus, Tokyo, Japan 
DMRE Laser-scanning confocal microscope – Leica, Milton Keynes, UK 
DNA sequencer – Molecular Biology Lab, Department of Life Sciences, 
University of Warwick, UK  
 
ELISA plate reader – EL800, Bio-Tek Instruments, Inc., Winooski, VT, USA 
 
Freezing container – Nalgene® Mr Frosty, Sigma-Aldrich, UK 
 
Fuji medical X-ray film – Fuji Photo Film Company, Tokyo, Japan 
 
Luminex® 100 instrument  
 
Leica model DMRE laser-scanning confocal microscope – Milton  Keynes, UK 
Mr Frosty cryofreezing container – Fischer Scientific, Loughborough, UK 
NanoDrop spectrophotometer – Labtech International, Ringmer, UK 
Plate reader – Multiskan Ascent 96/384 Plate Reader 
Pro-plus software – Media Cybernetics, Bethesda, MD 
Roche Light CyclerTM System – Roche Molecular Biochemicals, Mannheim, 
Germany 
Scion Image™ – Scion Corporation, Maryland, USA 
Spectrophotomer – Beckman Instruments Inc., California, USA 
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1.7 Specialised assay kits 
 
Assay kits Supplier name 
 
BioCoat Angiogenesis System 
 
BD Biosciences, UK 
Cell DNA Fragmentation Assay 
 
Roche Diagnostics, UK 
CellTitre 96 Aqueous one solution 
Cell Proliferation assay kit 
 
Promega, UK 
GenElute Plasmid Miniprep Kit Qiagen, Crawley, UK 
Growth Factor Reduced Matrigel BD Biosciences, San Jose, 
CA, USA 
QIAquick Gel Extraction kit 
 
Qiagen, Crawley, UK 
QIAGEN Plasmid Maxi Kit 
 
Qiagen, Crawley, UK 
sE-selectin, sICAM-1, sVCAM-1 and 
sPAI-1 multiplex assay kit 
Millipore, UK 
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1.8 Antibodies 
 
Antibodies Supplier name 
 
Akt antibody 
 
Cell Signalling, Beverly, MA, 
USA 
Anti-MMP-2 antibody 
 
Abcam, Cambridge, UK 
Anti-MMP-9 antibody 
 
Abcam, Cambridge, UK 
Anti-rabbit horseradish peroxide-
conjugated antibody 
 
Dako, Ely, UK 
 
Alexa 680 conjugated anti-mouse IgG Cell Signalling, Beverly, MA, 
USA 
AMPKα antibody 
 
Cell Signalling, Beverly, MA, 
USA 
β-actin antibody  Rabbit Cell signalling, Beverly, MA, 
USA 
Caveolin-1 antibody Cell Signalling, Beverly, MA, 
USA 
Chemerin antibody 
 
R and D Systems, UK 
Chemerin receptor, CMKLR1 
antibody 
 
Santa Cruz, California, USA 
E-selectin antibody 
 
Santa Cruz, California, USA 
ERK 44/42 MAPK (Erk1/2) 
 
Cell Signalling, Beverly, MA, 
USA 
GPR-1 antibody 
 
Santa Cruz, California, USA 
ICAM-1 antibody Santa Cruz, California, USA 
 
MCP-1 monoclonal antibody 
 
Cell Signalling, Beverly, MA, 
USA 
PAI-1 antibody 
 
Abcam, Cambridge, UK 
Phospho-Akt (Ser473) (193H12) 
Rabbit mAb 
 
Cell Signalling, Beverly, MA, 
USA 
Phospho-AMPKα (Thr172) (40H9) 
Rabbit mAb 
 
Cell Signalling, Beverly, MA, 
USA 
Phospho ERK-44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) Rabbit mAb 
 
Cell Signalling, Beverly, MA, 
USA 
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All chemical reagents and materials were stored at temperatures of 4-6
o
C, - 20
o
C and 
- 80
oC according to manufacturer’s instructions. 
 
 
 
 
 
 
 
 
 
 
 
p38 MAPK Antibody 
 
Cell Signalling, Beverly, MA, 
USA 
VCAM-1 antibody 
 
Santa Cruz, California, USA 
VEGF (Ab)-1  antibody 
 
Lab Vision, Suffolk, UK 
VEGF165b antibody  
 
R and D Systems, UK 
VEGFR2 antibody 
 
Cell Signalling, Beverly, MA, 
USA 
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2. CMKLR1 Receptor Staining Using Immunostaining 
 
HMEC-1 cells were immunostained for CMKLR1 receptor; cells were plated 
on sterilised coverslips, and slides were prepared using Immunostaining method 
(Chapter 2, section 2.3.8, page numbers 59-61). CMKLR1 receptor was present in 
HMEC-1 cells (Fig. 2.1a). TNF-α [10ng/ml] was used as a positive control. 
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Figure 2.1a CMKLR1 receptor localisation and distribution in HMEC-1 cell 
line 
HMEC-1 cells were incubated with anti-CMKLR1 antibody [(1:400); Santa Cruz, 
USA] constituted in PBS-T overnight at 4
o
C. After removing the antibody, cells 
were washed with PBS and incubated with anti-mouse Alexa 680-conjugated IgG 
antibody [(1:400); Sigma, UK] and incubated in the dark for 2 hours. Cells were 
mounted in VECTASHIELD mounting medium with DAPI (Vector Laboratories, 
Inc Orton Southgate, Peterborough, UK) on microscope slides. Cells were observed 
under an oil immersion objective lens using a Leica model DMRE laser-scanning 
confocal microscope (Milton Keynes, UK). TNF-α [10ng/ml] served as a positive 
control and DAPI stain was used as a negative control. 
 
 
 
 
 
 
 
 
          CMKLR1                               TNF-α [10ng/ml]                       (-ve DAPI stain)                    
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3. Chemerin (21-157) Upregulated Hypoxia-inducible Factor (HIF)-1α Protein 
Expression in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. HMEC-1 cells were treated 
with different chemerin (21-157) [0-10nM] concentrations for 6 hours. Cells were 
lysed in 1x RIPA buffer and protein lysates were separated using SDS-PAGE. 
Chemerin (21-157) significantly increased HIF-1α cellular protein expressions at 
[0.01-1nM] concentrations (p < 0.001) and decreasing significantly at [10nM] (p  < 
0.01) (Fig. 3.1a).  
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Figure 3.1a Chemerin (21-157) upregulated HIF-1α protein expression in 
HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 6 hours. Following cell lysis and sample preparations, the protein lysates 
were separated using 10% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific mouse HIF-1α 
antibody [(1:1000); Santa Cruz, USA] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-mouse IgG-HRP labelled 
antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membrane were re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for HIF-1α and β-actin were 
detected as 93kDa and 45kDa products. The band intensities were measured using 
Scion Image™ densitometer (Scion Corporation, Maryland, USA). The data are 
presented as mean ± SEM of three independent experiments in duplicates ***p < 
0.001 and **p < 0.01 compared to basal. 
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4. Angiogenic Pathways Independent of VEGF – Notch/DLL4 
 
Cellular signalling pathways independent of VEGF/VEGFR1/VEGFR2 system 
are also known to mediate angiogenesis. Inter-endothelial signalling via Delta-like 4 
(DLL4) and Notch has recently emerged as important regulators of endothelial 
heterogeneity, and controls arterial cell specification as well as tip versus stalk cell 
selection. Tip cell formation during angiogenesis is mediated by VEGF-dependent 
angiogenesis and Notch/DLL4-mediated through stalk cell phenotype. VEGFR2 
system is also required by Notch. Notch receptors are required during vascular 
development and  morphogenesis (Harrington et al., 2008). 
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5. Anti-angiogenic VEGF Isoforms and Angiogenesis  
 
In 2002, VEGF165b was the first anti-angiogenic isoform identified (Bates et 
al., 2002) formed by differential splice-acceptor-site selection in the 3` UTR within 
exon 8 of the VEGF gene (Fig. 5.1a). The alternate splicing of VEGF gene results in 
the formation of anti-antigenic isoforms of VEGF which are grouped together in 
VEGFxxxb family; where xxx represents the number of amino acids. The 
VEGFxxxb isoforms correspond to that of their existing angiogenic counterparts of 
VEGF and are denoted as VEGF121b, VEGF145b, VEGF165b and VEGF189b 
(Perrin et al., 2005). The VEGF165b is an opposite counterpart of VEGF165 and 
inhibits VEGF165-induced endothelial cell proliferation, migration and vasodilation 
(Bates et al., 2002). In addition, VEGF165b also inhibits in vivo experimental and 
physiological angiogenesis and tumour growth and is reported to be down-regulated 
in cancers. 
Figure 5.1a The alternative splicing of VEGF gene 
Figure shows the alternative splicing of VEGF gene at exon 8. Exon 8b translates 
anti-angiogenic VEGF isoforms which are grouped together in VEGFxxxb, xxx 
representing the number of amino acids. VEGF121b, VEGF145b, VEGF165b, 
VEGF183b and VEGF189b are different anti-angiogenic VEGF isoforms formed by 
alternative splicing. Adapted from (Nowak et al., 2008). 
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6. Interleukin (IL)-1β Increased VCAM-1 and ICAM-1 Protein Expression in 
HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. For studying 
optimum incubation time for IL-1β-induced VCAM-1 and ICAM-1 protein 
expressions in HMEC-1 cell line, cells were treated with [10ng/ml] IL-1β at different 
time-point for a maximum of 18 hours. Cells were lysed in 1x RIPA buffer and 
protein lysates were separated using SDS-PAGE. IL-1β increased both VCAM-1 
(Fig. 6.1a) and ICAM-1 (Fig. 6.1b) protein expression in HMEC-1 cells, showing 
maximum protein expression at 6 hours, which then decreased with prolonged 
incubation times.  
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Figure 6.1a  IL-1β increased VCAM-1 protein expression in HMEC-1 cell line 
HMEC-1 cells were treated with IL-1β [10ng/ml] at different time-points for a 
maximum of 18 hours. Following cell lysis and sample preparations, the protein 
lysates were separated using 8% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with specific mouse 
anti-VCAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. After 
removing the primary antibody complexes, membranes were incubated with anti-
mouse IgG-HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membrane was re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for 
VCAM-1 and β-actin were detected as 110kDa and 45kDa products. 
 
 
 
 
 
 
 
 
VCAM-1 
β-actin 
Time (hours)   -            2             4            6            8          12           18 
110 kDa 
45 kDa 
IL-1β [10ng/ml]   -            +             +            +           +           +             + 
  251 
 
 
 
 
 
 
 
 
 
 
Figure  6.1b  IL-1β increased ICAM-1 protein expression in HMEC-1 cell line 
HMEC-1 cells were treated with IL-1β [10ng/ml] at different time-points for a 
maximum of 18 hours. Following cell lysis and sample preparations, the protein 
lysates were separated using 8% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with specific mouse 
anti-ICAM-1 antibody [(1:800); Santa Cruz, USA] overnight at 4
o
C. After removing 
the primary antibody complexes, membranes were incubated with anti-mouse IgG-
HRP labelled antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein 
complexes were visualised using ECL plus detection reagent on X-ray films. 
Membrane was re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. The corresponding bands for 
ICAM-1 and β-actin were detected as 85kDa and 45kDa products. 
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7. Cell Adhesion Molecules Secretion in HMEC-1 Cell  Supernatants 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 4, 12 and 24 hours and cell supernatants were collected. 
Luminex® 100 system (Chapter 2, section 2.4.9, page numbers 70-1) was used to 
quantify the secreted levels of E-selectin (sE-selectin), VCAM-1 (sVCAM-1) and 
ICAM-1 (sICAM-1) proteins in HMEC-1 cell culture supernatants. TNF-α [10ng/ml] 
and IL-1β [10ng/ml] were used as positive controls. 
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7.1 sE-selectin protein secretion in HMEC-1 cell supernatants  
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 4, 12 and 24 hours. Post incubations, HMEC-1 cell supernatants 
were collected and protein secretion levels were measured using Luminex® 100 
system. Different chemerin (21-157) treatments failed to show any change in sE-
selectin protein secretion in HMEC-1 cell supernatants at all three different time-
points (Table 7.1a, b and c respectively). 
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Table 7.1a 
Chemerin (21-157) and sE-selectin protein secretion in HMEC-1 cell 
supernatants after 4 hours 
 
Treatments 4 hours 
(n=1) 
pg/mL 
4 hours 
(n=2) 
pg/mL 
Basal  0.1 nd 
[0.01nM] chemerin (21-157) 0.05 0.05 
[0.1nM] chemerin (21-157) 0.08 nd 
[1nM] chemerin (21-157) 0.05 0.08 
[10nM] chemerin (21-157) nd 0.08 
[30nM] chemerin (21-157) nd 0.08 
TNF-α [10ng/ml] 0.05 0.05 
TNF-α [10ng/ml] 0.03 0.03 
IL-1β [10ng/ml] 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
  255 
Table 7.1b  
Chemerin (21-157) and sE-selectin protein secretion in HMEC-1 cell 
supernatants after 12 hours 
 
Treatments 12 hours 
(n=1) 
pg/mL 
12 hours 
(n=2) 
pg/mL 
Basal  nd nd 
[0.01nM] chemerin (21-157) nd 0.07 
[0.1nM] chemerin (21-157) 0.08 0.04 
[1nM] chemerin (21-157) nd nd 
[10nM] chemerin (21-157) nd 0.07 
[30nM] chemerin (21-157) 0.07 0.05 
TNF-α [10ng/ml] 0.05 0.05 
TNF-α [10ng/ml] 0.03 0.03 
IL-1β [10ng/ml] 0 0 
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Table 7.1c 
Chemerin (21-157) and sE-selectin protein secretion in HMEC-1 cell 
supernatants after 24 hours 
 
Treatments 24 hours 
(n=1) 
pg/mL 
24hours 
(n=2) 
pg/mL 
Basal  nd nd 
[0.01nM] chemerin (21-157) 0.02 nd 
[0.1nM] chemerin (21-157) nd nd 
[1nM] chemerin (21-157) nd nd 
[10nM] chemerin (21-157) nd nd 
[30nM] chemerin (21-157) nd nd 
TNF-α [10ng/ml] 0.05 0.05 
TNF-α [10ng/ml] 0.03 0.03 
IL-1β [10ng/ml] 0 0 
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7.2 sVCAM-1 protein secretion in HMEC-1 cell supernatants 
 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 4, 12 and 24 hours. Post incubations, HMEC-1 cell supernatants 
were collected and protein secretion levels were measured using Luminex® 100 
system. sVCAM-1 protein levels were not detected in HMEC-1 cell supernatants in 
any treatment group (Table 7.2a, b and c respectively). 
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Table 7.2a 
Chemerin (21-157) and sVCAM-1 protein secretion in HMEC-1 cell 
supernatants after 4 hours 
 
Treatments 4 hours 
(n=1) 
pg/mL 
4hours 
(n=2) 
pg/mL 
Basal  nd nd 
[0.01nM] chemerin (21-157) nd nd 
[0.1nM] chemerin (21-157) nd nd 
[1nM] chemerin (21-157) nd nd 
[10nM] chemerin (21-157) nd nd 
[30nM] chemerin (21-157) nd nd 
TNF-α [10ng/ml] 9.62 9.00 
TNF-α [10ng/ml] 57.88 54.63 
IL-1β [10ng/ml] 129.68 125.76 
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Table 7.2b  
Chemerin (21-157) and sVCAM-1 protein secretion in HMEC-1 cell 
supernatants after 12 hours 
 
Treatments 12 hours 
(n=1) 
pg/mL 
12hours 
(n=2) 
pg/mL 
Basal  nd nd 
[0.01nM] chemerin (21-157) nd nd 
[0.1nM] chemerin (21-157) nd nd 
[1nM] chemerin (21-157) nd nd 
[10nM] chemerin (21-157) nd nd 
[30nM] chemerin (21-157) nd nd 
TNF-α [10ng/ml] 10 9.58 
TNF-α [10ng/ml] 50 47.25 
IL-1β [10ng/ml] 250 245.46 
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Table 7.2c 
Chemerin (21-157) and sVCAM-1 protein secretion in HMEC-1 cell 
supernatants after 24 hours 
 
Treatments 24 hours 
(n=1) 
pg/mL 
24 hours 
(n=2) 
pg/mL 
Basal  nd nd 
[0.01nM] chemerin (21-157) nd nd 
[0.1nM] chemerin (21-157) nd nd 
[1nM] chemerin (21-157) nd nd 
[10nM] chemerin (21-157) nd nd 
[30nM] chemerin (21-157) nd nd 
TNF-α [10ng/ml] 96 94.56 
TNF-α [10ng/ml] 116 105.26 
IL-1β [10ng/ml] 52 49.56 
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7.3 sICAM-1 protein secretion in HMEC-1 cell supernatants 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 4, 12 and 24 hours. Post incubations, HMEC-1 cell supernatants 
were collected and protein secretion levels were determined using Luminex® 100 
system. Different chemerin (21-157) treatments failed to show any changes in 
sICAM-1 protein secretion in HMEC-1 cell supernatants at all three different time-
points (Table 7.3a, b and c respectively). 
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Table 7.3a 
Chemerin (21-157) and sICAM-1 protein secretion in HMEC-1 cell 
supernatants after 4 hours 
 
Treatments 4 hours 
(n=1) 
pg/mL 
4 hours 
(n=2) 
pg/mL 
Basal  0.33 0.3 
[0.01nM] chemerin (21-157) 0.26 0.26 
[0.1nM] chemerin (21-157) 0.29 0.25 
[1nM] chemerin (21-157) 0.24 0.25 
[10nM] chemerin (21-157) 0.26 0.29 
[30nM] chemerin (21-157) 0.22 0.3 
TNF-α [10ng/ml] 4.54 4.54 
TNF-α [10ng/ml] 3.25 3.25 
IL-1β [10ng/ml] 8.04 8.04 
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Table 7.3b 
Chemerin (21-157) and sICAM-1 protein secretion in HMEC-1 cell 
supernatants after 12 hours 
 
Treatments 12 hours 
(n=1) 
pg/mL 
12 hours 
(n=2) 
pg/mL 
Basal  0.6 0.54 
[0.01nM] chemerin (21-157) 0.52 0.57 
[0.1nM] chemerin (21-157) 0.56 0.59 
[1nM] chemerin (21-157) 0.55 0.53 
[10nM] chemerin (21-157) 0.76 0.59 
[30nM] chemerin (21-157) 0.81 0.73 
TNF-α [10ng/ml] 4.54 4.54 
TNF-α [10ng/ml] 3.25 3.25 
IL-1β [10ng/ml] 8.04 8.04 
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Table 7.3c 
Chemerin (21-157) and sICAM-1 protein secretion in HMEC-1 cell 
supernatants after 24 hours 
 
Treatments 24 hours 
(n=1) 
pg/mL 
24 hours 
(n=2) 
pg/mL 
Basal  1.01 1.42 
[0.01nM] chemerin (21-157) 1.06 1.29 
[0.1nM] chemerin (21-157) 1.11 1.29 
[1nM] chemerin (21-157) 1.01 1.45 
[10nM] chemerin (21-157) 1.1 1.65 
[30nM] chemerin (21-157) 1.31 1.72 
TNF-α [10ng/ml] 4.54 4.54 
TNF-α [10ng/ml] 3.25 3.25 
IL-1β [10ng/ml] 8.04 8.04 
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8. Chemerin (21-157) Increased Caveolin-1 Protein Expression in a Time- and 
Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
caveolin-1 protein expression, HMEC-1 cells were treated with [30nM] chemerin 
(21-157) at different time-points for a maximum of 24 hours. For concentration-
dependent caveolin-1 protein expression, HMEC-1 cells were treated with different 
chemerin (21-157) [0-30nM] concentrations for 12 hours. Cells were lysed in 1x 
RIPA buffer and protein lysates were separated using SDS-PAGE. Chemerin (21-
157) increased caveolin-1 protein expression in a time-dependent manner with a 
maximum response at 12 hours (Fig. 8.1a). Chemerin (21-157) increased caveolin-1 
protein expression in a concentration-dependent manner showing maximum response 
at [30nM] chemerin (21-157) (Fig. 8.1b).  
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Figure 8.1a Chemerin (21-157) increased caveolin-1 protein expression in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [30nM] chemerin (21-157) for a maximum of 24 
hours. Following cell lysis and sample preparations, the protein lysates were 
separated using 15% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific caveolin-1 antibody 
[(1:2000); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti- rabbit IgG-HRP 
labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes 
were visualised using ECL plus detection reagent on X-ray films. Membranes were 
re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both caveolin-1 and β-
actin were detected as 24/21kDa and 45kDa products. 
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Figure 8.1b Chemerin (21-157) increased caveolin-1 protein expression in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 24 hours. Following cell lysis and sample preparations, protein lysates 
were separated using 15% polyacrylamide gels and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific caveolin-1 antibody 
[(1:2000); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti- rabbit IgG-HRP 
labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes 
were visualised using ECL plus detection reagent on X-ray films. Membranes were 
re-probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both caveolin-1 and β-
actin were detected as 24/21kDa and 45kDa products. 
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9. Chemerin Increased  Heat-Shock Protein (HSP90) Protein Expression in a 
Time- and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. For studying time-point 
response, HMEC-1 cells were treated with [10nM] chemerin (21-157) at different 
time-points for a maximum of 24 hours. For concentration-dependent response, 
HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations  for 6 hours. Cells were lysed in 1x RIPA buffer and protein lysates 
were separated using SDS-PAGE. Chemerin (21-157) increased HSP90 protein 
expression in HMEC-1 cell line in a time-dependent manner showing a peak 
response at 6 hours (Fig. 9.1a). Chemerin (21-157) increased HSP90 protein 
expression in a concentration-dependent manner showing maximum response at 
[10nM] chemerin (21-157) (Fig. 9.1b).  
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Figure 9.1a Chemerin (21-157) increased HSP90 protein expression in a time-
dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [10nM] chemerin (21-157) for a maximum of 24 
hours. Following cell lysis and sample preparations, the protein lysates were 
separated using 10% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with specific HSP90 antibody 
[(1:1500); Abcam Cambridge, UK] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with rabbit IgG-HRP labelled 
antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT.  Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membranes were re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for HSP90 and β-actin were 
detected as 90kDa and 45kDa products. 
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Figure 9.1b Chemerin (21-157) increased HSP90 protein expression in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
30nM] for 6 hours. Following cell lysis and sample preparations, the protein lysates 
were separated using 10% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific HSP90 antibody 
[(1:1500); Abcam Cambridge, UK] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with rabbit IgG-HRP labelled 
antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT.  Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membranes were re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for HSP90 and β-actin were 
detected as 90kDa and 45kDa products. 
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10. Chemerin (21-157) Increased Plasminogen Activator Inhibitor (PAI)-1 
Protein Expression and Secretion in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing various different treatments. To study cellular 
protein expression of PAI-1, HMEC-1 cells were treated with different chemerin 
(21-157) [0-10nM] concentrations for 6 hours. Cells were lysed in 1x RIPA buffer 
and protein lysates were separated using SDS-PAGE. To study secreted levels of 
PAI-1, HMEC-1 cells were treated with different chemerin (21-157) [0-30nM] 
concentrations for 4, 12 and 24 hours. Cell supernatants were collected and soluble 
PAI-1 levels were determined using Luminex® 100 system in all three different 
treatment groups. In addition, in 24 hours cell supernatants, PAI-1 protein expression 
was also studied using SDS-PAGE. Chemerin (21-157) increased PAI-1 protein 
expression in a concentration-dependent manner in HMEC-1 cell lysates (Fig. 10.1a). 
Secreted PAI-1 protein levels were detected by SDS-PAGE in 24 hours cell 
supernatants (Fig. 10.1b). In contrast, different chemerin (21-157) treatments did not 
show any changes in PAI-1 levels in HMEC-1 cell supernatants (Table 10.1a, b and 
c respectively). TNF-α [10ng/ml] and IL-1β [10ng/ml] were used as positive controls. 
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Figure 10.1a Chemerin (21-157) increased PAI-1 protein expression in HMEC-1 
cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 6 hours. Following cell lysis and sample preparations, the protein lysates 
were separated using 12% polyacrylamide gels, and transferred to PVDF membranes 
at 100V for 1 hour. Membranes were incubated with specific mouse PAI-1 antibody 
[(1:1000); Abcam Cambridge, UK] overnight at 4
o
C. After removing the primary 
antibody complexes, membranes were incubated with anti-mouse IgG-HRP labelled 
antibody [(1:8000); Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films. Membranes were re-
probed with rabbit β-actin antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for PAI-1 and β-actin were 
detected as 47kDa and 45 kDa products. 
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Figure 10.1b Chemerin (21-157) and PAI-1 protein secretion in HMEC-1 cell 
supernatants 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 24 hours and cell supernatants were collected. Samples were prepared by 
mixing equal volumes of cell supernatants and 1x Laemmili buffer solution. 
Following sample preparations, the proteins were separated using 12% 
polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 hour. 
Membranes were incubated with specific mouse PAI-1 antibody [(1:1000); Abcam 
Cambridge, UK] overnight at 4
o
C. After removing the primary antibody complexes, 
membranes were incubated with anti-mouse IgG-HRP labelled antibody [(1:8000); 
Sigma-Aldrich, UK] for 1 hour at RT. Protein complexes were visualised using ECL 
plus detection reagent on X-ray films. The corresponding bands for PAI-1 were 
detected as 47kDa products. 
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Table 10.1a 
Chemerin (21-157) and PAI-1 protein secretion in HMEC-1 cell supernatants 
after 4 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatments 4 hours 
(n=1) 
pg/mL 
4 hours 
(n=2) 
pg/mL 
Basal  4.75298 5.20259 
[0.01nM] chemerin (21-157) 4.89021 7.48906 
[0.1nM] chemerin (21-157) 5.16941 3.1263 
[1nM] chemerin (21-157) 4.92472 4.70012 
[10nM] chemerin (21-157) 4.86558 4.51402 
[30nM] chemerin (21-157) 5.0147 5.07345 
TNF-α [10ng/ml] 9.02581 9.02581 
TNF-α [10ng/ml] 10.34339 10.34339 
IL-1β [10ng/ml] 11.18808 11.18808 
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Table 10.1b 
Chemerin (21-157) and sPAI-1 protein secretion in HMEC-1 cell supernatants 
after 12 hours 
 
Treatments 12 hours 
(n=1) 
pg/mL 
12 hours 
(n=2) 
pg/mL 
Basal  8.57681 8.345 
[0.01nM] chemerin (21-157) 7.33019 5.145 
[0.1nM] chemerin (21-157) 7.4077 6.845 
[1nM] chemerin (21-157) 6.35122 7.212 
[10nM] chemerin (21-157) 8.46765 7.751 
[30nM] chemerin (21-157) 5.76457 6.167 
TNF-α [10ng/ml] 9.02581 9.026 
TNF-α [10ng/ml] 10.3434 10.34 
IL-1β [10ng/ml] 11.1881 11.19 
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Table 10.1c 
Chemerin (21-157) and sPAI-1 protein secretion in HMEC-1 cell supernatants 
after 24 hours 
 
Treatments 24 hours 
(n=1) 
pg/mL 
24 hours 
(n=2) 
pg/mL 
Basal  8.61724 9.12865 
[0.01nM] chemerin (21-157) 8.58847 9.97703 
[0.1nM] chemerin (21-157) 10.06147 9.48074 
[1nM] chemerin (21-157) 8.4005 8.85272 
[10nM] chemerin (21-157) 9.38937 0.85836 
[30nM] chemerin (21-157) 9.554 8.55766 
TNF-α [10ng/ml] 9.02581 9.02581 
TNF-α [10ng/ml] 10.34339 10.34339 
IL-1β [10ng/ml] 11.18808 11.18808 
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11. Chemerin (21-157) and SAPK/JNK MAPK Phosphorylation in a Time- 
and Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
SAPK/JNK MAPK phosphorylation, HMEC-1 cells were treated with [1.0nM] 
chemerin (21-157) at different time-points for a maximum of 30 minutes. For 
concentration-dependent SAPK/JNK MAPK phosphorylation, HMEC-1 cells were 
treated with different chemerin (21-157) [0-10nM] concentrations for 30 minute. 
Cells were lysed in 1x RIPA buffer and protein lysates were separated using SDS-
PAGE. Chemerin (21-157) phosphorylated SAPK/JNK MAPK in a time- and 
concentration-dependent  manner  (Fig. 11.1a and b respectively).  
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Figure 11.1a Chemerin (21-157) lead to SAPK/JNK MAPK phosphorylation in 
a time-dependent manner in HMEC-1 cell line 
 
HMEC-1 cells were treated with [1.0nM] chemerin (21-157) for 0-60 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with phospho-SAPK/JNK (Thr183/Tyr185) 
MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Protein complexes were visualised using ECL plus detection reagent on X-ray films. 
Membrane was re-probed with total SAPK/JNK MAPK antibody [(1:1500); Cell 
signalling, Beverly, MA, USA] and used as a loading control. The corresponding 
bands for both phospho-SAPK/JNK and total SAPK/JNK MAPK were detected as 
54/46kDa products. 
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Figure 11.1b Chemerin (21-157) lead to SAPK/JNK MAPK phosphorylation in 
a concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations for 30 
minutes. Following cell lysis and sample preparations, the protein lysates were 
separated using 10% polyacrylamide gels, and transferred to PVDF membranes at 
100V for 1 hour. Membranes were incubated with phospho-SAPK/JNK 
(Thr183/Tyr185) MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
overnight at 4
o
C. After removing the primary antibody complexes, membranes were 
incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 
1 hour at RT. Protein complexes were visualised using ECL plus detection reagent 
on X-ray films. Membranes were re-probed with total SAPK/JNK MAPK antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading control. The 
corresponding bands for both phospho-SAPK/JNK and total SAPK/JNK MAPK 
were detected as 54/46kDa products. 
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12. Chemerin (21-157) and AMPKα Phosphorylation in a Time- and 
Concentration-dependent Manner in HMEC-1 Cell Line 
 
HMEC-1 cells were cultured in 6-well plates in MCDB cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. To study time-dependent 
AMPKα kinases phosphorylation, HMEC-1 cells were treated with [1.0M] chemerin 
(21-157) at different time-points for a maximum of 60 minutes. For concentration-
dependent AMPKα kinases phosphorylation, HMEC-1 cells were treated with 
different chemerin (21-157) [0-10M] concentrations for 10 minute. Cells were lysed 
in 1x RIPA buffer and protein lysates were separated using SDS-PAGE. Chemerin 
(21-157) phosphorylated AMPKα in a time- and concentration-dependent manner 
(Fig. 12.1a and b respectively). 
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Figure 12.1a Chemerin (21-157) lead to AMPKα kinase phosphorylation in a 
time-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with [1.0nM] chemerin (21-157) for 0-60 minutes. 
Following cell lysis and sample preparations, the protein lysates were separated 
using 10% polyacrylamide gels, and transferred to PVDF membranes at 100V for 1 
hour. Membranes were incubated with phospho-AMPKα (Thr172) antibody 
[(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. After removing the 
primary antibody complexes, membranes were incubated with anti-rabbit IgG-HRP 
labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes 
were visualised using ECL plus detection reagent on X-ray films. Membranes were 
re-probed with total AMPKα antibody [(1:1500); Cell signalling, Beverly, MA, USA] 
and used as a loading control. The corresponding bands for both phospho-AMPKα 
and total AMPKα were detected as 68kDs products. 
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Figure 12.1b Chemerin (21-157) lead to AMPKα kinase phosphorylation in a 
concentration-dependent manner in HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (21-157) concentrations [0-
10nM] for 30 minutes. Following cell lysis and sample preparations, the protein 
lysates were separated using 10% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with phospho-AMPKα 
(Thr172) antibody [(1:1500); Cell signalling, Beverly, MA, USA] overnight at 4
o
C. 
After removing the primary antibody complexes, membranes were incubated with 
anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, UK] for 1 hour at RT. 
Membranes were re-probed with total AMPKα antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] and used as a loading control. Protein complexes were 
visualised using ECL plus detection reagent on X-ray films and corresponding bands 
for both phospho-AMPKα and total AMPKα were detected as 68kDa products. 
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13. Shortest Chemerin Peptide, Chemerin (149-157), and ERK1/2 
Phosphorylation in HMEC-1 Cell Line in Nanomolar Concentrations 
 
In 2004, Wittamer and colleagues found that chemerin (149-157) is the 
shortest chemerin fragment known to bind CMKLR1, and retains most of the activity 
of full length chemerin (21-157). Chemerin (149-157) is reported to bind CMKLR1 
in micromolar concentrations, compared to nanomolar concentration of full length 
chemerin (21-157) (Wittamer et al., 2004, Wong et al., 2011) . In order to see the 
effects of chemerin (149-157) in nanomolar concentrations, HMEC-1 cells were 
treated with different nanomolar chemerin (149-157) concentrations [0-1000nM] and 
ERK1/2 MAPK phosphorylation was studied. Chemerin (149-157), at low 
nanomolar concentrations, failed to show any changes in ERK1/2 MAPK 
phosphorylation (Fig. 13.1a). 
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Figure 13.1a Chemerin (149-157) and ERK1/2 MAPK phosphorylation in 
HMEC-1 cell line 
HMEC-1 cells were treated with different chemerin (149-157) concentrations [0-
1000nM] for 5 minutes. Following cell lysis and sample preparations, the protein 
lysates were separated using 12% polyacrylamide gels, and transferred to PVDF 
membranes at 100V for 1 hour. Membranes were incubated with specific phospho-
ERK1/2 (Thr202/Tyr204) MAPK antibody [(1:1500); Cell signalling, Beverly, MA, 
USA] overnight at 4
o
C. After removing the primary antibody complexes, membranes 
were incubated with anti-rabbit IgG-HRP labelled antibody [(1:2000); Dako, Ely, 
UK] for 1 hour at RT. Protein complexes were visualised using ECL plus detection 
reagent on X-ray films. Membranes were re-probed with total ERK1/2 MAPK 
antibody [(1:1500); Cell signalling, Beverly, MA, USA] and used as a loading 
control. The corresponding bands for both phospho-ERK1/2 and total ERK1/2 
MAPK were detected as 44/42kDa products. 
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14. Chemerin (21-157) and ERK1/2 MAPK Phosphorylation in Stable 
CMKLR1 Transfected HEK293T Cells 
 
HEK293T cells were stable transfected with pcDNA3.1-CMKLR1 plasmid 
and stable cell line expressing CMKLR1 was prepared (HEK293T.CMKLR1). 
HEK293T.CMKLR1 cells were cultured in 6-well plates in DMEM cell medium 
containing 10% FCS, and were serum starved in the same medium containing 1% 
FCS overnight before performing different treatments. HEK293T.CMKLR1 cells 
were treated with different chemerin (21-157) [0-30nM] concentrations for 5 minutes. 
Cells were lysed in 1x RIPA buffer and protein lysates were separated using SDS-
PAGE. Chemerin (21-157) phosphorylated ERK1/2 MAPK in a concentration-
dependent manner in HEK293T.CMKLR1 (Fig. 14.1a). 
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Figure 14.1a Chemerin (21-157) and ERK1/2 MAPK phosphorylation in 
CMKLR1 stable transfected HEK293T.CMKLR1 cells 
HEK293T.CMKLR1 cells were treated with different chemerin (21-157) 
concentrations [0-10nM] for 5 minutes. Following cell lysis and sample preparations, 
the protein lysates were separated using 12% polyacrylamide gels, and transferred to 
PVDF membranes at 100V for 1 hour. Membranes were incubated with specific 
phospho-ERK1/2 (Thr202/Tyr204) MAPK antibody [(1:1500); Cell signalling, 
Beverly, MA, USA] overnight at 4
o
C. After removing the primary antibody 
complexes, membranes were incubated with anti-rabbit IgG-HRP labelled antibody 
[(1:2000); Dako, Ely, UK] for 1 hour at RT. Protein complexes were visualised 
using ECL plus detection reagent on X-ray films. Membranes were re-probed with 
total ERK1/2 MAPK antibody [(1:1500); Cell signalling, Beverly, MA, USA] and 
used as a loading control. The corresponding bands for both phospho-ERK1/2 and 
total ERK1/2 MAPK were detected as 44/42kDa products. 
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15. List of Experiments and Methods Contributed by Others Researchers 
 
Following is the list of experiments and methods contributed by other researchers 
Chapter 
number 
Method/experiments Person’s 
name 
Role I 
played 
Page 
numbers 
2 Primary Human Umbilical 
Vein endothelial Cells 
(HUVECs) 
Dr R Adya None 41-3 
2 Making competent E.coli cells 
for transformation 
Dr J Chen Observed 
and 
assisted 
51 
2 Transient transfection of NF-
κB-Luc plasmid in HMEC-1 
cell line 
Dr R Adya None 55-6 
2 Stable CMKLR1 transfections 
in HEK293T Cell Line 
Dr J Chen None 56 
2 and 4 Gelatin Zymography Dr R Adya Observed 
only  
61 
2 and 4 Wound-healing Cell Motility 
Assay 
Dr R Adya None 63-4 
2 and 4 In vitro Cell Invasion Assay Dr R Adya None 64-5 
2 and 4 Endothelial cell capillary tube 
formation assay for generating 
data presented on page 
number 136 (Fig. 4.3.11a) 
Dr R Adya Observed 
and 
assisted 
65-6 
2 and 
future 
work 
Capillary tube formation 
experiment using chemerin 
(149-157) (Fig. 8.6a, page 
number 232).  
myself n/a 65-6 
2 and 5 NF-κB Luciferase Activity 
Assay 
Dr R Adya None 68 
2 and 5 Endothelial-Monocyte Cell 
Adhesion Assay 
Dr R Adya None 69-70 
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